{
  "doc_id": "17",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "中国住院患者血糖管理专家共识",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "中国住院患者血糖管理专家共识",
          "start_idx": 0,
          "end_idx": 14,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 6,
              "end_idx": 8,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "Expert consensus on blood glucose management for hospitalized patients in China"
        }
      ],
      "paragraph_en": "Expert consensus on blood glucose management for hospitalized patients in China"
    },
    {
      "paragraph_id": "1",
      "paragraph": "一、住院患者高血糖概述",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "一、住院患者高血糖概述",
          "start_idx": 0,
          "end_idx": 11,
          "entities": [
            {
              "entity_id": "T1",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "1. Overview of Hyperglycemia in Hospitalized Patients"
        }
      ],
      "paragraph_en": "1. Overview of Hyperglycemia in Hospitalized Patients"
    },
    {
      "paragraph_id": "2",
      "paragraph": "院内高血糖是指血糖水平>7.8mmol/L，若血糖水平持续而明显地高于此水平则提示患者有可能需要接受治疗。造成高血糖的原因既可以是由于已知的或未诊断的糖尿病，也可以是由于急危重症所致的应激性高血糖。不论高血糖的原因如何，也不论患者是否伴有糖尿病，高血糖均会增加住院患者的并发症和死亡风险。对所有的高血糖患者在入院时均应检测血糖并应询问是否有糖尿病病史，必要时检测HbA1c水平以明确患者住院前是否已经存在糖尿病。新诊断的糖尿病患者HbA1c≥6.5%；而应激性高血糖患者的HbA1c水平一般不高；血糖的水平通常随导致血糖升高的急危重症的出现或缓解而升高或恢复正常。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "院内高血糖是指血糖水平>7.8mmol/L，若血糖水平持续而明显地高于此水平则提示患者有可能需要接受治疗。造成高血糖的原因既可以是由于已知的或未诊断的糖尿病，也可以是由于急危重症所致的应激性高血糖。不论高血糖的原因如何，也不论患者是否伴有糖尿病，高血糖均会增加住院患者的并发症和死亡风险。对所有的高血糖患者在入院时均应检测血糖并应询问是否有糖尿病病史，必要时检测HbA1c水平以明确患者住院前是否已经存在糖尿病。",
          "start_idx": 0,
          "end_idx": 206,
          "entities": [
            {
              "entity_id": "T2",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T3",
              "entity": "血糖水平",
              "entity_type": "Test_items",
              "start_idx": 7,
              "end_idx": 11,
              "entity_en": "Blood sugar levels"
            },
            {
              "entity_id": "T4",
              "entity": ">7.8mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 11,
              "end_idx": 21,
              "entity_en": ">7.8mmol/L"
            },
            {
              "entity_id": "T5",
              "entity": "血糖水平",
              "entity_type": "Test_items",
              "start_idx": 23,
              "end_idx": 27,
              "entity_en": "Blood sugar levels"
            },
            {
              "entity_id": "T6",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 55,
              "end_idx": 58,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T7",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 78,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T8",
              "entity": "应激性高血糖",
              "entity_type": "Disease",
              "start_idx": 92,
              "end_idx": 98,
              "entity_en": "Stress-induced hyperglycemia"
            },
            {
              "entity_id": "T9",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 101,
              "end_idx": 104,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T10",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 119,
              "end_idx": 122,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T11",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 123,
              "end_idx": 126,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T12",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 148,
              "end_idx": 151,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T13",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 161,
              "end_idx": 163,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T14",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 170,
              "end_idx": 173,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T15",
              "entity": "HbA1c水平",
              "entity_type": "Test_items",
              "start_idx": 181,
              "end_idx": 188,
              "entity_en": "HbA1c Level"
            },
            {
              "entity_id": "T16",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 202,
              "end_idx": 205,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T25",
              "entity": "高于此水平",
              "entity_type": "Test_Value",
              "start_idx": 33,
              "end_idx": 38,
              "entity_en": "Above this level"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R0",
              "head_entity_id": "T3",
              "tail_entity_id": "T2"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R1",
              "head_entity_id": "T13",
              "tail_entity_id": "T12"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R2",
              "head_entity_id": "T15",
              "tail_entity_id": "T16"
            }
          ],
          "sentence_en": "In-hospital hyperglycemia refers to a blood glucose level >7.8mmol/L. If the blood glucose level is persistently and significantly higher than this level, it indicates that the patient may need treatment. Hyperglycemia can be caused by known or undiagnosed diabetes, or stress hyperglycemia caused by critical illness. Regardless of the cause of hyperglycemia and whether the patient has diabetes, hyperglycemia increases the risk of complications and death in hospitalized patients. All patients with hyperglycemia should have their blood glucose tested upon admission and should be asked whether they have a history of diabetes. If necessary, the HbA1c level should be tested to determine whether the patient already had diabetes before hospitalization."
        },
        {
          "sentence_id": "1",
          "sentence": "新诊断的糖尿病患者HbA1c≥6.5%；而应激性高血糖患者的HbA1c水平一般不高；血糖的水平通常随导致血糖升高的急危重症的出现或缓解而升高或恢复正常。",
          "start_idx": 206,
          "end_idx": 282,
          "entities": [
            {
              "entity_id": "T17",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T18",
              "entity": "HbA1",
              "entity_type": "Test_items",
              "start_idx": 9,
              "end_idx": 13,
              "entity_en": "HbA1"
            },
            {
              "entity_id": "T19",
              "entity": "c≥6.5%",
              "entity_type": "Test_Value",
              "start_idx": 13,
              "end_idx": 19,
              "entity_en": "c≥6.5%"
            },
            {
              "entity_id": "T20",
              "entity": "应激性高血糖",
              "entity_type": "Disease",
              "start_idx": 21,
              "end_idx": 27,
              "entity_en": "Stress-induced hyperglycemia"
            },
            {
              "entity_id": "T21",
              "entity": "HbA1c水平",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 37,
              "entity_en": "HbA1c Level"
            },
            {
              "entity_id": "T22",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 42,
              "end_idx": 44,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T23",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 52,
              "end_idx": 54,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T24",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 54,
              "end_idx": 56,
              "entity_en": "Elevated"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R3",
              "head_entity_id": "T18",
              "tail_entity_id": "T17"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R4",
              "head_entity_id": "T21",
              "tail_entity_id": "T20"
            }
          ],
          "sentence_en": "The HbA1c level of newly diagnosed diabetic patients is ≥6.5%, while the HbA1c level of patients with stress hyperglycemia is generally not high. The blood sugar level usually increases or returns to normal with the occurrence or relief of the critical illness that causes the increase in blood sugar."
        }
      ],
      "paragraph_en": "In-hospital hyperglycemia refers to a blood glucose level >7.8mmol/L. If the blood glucose level is persistently and significantly higher than this level, it indicates that the patient may need treatment. Hyperglycemia can be caused by known or undiagnosed diabetes or stress hyperglycemia caused by critical illness. Regardless of the cause of hyperglycemia and whether the patient has diabetes, hyperglycemia increases the risk of complications and death in hospitalized patients. All patients with hyperglycemia should have their blood glucose tested upon admission and should be asked whether they have a history of diabetes. If necessary, HbA1c levels should be tested to determine whether the patient already had diabetes before hospitalization. Newly diagnosed patients with diabetes have HbA1c ≥6.5%; while patients with stress hyperglycemia generally have low HbA1c levels; blood glucose levels usually increase or return to normal with the onset or relief of the critical illness that caused the increase in blood glucose."
    },
    {
      "paragraph_id": "3",
      "paragraph": "住院患者发生高血糖非常普通，包括入住内分泌科的成人糖尿病患者，其他内科、外科、急诊、重症监护科室的糖尿病或高血糖患者以及妊娠糖尿病或糖尿病妊娠患者等，针对不同患者的具体血糖控制目标见表1和表2。另外，院内高血糖的管理主要分为危重患者和非危重患者的高血糖的管理(图1)。结合患者入院的原因以及患者的疾病状况，需要对患者进行分层管理，设定不同的血糖控制目标。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "住院患者发生高血糖非常普通，包括入住内分泌科的成人糖尿病患者，其他内科、外科、急诊、重症监护科室的糖尿病或高血糖患者以及妊娠糖尿病或糖尿病妊娠患者等，针对不同患者的具体血糖控制目标见表1和表2。",
          "start_idx": 0,
          "end_idx": 97,
          "entities": [
            {
              "entity_id": "T26",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T27",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 28,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T28",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 49,
              "end_idx": 52,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T29",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 53,
              "end_idx": 56,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T30",
              "entity": "妊娠糖尿病",
              "entity_type": "Disease",
              "start_idx": 60,
              "end_idx": 65,
              "entity_en": "Gestational diabetes"
            },
            {
              "entity_id": "T35",
              "entity": "糖尿病妊娠",
              "entity_type": "Disease",
              "start_idx": 66,
              "end_idx": 71,
              "entity_en": "Diabetic pregnancy"
            },
            {
              "entity_id": "T37",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 84,
              "end_idx": 86,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R5",
              "head_entity_id": "T37",
              "tail_entity_id": "T28"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R6",
              "head_entity_id": "T37",
              "tail_entity_id": "T29"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R7",
              "head_entity_id": "T37",
              "tail_entity_id": "T30"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R8",
              "head_entity_id": "T37",
              "tail_entity_id": "T35"
            }
          ],
          "sentence_en": "Hyperglycemia is very common in hospitalized patients, including adult diabetic patients admitted to the endocrinology department, patients with diabetes or hyperglycemia in other internal medicine, surgery, emergency, and intensive care departments, and patients with gestational diabetes or diabetic pregnancy. Specific blood sugar control targets for different patients are shown in Tables 1 and 2."
        },
        {
          "sentence_id": "1",
          "sentence": "另外，院内高血糖的管理主要分为危重患者和非危重患者的高血糖的管理(图1)。",
          "start_idx": 97,
          "end_idx": 134,
          "entities": [
            {
              "entity_id": "T31",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T32",
              "entity": "危重",
              "entity_type": "Level",
              "start_idx": 15,
              "end_idx": 17,
              "entity_en": "Critical"
            },
            {
              "entity_id": "T33",
              "entity": "非危重",
              "entity_type": "Level",
              "start_idx": 20,
              "end_idx": 23,
              "entity_en": "Non-critical"
            },
            {
              "entity_id": "T34",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 26,
              "end_idx": 29,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "In addition, the management of hyperglycemia in the hospital is mainly divided into the management of hyperglycemia in critically ill patients and non-critically ill patients (Figure 1)."
        },
        {
          "sentence_id": "2",
          "sentence": "结合患者入院的原因以及患者的疾病状况，需要对患者进行分层管理，设定不同的血糖控制目标。",
          "start_idx": 134,
          "end_idx": 177,
          "entities": [
            {
              "entity_id": "T36",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 36,
              "end_idx": 38,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "Based on the reason for the patient's hospitalization and the patient's disease condition, patients need to be stratified and managed, and different blood sugar control goals need to be set."
        }
      ],
      "paragraph_en": "Hyperglycemia is very common in hospitalized patients, including adult diabetic patients admitted to the endocrinology department, diabetic or hyperglycemic patients in other internal medicine, surgery, emergency, and intensive care departments, and patients with gestational diabetes or diabetic pregnancy. The specific blood sugar control targets for different patients are shown in Tables 1 and 2. In addition, the management of hyperglycemia in hospitals is mainly divided into the management of hyperglycemia in critically ill patients and non-critically ill patients (Figure 1). Combined with the reasons for the patient's admission and the patient's disease condition, the patient needs to be managed in a stratified manner and different blood sugar control targets should be set."
    },
    {
      "paragraph_id": "4",
      "paragraph": "二、住院患者的血糖控制目标",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二、住院患者的血糖控制目标",
          "start_idx": 0,
          "end_idx": 13,
          "entities": [
            {
              "entity_id": "T38",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 7,
              "end_idx": 9,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "2. Blood glucose control goals for hospitalized patients"
        }
      ],
      "paragraph_en": "2. Blood glucose control goals for hospitalized patients"
    },
    {
      "paragraph_id": "5",
      "paragraph": "在本世纪初的住院患者血糖管理中，重点关注降低高血糖，倾向于较低的血糖控制目标，而这种治疗模式导致低血糖的风险明显增加。近年来，随着对住院高血糖管理认识的不断深化和证据积累，血糖控制目标已由强化血糖控制发展至多样化的个体化目标。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "在本世纪初的住院患者血糖管理中，重点关注降低高血糖，倾向于较低的血糖控制目标，而这种治疗模式导致低血糖的风险明显增加。",
          "start_idx": 0,
          "end_idx": 59,
          "entities": [
            {
              "entity_id": "T39",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 25,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T40",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 51,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T42",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 10,
              "end_idx": 12,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T43",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R9",
              "head_entity_id": "T42",
              "tail_entity_id": "T39"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R10",
              "head_entity_id": "T43",
              "tail_entity_id": "T40"
            }
          ],
          "sentence_en": "In the early 2000s, the focus of inpatient glycemic management was on reducing hyperglycemia and tending to lower glycemic control targets, and this treatment model resulted in a significantly increased risk of hypoglycemia."
        },
        {
          "sentence_id": "1",
          "sentence": "近年来，随着对住院高血糖管理认识的不断深化和证据积累，血糖控制目标已由强化血糖控制发展至多样化的个体化目标。",
          "start_idx": 59,
          "end_idx": 113,
          "entities": [
            {
              "entity_id": "T41",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T44",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 27,
              "end_idx": 29,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T45",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 37,
              "end_idx": 39,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R11",
              "head_entity_id": "T44",
              "tail_entity_id": "T41"
            }
          ],
          "sentence_en": "In recent years, with the deepening of understanding of hospitalized hyperglycemia management and the accumulation of evidence, blood glucose control goals have evolved from intensive blood glucose control to diversified individualized goals."
        }
      ],
      "paragraph_en": "In the early 2000s, the focus of blood glucose management in hospitalized patients was on reducing hyperglycemia, with a tendency to lower blood glucose control targets, and this treatment model led to a significantly increased risk of hypoglycemia. In recent years, with the deepening of understanding of hospitalized hyperglycemia management and the accumulation of evidence, blood glucose control targets have evolved from intensive blood glucose control to diversified individualized targets."
    },
    {
      "paragraph_id": "6",
      "paragraph": "我们在参考多个国内外指南的基础上，结合中国的临床实际情况及特点，推荐对不同的住院患者使用不同的血糖控制目标，达到更为精细和个体化的管理推荐的血脑控制目标分层如表1所示。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "我们在参考多个国内外指南的基础上，结合中国的临床实际情况及特点，推荐对不同的住院患者使用不同的血糖控制目标，达到更为精细和个体化的管理推荐的血脑控制目标分层如表1所示。",
          "start_idx": 0,
          "end_idx": 84,
          "entities": [
            {
              "entity_id": "T46",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 47,
              "end_idx": 49,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "Based on reference to multiple domestic and international guidelines and in combination with China's actual clinical situation and characteristics, we recommend using different blood glucose control targets for different hospitalized patients to achieve more refined and individualized management. The recommended blood-brain control target stratification is shown in Table 1."
        }
      ],
      "paragraph_en": "Based on reference to multiple domestic and international guidelines and in combination with China's actual clinical situation and characteristics, we recommend using different blood glucose control targets for different hospitalized patients to achieve more refined and individualized management. The recommended blood-brain control target stratification is shown in Table 1."
    },
    {
      "paragraph_id": "7",
      "paragraph": "不同住院人群的控制目标如表2所示。与非妊娠的糖尿病或高血糖患者相比，妊娠患者由于涉及到母亲和胎儿两方面，其控制目标需要更为严格，具体目标见“糖尿病妊娠及妊娠糖尿病住院患者的血糖管理”章节。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "不同住院人群的控制目标如表2所示。与非妊娠的糖尿病或高血糖患者相比，妊娠患者由于涉及到母亲和胎儿两方面，其控制目标需要更为严格，具体目标见“糖尿病妊娠及妊娠糖尿病住院患者的血糖管理”章节。",
          "start_idx": 0,
          "end_idx": 94,
          "entities": [
            {
              "entity_id": "T47",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 25,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T48",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 26,
              "end_idx": 29,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T49",
              "entity": "糖尿病妊娠",
              "entity_type": "Disease",
              "start_idx": 70,
              "end_idx": 75,
              "entity_en": "Diabetic pregnancy"
            },
            {
              "entity_id": "T50",
              "entity": "妊娠糖尿病",
              "entity_type": "Disease",
              "start_idx": 76,
              "end_idx": 81,
              "entity_en": "Gestational diabetes"
            },
            {
              "entity_id": "T51",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 86,
              "end_idx": 88,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R12",
              "head_entity_id": "T51",
              "tail_entity_id": "T49"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R13",
              "head_entity_id": "T51",
              "tail_entity_id": "T50"
            }
          ],
          "sentence_en": "The control targets for different inpatient populations are shown in Table 2. Compared with non-pregnant patients with diabetes or hyperglycemia, pregnant patients need stricter control targets because both the mother and the fetus are involved. For specific targets, see the section “Glycemic Management of Diabetic Pregnancy and Inpatients with Gestational Diabetes”."
        }
      ],
      "paragraph_en": "The control targets for different inpatient populations are shown in Table 2. Compared with non-pregnant patients with diabetes or hyperglycemia, pregnant patients need stricter control targets because both the mother and the fetus are involved. For specific targets, see the section “Glycemic Management of Diabetic Pregnancy and Inpatients with Gestational Diabetes”."
    },
    {
      "paragraph_id": "8",
      "paragraph": "三、住院患者的血糖管理",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "三、住院患者的血糖管理",
          "start_idx": 0,
          "end_idx": 11,
          "entities": [
            {
              "entity_id": "T52",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 7,
              "end_idx": 9,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "III. Blood Glucose Management in Hospitalized Patients"
        }
      ],
      "paragraph_en": "III. Blood Glucose Management in Hospitalized Patients"
    },
    {
      "paragraph_id": "9",
      "paragraph": "(一)内分泌科住院糖尿病患者的血糖管理",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(一)内分泌科住院糖尿病患者的血糖管理",
          "start_idx": 0,
          "end_idx": 19,
          "entities": [
            {
              "entity_id": "T53",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T54",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 15,
              "end_idx": 17,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R14",
              "head_entity_id": "T54",
              "tail_entity_id": "T53"
            }
          ],
          "sentence_en": "1. Blood glucose management of diabetic patients hospitalized in the endocrinology department"
        }
      ],
      "paragraph_en": "1. Blood glucose management of diabetic patients hospitalized in the endocrinology department"
    },
    {
      "paragraph_id": "10",
      "paragraph": "1.内分泌科糖尿病患者的住院标准",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.内分泌科糖尿病患者的住院标准",
          "start_idx": 0,
          "end_idx": 16,
          "entities": [
            {
              "entity_id": "T55",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "diabetes"
            }
          ],
          "relations": [],
          "sentence_en": "1. Hospitalization criteria for diabetic patients in the endocrinology department"
        }
      ],
      "paragraph_en": "1. Hospitalization criteria for diabetic patients in the endocrinology department"
    },
    {
      "paragraph_id": "11",
      "paragraph": "糖尿病患者在其长期的治疗过程中涉及到“家—医院—家“的一体化管理，糖尿病患者绝大多数时间需要在家和门诊进行调整和管理血糖，但许多情况下可能需要住院进行短期血糖管理和优化治疗、并发症筛查和应激状态的控制等，尤其在需要起始胰岛素治疗的情况下。糖尿病患者有以下情况建议住院：",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "糖尿病患者在其长期的治疗过程中涉及到“家—医院—家“的一体化管理，糖尿病患者绝大多数时间需要在家和门诊进行调整和管理血糖，但许多情况下可能需要住院进行短期血糖管理和优化治疗、并发症筛查和应激状态的控制等，尤其在需要起始胰岛素治疗的情况下。",
          "start_idx": 0,
          "end_idx": 119,
          "entities": [
            {
              "entity_id": "T56",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T57",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 36,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T58",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 58,
              "end_idx": 60,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T59",
              "entity": "并发症筛查",
              "entity_type": "Treatment",
              "start_idx": 87,
              "end_idx": 92,
              "entity_en": "Screening for complications"
            },
            {
              "entity_id": "T60",
              "entity": "应激状态的控制",
              "entity_type": "Treatment",
              "start_idx": 93,
              "end_idx": 100,
              "entity_en": "Control of stress"
            },
            {
              "entity_id": "T61",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 109,
              "end_idx": 112,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T63",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 77,
              "end_idx": 79,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R15",
              "head_entity_id": "T58",
              "tail_entity_id": "T57"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R16",
              "head_entity_id": "T63",
              "tail_entity_id": "T57"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R17",
              "head_entity_id": "T59",
              "tail_entity_id": "T57"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R18",
              "head_entity_id": "T60",
              "tail_entity_id": "T57"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R19",
              "head_entity_id": "T61",
              "tail_entity_id": "T57"
            }
          ],
          "sentence_en": "The long-term treatment process of diabetic patients involves integrated management of \"home-hospital-home\". Most of the time, diabetic patients need to adjust and manage their blood sugar at home and in outpatient clinics, but in many cases they may need to be hospitalized for short-term blood sugar management and optimization of treatment, complication screening, and control of stress states, especially when insulin treatment needs to be initiated."
        },
        {
          "sentence_id": "1",
          "sentence": "糖尿病患者有以下情况建议住院：",
          "start_idx": 119,
          "end_idx": 134,
          "entities": [
            {
              "entity_id": "T62",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "diabetes"
            }
          ],
          "relations": [],
          "sentence_en": "Diabetic patients are advised to be hospitalized if they:"
        }
      ],
      "paragraph_en": "The long-term treatment of diabetic patients involves integrated management of \"home-hospital-home\". Most of the time, diabetic patients need to adjust and manage blood sugar at home and in outpatient clinics, but in many cases, they may need to be hospitalized for short-term blood sugar management and optimization treatment, complication screening, and stress control, especially when insulin treatment is required. Diabetic patients are recommended to be hospitalized in the following situations:"
    },
    {
      "paragraph_id": "12",
      "paragraph": "·新诊断1型糖尿病；",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·新诊断1型糖尿病；",
          "start_idx": 0,
          "end_idx": 10,
          "entities": [
            {
              "entity_id": "T64",
              "entity": "1型糖尿病",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Type 1 diabetes"
            },
            {
              "entity_id": "T65",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "Type 1"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R20",
              "head_entity_id": "T65",
              "tail_entity_id": "T64"
            }
          ],
          "sentence_en": "Newly diagnosed type 1 diabetes;"
        }
      ],
      "paragraph_en": "Newly diagnosed type 1 diabetes;"
    },
    {
      "paragraph_id": "13",
      "paragraph": "·新诊断2型糖尿病需进行慢性并发症筛查或评估，或血糖较高需考虑胰岛素强化治疗；",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·新诊断2型糖尿病需进行慢性并发症筛查或评估，或血糖较高需考虑胰岛素强化治疗；",
          "start_idx": 0,
          "end_idx": 39,
          "entities": [
            {
              "entity_id": "T66",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T67",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T68",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 24,
              "end_idx": 26,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T69",
              "entity": "较高",
              "entity_type": "Test_Value",
              "start_idx": 26,
              "end_idx": 28,
              "entity_en": "Higher"
            },
            {
              "entity_id": "T70",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 31,
              "end_idx": 34,
              "entity_en": "insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R21",
              "head_entity_id": "T67",
              "tail_entity_id": "T66"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R22",
              "head_entity_id": "T68",
              "tail_entity_id": "T66"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R23",
              "head_entity_id": "T70",
              "tail_entity_id": "T66"
            }
          ],
          "sentence_en": "Newly diagnosed type 2 diabetes patients need to be screened or evaluated for chronic complications, or those with high blood sugar levels need to consider intensive insulin therapy;"
        }
      ],
      "paragraph_en": "Newly diagnosed type 2 diabetes patients need to be screened or evaluated for chronic complications, or those with high blood sugar levels need to consider intensive insulin therapy;"
    },
    {
      "paragraph_id": "14",
      "paragraph": "·新诊断的糖尿病患者，不能明确分型，需入院进一步明确分型；",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·新诊断的糖尿病患者，不能明确分型，需入院进一步明确分型；",
          "start_idx": 0,
          "end_idx": 29,
          "entities": [
            {
              "entity_id": "T71",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "diabetes"
            }
          ],
          "relations": [],
          "sentence_en": "Newly diagnosed diabetic patients cannot be clearly classified and need to be admitted to the hospital for further classification;"
        }
      ],
      "paragraph_en": "Newly diagnosed diabetic patients cannot be clearly classified and need to be admitted to the hospital for further classification;"
    },
    {
      "paragraph_id": "15",
      "paragraph": "·糖尿病妊娠或妊娠糖尿病(详见“糖尿病妊娠及妊娠糖尿病住院患者的血糖管理”部分)；",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·糖尿病妊娠或妊娠糖尿病(详见“糖尿病妊娠及妊娠糖尿病住院患者的血糖管理”部分)；",
          "start_idx": 0,
          "end_idx": 41,
          "entities": [
            {
              "entity_id": "T72",
              "entity": "糖尿病妊娠",
              "entity_type": "Disease",
              "start_idx": 1,
              "end_idx": 6,
              "entity_en": "Diabetic pregnancy"
            },
            {
              "entity_id": "T73",
              "entity": "妊娠糖尿病",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 12,
              "entity_en": "Gestational diabetes"
            },
            {
              "entity_id": "T74",
              "entity": "糖尿病妊娠",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 21,
              "entity_en": "Diabetic pregnancy"
            },
            {
              "entity_id": "T75",
              "entity": "妊娠糖尿病",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 27,
              "entity_en": "Gestational diabetes"
            },
            {
              "entity_id": "T76",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R24",
              "head_entity_id": "T76",
              "tail_entity_id": "T74"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R25",
              "head_entity_id": "T76",
              "tail_entity_id": "T75"
            }
          ],
          "sentence_en": "Diabetic pregnancy or gestational diabetes (see the section \"Glycemic management of hospitalized patients with diabetic pregnancy and gestational diabetes\" for details);"
        }
      ],
      "paragraph_en": "Diabetic pregnancy or gestational diabetes (see the section \"Glycemic management of patients hospitalized with diabetic pregnancy and gestational diabetes\" for details);"
    },
    {
      "paragraph_id": "16",
      "paragraph": "·糖尿病合并急性并发症如糖尿病酮症或糖尿病酮症酸中毒(DKA)、高血糖高渗状态和乳酸酸中毒伴高血糖等；",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·糖尿病合并急性并发症如糖尿病酮症或糖尿病酮症酸中毒(DKA)、高血糖高渗状态和乳酸酸中毒伴高血糖等；",
          "start_idx": 0,
          "end_idx": 51,
          "entities": [
            {
              "entity_id": "T77",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 1,
              "end_idx": 4,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T78",
              "entity": "糖尿病酮症",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 17,
              "entity_en": "Diabetic ketoacidosis"
            },
            {
              "entity_id": "T79",
              "entity": "糖尿病酮症酸中毒(DKA)",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 31,
              "entity_en": "Diabetic ketoacidosis (DKA)"
            },
            {
              "entity_id": "T80",
              "entity": "高血糖高渗状态",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 39,
              "entity_en": "Hyperglycemic hyperosmolar state"
            },
            {
              "entity_id": "T81",
              "entity": "乳酸酸中毒",
              "entity_type": "Disease",
              "start_idx": 40,
              "end_idx": 45,
              "entity_en": "Lactic acidosis"
            },
            {
              "entity_id": "T82",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 49,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "Diabetes with acute complications such as diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state, and lactic acidosis with hyperglycemia;"
        }
      ],
      "paragraph_en": "Diabetes with acute complications such as diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state, and lactic acidosis with hyperglycemia;"
    },
    {
      "paragraph_id": "17",
      "paragraph": "·糖尿病血糖控制差或不稳定，经门诊调整治疗不达标；",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·糖尿病血糖控制差或不稳定，经门诊调整治疗不达标；",
          "start_idx": 0,
          "end_idx": 25,
          "entities": [
            {
              "entity_id": "T83",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 1,
              "end_idx": 4,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T84",
              "entity": "不稳定",
              "entity_type": "Test_Value",
              "start_idx": 10,
              "end_idx": 13,
              "entity_en": "Unstable"
            },
            {
              "entity_id": "T85",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T86",
              "entity": "控制差",
              "entity_type": "Test_Value",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "Poor control"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R26",
              "head_entity_id": "T85",
              "tail_entity_id": "T83"
            }
          ],
          "sentence_en": "· Poor or unstable blood sugar control in patients with diabetes, and treatment adjustment in the outpatient clinic fails to meet the standard;"
        }
      ],
      "paragraph_en": "· Poor or unstable blood sugar control in patients with diabetes, and treatment adjustment in the outpatient clinic fails to meet the standard;"
    },
    {
      "paragraph_id": "18",
      "paragraph": "·病程长的糖尿病需进行慢性并发症筛查或评估；",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·病程长的糖尿病需进行慢性并发症筛查或评估；",
          "start_idx": 0,
          "end_idx": 22,
          "entities": [
            {
              "entity_id": "T87",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T88",
              "entity": "慢性并发症筛查或评估",
              "entity_type": "Test",
              "start_idx": 11,
              "end_idx": 21,
              "entity_en": "Screening or evaluation for chronic complications"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_Disease",
              "relation_id": "R27",
              "head_entity_id": "T88",
              "tail_entity_id": "T87"
            }
          ],
          "sentence_en": "Long-term diabetes requires screening or assessment for chronic complications;"
        }
      ],
      "paragraph_en": "Long-term diabetes requires screening or assessment for chronic complications;"
    },
    {
      "paragraph_id": "19",
      "paragraph": "·糖尿病合并各种应激状态如心脑血管意外、创伤，感染和手术等；",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·糖尿病合并各种应激状态如心脑血管意外、创伤，感染和手术等；",
          "start_idx": 0,
          "end_idx": 30,
          "entities": [
            {
              "entity_id": "T89",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 1,
              "end_idx": 4,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T90",
              "entity": "心脑血管意外",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 19,
              "entity_en": "Cardiovascular and cerebrovascular accidents"
            },
            {
              "entity_id": "T91",
              "entity": "创伤",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 22,
              "entity_en": "trauma"
            },
            {
              "entity_id": "T92",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 25,
              "entity_en": "Infect"
            }
          ],
          "relations": [],
          "sentence_en": "Diabetes combined with various stress states such as cardiovascular and cerebrovascular accidents, trauma, infection and surgery;"
        }
      ],
      "paragraph_en": "Diabetes combined with various stress states such as cardiovascular and cerebrovascular accidents, trauma, infection and surgery;"
    },
    {
      "paragraph_id": "20",
      "paragraph": "·糖尿病患者围手术期血糖不达标者；",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·糖尿病患者围手术期血糖不达标者；",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [
            {
              "entity_id": "T93",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 1,
              "end_idx": 4,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T94",
              "entity": "围手术期血糖",
              "entity_type": "Test_items",
              "start_idx": 6,
              "end_idx": 12,
              "entity_en": "Perioperative blood sugar"
            },
            {
              "entity_id": "T95",
              "entity": "不达标",
              "entity_type": "Test_Value",
              "start_idx": 12,
              "end_idx": 15,
              "entity_en": "Not up to standard"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R28",
              "head_entity_id": "T94",
              "tail_entity_id": "T93"
            }
          ],
          "sentence_en": "Diabetic patients whose blood sugar level does not meet the standard during perioperative period;"
        }
      ],
      "paragraph_en": "Diabetic patients whose blood sugar level does not meet the standard during perioperative period;"
    },
    {
      "paragraph_id": "21",
      "paragraph": "·糖尿病合开各种严重慢性开发症如各种神经病变、视网膜病变、肾病、糖尿病足溃疡伴或不伴感染等；",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·糖尿病合开各种严重慢性开发症如各种神经病变、视网膜病变、肾病、糖尿病足溃疡伴或不伴感染等；",
          "start_idx": 0,
          "end_idx": 46,
          "entities": [
            {
              "entity_id": "T96",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 1,
              "end_idx": 4,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T97",
              "entity": "神经病变",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 22,
              "entity_en": "Neuropathy"
            },
            {
              "entity_id": "T98",
              "entity": "神经",
              "entity_type": "Anatomy",
              "start_idx": 18,
              "end_idx": 20,
              "entity_en": "nerve"
            },
            {
              "entity_id": "T99",
              "entity": "视网膜病变",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 28,
              "entity_en": "Retinopathy"
            },
            {
              "entity_id": "T100",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 23,
              "end_idx": 26,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T101",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 31,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T102",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 29,
              "end_idx": 30,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T103",
              "entity": "糖尿病足溃疡",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 38,
              "entity_en": "Diabetic foot ulcer"
            },
            {
              "entity_id": "T104",
              "entity": "足",
              "entity_type": "Anatomy",
              "start_idx": 35,
              "end_idx": 36,
              "entity_en": "foot"
            },
            {
              "entity_id": "T105",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 42,
              "end_idx": 44,
              "entity_en": "Infect"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R29",
              "head_entity_id": "T98",
              "tail_entity_id": "T97"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R30",
              "head_entity_id": "T100",
              "tail_entity_id": "T99"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R31",
              "head_entity_id": "T102",
              "tail_entity_id": "T101"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R32",
              "head_entity_id": "T104",
              "tail_entity_id": "T103"
            }
          ],
          "sentence_en": "Diabetes combined with various serious chronic developmental diseases such as various neuropathy, retinopathy, nephropathy, diabetic foot ulcer with or without infection, etc.;"
        }
      ],
      "paragraph_en": "Diabetes combined with various serious chronic developmental diseases such as various neuropathy, retinopathy, nephropathy, diabetic foot ulcer with or without infection, etc.;"
    },
    {
      "paragraph_id": "22",
      "paragraph": "·糖尿病合并多脏器功能不全如肝肾心肺功能不全等；",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·糖尿病合并多脏器功能不全如肝肾心肺功能不全等；",
          "start_idx": 0,
          "end_idx": 24,
          "entities": [
            {
              "entity_id": "T106",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 1,
              "end_idx": 4,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T107",
              "entity": "肝肾心肺功能不全",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 22,
              "entity_en": "Liver, kidney, heart and lung dysfunction"
            },
            {
              "entity_id": "T108",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 14,
              "end_idx": 15,
              "entity_en": "liver"
            },
            {
              "entity_id": "T109",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 15,
              "end_idx": 16,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T110",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 16,
              "end_idx": 17,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T111",
              "entity": "肺",
              "entity_type": "Anatomy",
              "start_idx": 17,
              "end_idx": 18,
              "entity_en": "lung"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R33",
              "head_entity_id": "T108",
              "tail_entity_id": "T107"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R34",
              "head_entity_id": "T109",
              "tail_entity_id": "T107"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R35",
              "head_entity_id": "T110",
              "tail_entity_id": "T107"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R36",
              "head_entity_id": "T111",
              "tail_entity_id": "T107"
            }
          ],
          "sentence_en": "Diabetes combined with multiple organ dysfunction such as liver, kidney, heart and lung dysfunction;"
        }
      ],
      "paragraph_en": "Diabetes combined with multiple organ dysfunction such as liver, kidney, heart and lung dysfunction;"
    },
    {
      "paragraph_id": "23",
      "paragraph": "·特殊类型糖尿病；",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·特殊类型糖尿病；",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [
            {
              "entity_id": "T112",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "diabetes"
            }
          ],
          "relations": [],
          "sentence_en": "·Special types of diabetes;"
        }
      ],
      "paragraph_en": "·Special types of diabetes;"
    },
    {
      "paragraph_id": "24",
      "paragraph": "·糖尿病患者在门诊治疗过程中，出现严重低血糖或经常出现低血糖症状者；",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·糖尿病患者在门诊治疗过程中，出现严重低血糖或经常出现低血糖症状者；",
          "start_idx": 0,
          "end_idx": 34,
          "entities": [
            {
              "entity_id": "T113",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 1,
              "end_idx": 4,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T114",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "serious"
            },
            {
              "entity_id": "T115",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 22,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T116",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 30,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [],
          "sentence_en": "Diabetic patients who experience severe hypoglycemia or frequent hypoglycemia symptoms during outpatient treatment;"
        }
      ],
      "paragraph_en": "Diabetic patients who experience severe hypoglycemia or frequent hypoglycemia symptoms during outpatient treatment;"
    },
    {
      "paragraph_id": "25",
      "paragraph": "·需要安装胰岛素泵治疗的患者；",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·需要安装胰岛素泵治疗的患者；",
          "start_idx": 0,
          "end_idx": 15,
          "entities": [],
          "relations": [],
          "sentence_en": "Patients who need insulin pump therapy;"
        }
      ],
      "paragraph_en": "Patients who need insulin pump therapy;"
    },
    {
      "paragraph_id": "26",
      "paragraph": "·糖尿病患者需要接受胰岛细胞移植或干细胞治疗者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·糖尿病患者需要接受胰岛细胞移植或干细胞治疗者。",
          "start_idx": 0,
          "end_idx": 24,
          "entities": [
            {
              "entity_id": "T117",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 1,
              "end_idx": 4,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T118",
              "entity": "胰岛细胞移植",
              "entity_type": "Operation",
              "start_idx": 10,
              "end_idx": 16,
              "entity_en": "Islet cell transplantation"
            },
            {
              "entity_id": "T119",
              "entity": "干细胞治疗",
              "entity_type": "Treatment",
              "start_idx": 17,
              "end_idx": 22,
              "entity_en": "Stem Cell Therapy"
            }
          ],
          "relations": [
            {
              "relation_type": "Operation_Disease",
              "relation_id": "R37",
              "head_entity_id": "T118",
              "tail_entity_id": "T117"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R38",
              "head_entity_id": "T119",
              "tail_entity_id": "T117"
            }
          ],
          "sentence_en": "Diabetic patients who need islet cell transplantation or stem cell therapy."
        }
      ],
      "paragraph_en": "Diabetic patients who need islet cell transplantation or stem cell therapy."
    },
    {
      "paragraph_id": "27",
      "paragraph": "糖尿病患者在经住院短期优化血糖控制，完善相关检查和缓解应激状态和病情之后，可在出院前修改为出院可维持的方案或维持住院治疗的方案门诊治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "糖尿病患者在经住院短期优化血糖控制，完善相关检查和缓解应激状态和病情之后，可在出院前修改为出院可维持的方案或维持住院治疗的方案门诊治疗。",
          "start_idx": 0,
          "end_idx": 68,
          "entities": [
            {
              "entity_id": "T120",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T121",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R39",
              "head_entity_id": "T121",
              "tail_entity_id": "T120"
            }
          ],
          "sentence_en": "After optimizing blood sugar control, completing relevant examinations and alleviating stress and condition through short-term hospitalization, diabetic patients can change to outpatient treatment before discharge, which can be maintained after discharge or maintained in hospital."
        }
      ],
      "paragraph_en": "After optimizing blood sugar control, completing relevant examinations and alleviating stress and condition through short-term hospitalization, diabetic patients can change to outpatient treatment before discharge with a plan that can be maintained after discharge or a plan that maintains hospitalization."
    },
    {
      "paragraph_id": "28",
      "paragraph": "2.内分泌科住院糖尿病患者的血糖管理",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.内分泌科住院糖尿病患者的血糖管理",
          "start_idx": 0,
          "end_idx": 18,
          "entities": [
            {
              "entity_id": "T122",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 11,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T123",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 14,
              "end_idx": 16,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R40",
              "head_entity_id": "T123",
              "tail_entity_id": "T122"
            }
          ],
          "sentence_en": "2. Blood glucose management for diabetic patients hospitalized in the endocrinology department"
        }
      ],
      "paragraph_en": "2. Blood glucose management for diabetic patients hospitalized in the endocrinology department"
    },
    {
      "paragraph_id": "29",
      "paragraph": "为了进一步规范内分泌科住院成人糖尿病患者的血糖管理，制定本共识。管理流程见图1，就其中血糖管理部分阐述如下。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "为了进一步规范内分泌科住院成人糖尿病患者的血糖管理，制定本共识。",
          "start_idx": 0,
          "end_idx": 32,
          "entities": [
            {
              "entity_id": "T124",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T125",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 21,
              "end_idx": 23,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R41",
              "head_entity_id": "T125",
              "tail_entity_id": "T124"
            }
          ],
          "sentence_en": "This consensus was developed to further standardize blood glucose management in adult patients with diabetes hospitalized in the endocrinology department."
        },
        {
          "sentence_id": "1",
          "sentence": "管理流程见图1，就其中血糖管理部分阐述如下。",
          "start_idx": 32,
          "end_idx": 54,
          "entities": [
            {
              "entity_id": "T126",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 11,
              "end_idx": 13,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "The management process is shown in Figure 1, and the blood sugar management part is explained as follows."
        }
      ],
      "paragraph_en": "This consensus was developed to further standardize the blood glucose management of hospitalized adult diabetic patients in the endocrinology department. The management process is shown in Figure 1, and the blood glucose management part is described as follows."
    },
    {
      "paragraph_id": "30",
      "paragraph": "(1)管理对象：内分泌科住院的成人糖尿病患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)管理对象：内分泌科住院的成人糖尿病患者。",
          "start_idx": 0,
          "end_idx": 23,
          "entities": [
            {
              "entity_id": "T127",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 20,
              "entity_en": "diabetes"
            }
          ],
          "relations": [],
          "sentence_en": "(1) Management targets: adult patients with diabetes hospitalized in the endocrinology department."
        }
      ],
      "paragraph_en": "(1) Management targets: adult patients with diabetes hospitalized in the endocrinology department."
    },
    {
      "paragraph_id": "31",
      "paragraph": "(2)入院时病情评估：入院即刻血糖(血糖≥16.7mmol/L时，需检测血酮或尿酮、血气、血钠、血钾、血乳酸、肝肾功能、血尿粪常规)、病史(病程、已诊断的并发症和伴发疾病，目前降糖方案及治疗依从性等)、现并存的临床症状、阳性体征和重要的阴性体征(包括生命体征、意识状态、有无脱水体征等）、既往检查的病历资料。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)入院时病情评估：入院即刻血糖(血糖≥16.7mmol/L时，需检测血酮或尿酮、血气、血钠、血钾、血乳酸、肝肾功能、血尿粪常规)、病史(病程、已诊断的并发症和伴发疾病，目前降糖方案及治疗依从性等)、现并存的临床症状、阳性体征和重要的阴性体征(包括生命体征、意识状态、有无脱水体征等）、既往检查的病历资料。",
          "start_idx": 0,
          "end_idx": 154,
          "entities": [
            {
              "entity_id": "T128",
              "entity": "入院即刻血糖",
              "entity_type": "Test_items",
              "start_idx": 11,
              "end_idx": 17,
              "entity_en": "Blood sugar level immediately after admission"
            },
            {
              "entity_id": "T129",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 18,
              "end_idx": 20,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T130",
              "entity": "≥16.7mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 20,
              "end_idx": 31,
              "entity_en": "≥16.7mmol/L"
            },
            {
              "entity_id": "T131",
              "entity": "血酮",
              "entity_type": "Test_items",
              "start_idx": 36,
              "end_idx": 38,
              "entity_en": "Blood ketones"
            },
            {
              "entity_id": "T132",
              "entity": "尿酮",
              "entity_type": "Test_items",
              "start_idx": 39,
              "end_idx": 41,
              "entity_en": "Urine Ketones"
            },
            {
              "entity_id": "T133",
              "entity": "血气",
              "entity_type": "Test_items",
              "start_idx": 42,
              "end_idx": 44,
              "entity_en": "Blood"
            },
            {
              "entity_id": "T134",
              "entity": "血钠",
              "entity_type": "Test_items",
              "start_idx": 45,
              "end_idx": 47,
              "entity_en": "Serum sodium"
            },
            {
              "entity_id": "T135",
              "entity": "血钾",
              "entity_type": "Test_items",
              "start_idx": 48,
              "end_idx": 50,
              "entity_en": "Serum potassium"
            },
            {
              "entity_id": "T136",
              "entity": "血乳酸",
              "entity_type": "Test_items",
              "start_idx": 51,
              "end_idx": 54,
              "entity_en": "Blood lactate"
            },
            {
              "entity_id": "T137",
              "entity": "肝肾功能",
              "entity_type": "Test",
              "start_idx": 55,
              "end_idx": 59,
              "entity_en": "Liver and kidney function"
            },
            {
              "entity_id": "T138",
              "entity": "血尿粪常规",
              "entity_type": "Test",
              "start_idx": 60,
              "end_idx": 65,
              "entity_en": "Blood, urine and stool routine"
            },
            {
              "entity_id": "T139",
              "entity": "脱水体征",
              "entity_type": "Symptom",
              "start_idx": 137,
              "end_idx": 141,
              "entity_en": "Signs of dehydration"
            }
          ],
          "relations": [],
          "sentence_en": "(2) Assessment of the patient's condition upon admission: blood glucose upon admission (when blood glucose ≥16.7 mmol/L, blood ketones or urine ketones, blood gas, blood sodium, blood potassium, blood lactate, liver and kidney function, and blood, urine and stool routine tests are required), medical history (disease course, diagnosed complications and concomitant diseases, current hypoglycemic regimen and treatment compliance, etc.), current coexisting clinical symptoms, positive signs and important negative signs (including vital signs, consciousness status, signs of dehydration, etc.), and medical records of previous examinations."
        }
      ],
      "paragraph_en": "(2) Assessment of the patient's condition upon admission: blood glucose upon admission (when blood glucose ≥16.7 mmol/L, blood ketones or urine ketones, blood gas, blood sodium, blood potassium, blood lactate, liver and kidney function, and blood, urine and stool routine tests are required), medical history (disease course, diagnosed complications and concomitant diseases, current hypoglycemic regimen and treatment compliance, etc.), current coexisting clinical symptoms, positive signs and important negative signs (including vital signs, consciousness status, signs of dehydration, etc.), and medical records of previous examinations."
    },
    {
      "paragraph_id": "32",
      "paragraph": "(3)经上述评估后分类：①合并急危重症者：(a)合并急性并发症：包括糖尿病酮症、DKA、高血糖高渗状态、乳酸酸中毒伴高血糖；(b)低血糖昏迷：(c)合并感染：包括糖尿病足或不明原因发热。②血糖控制差且非急危重症者：(a)符合下述特征的糖代谢严重絮乱状态：间断多次测定随机血糖≥16.7mmol/L；可有轻度脱水体征；血pH正常，尿酮阴性或弱阳性，或血酮≥1.0mmol/L且<3.0mmol/L；有效血浆渗透压<320.0mmol/L；(b)符合下述特征的较高血糖水平：尿酮阴性或血酮<1.0mmo/L、无明显脱水体征且满足空腹血糖(FPG)≥11.1mmol/L或随机血糖≥13.9mmol/L或近期HbA1c≥9.0%；(c)符合下述特征的高血糖水平：FPG<11.1mmol/L，或随机血糖<13.9mmo/L，或HbA1c<9.0%；伴严重慢性并发症或伴发病，或低血糖风险，或长病程，或2种以上口服降糖药或已使用胰岛素；(d)单纯的高血糖水平：FPG<11.1mmol/L，或随机血糖<13.9mmol/L，或HbA1c<9.0%；无明显慢性并发症或伴发病，或2种以因口服降糖药，或未规律饮食药物治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)经上述评估后分类：①合并急危重症者：(a)合并急性并发症：包括糖尿病酮症、DKA、高血糖高渗状态、乳酸酸中毒伴高血糖；(b)低血糖昏迷：(c)合并感染：包括糖尿病足或不明原因发热。",
          "start_idx": 0,
          "end_idx": 93,
          "entities": [
            {
              "entity_id": "T140",
              "entity": "糖尿病酮症",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 39,
              "entity_en": "Diabetic ketoacidosis"
            },
            {
              "entity_id": "T141",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 40,
              "end_idx": 43,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T142",
              "entity": "高血糖高渗状态",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 51,
              "entity_en": "Hyperglycemic hyperosmolar state"
            },
            {
              "entity_id": "T143",
              "entity": "乳酸酸中毒",
              "entity_type": "Disease",
              "start_idx": 52,
              "end_idx": 57,
              "entity_en": "Lactic acidosis"
            },
            {
              "entity_id": "T144",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 61,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T145",
              "entity": "低血糖昏迷",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 70,
              "entity_en": "Hypoglycemia coma"
            },
            {
              "entity_id": "T146",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 76,
              "end_idx": 78,
              "entity_en": "Infect"
            },
            {
              "entity_id": "T147",
              "entity": "糖尿病足",
              "entity_type": "Disease",
              "start_idx": 81,
              "end_idx": 85,
              "entity_en": "Diabetic foot"
            },
            {
              "entity_id": "T148",
              "entity": "足",
              "entity_type": "Anatomy",
              "start_idx": 84,
              "end_idx": 85,
              "entity_en": "foot"
            },
            {
              "entity_id": "T149",
              "entity": "发热",
              "entity_type": "Disease",
              "start_idx": 90,
              "end_idx": 92,
              "entity_en": "fever"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R42",
              "head_entity_id": "T148",
              "tail_entity_id": "T147"
            }
          ],
          "sentence_en": "(3) Classification after the above evaluation: ① Patients with combined critical illnesses: (a) Combined acute complications: including diabetic ketoacidosis, DKA, hyperosmolar hyperglycemic state, lactic acidosis with hyperglycemia; (b) Hypoglycemic coma; (c) Combined infection: including diabetic foot or fever of unknown cause."
        },
        {
          "sentence_id": "1",
          "sentence": "②血糖控制差且非急危重症者：(a)符合下述特征的糖代谢严重絮乱状态：间断多次测定随机血糖≥16.7mmol/L；可有轻度脱水体征；血pH正常，尿酮阴性或弱阳性，或血酮≥1.0mmol/L且<3.0mmol/L；有效血浆渗透压<320.0mmol/L；(b)符合下述特征的较高血糖水平：尿酮阴性或血酮<1.0mmo/L、无明显脱水体征且满足空腹血糖(FPG)≥11.1mmol/L或随机血糖≥13.9mmol/L或近期HbA1c≥9.0%；(c)符合下述特征的高血糖水平：FPG<11.1mmol/L，或随机血糖<13.9mmo/L，或HbA1c<9.0%；伴严重慢性并发症或伴发病，或低血糖风险，或长病程，或2种以上口服降糖药或已使用胰岛素；(d)单纯的高血糖水平：FPG<11.1mmol/L，或随机血糖<13.9mmol/L，或HbA1c<9.0%；无明显慢性并发症或伴发病，或2种以因口服降糖药，或未规律饮食药物治疗。",
          "start_idx": 93,
          "end_idx": 505,
          "entities": [
            {
              "entity_id": "T150",
              "entity": "糖代谢严重絮乱状态",
              "entity_type": "Symptom",
              "start_idx": 24,
              "end_idx": 33,
              "entity_en": "Severe disorder of sugar metabolism"
            },
            {
              "entity_id": "T151",
              "entity": "随机血糖",
              "entity_type": "Test_items",
              "start_idx": 40,
              "end_idx": 44,
              "entity_en": "Random blood sugar"
            },
            {
              "entity_id": "T152",
              "entity": "≥16.7mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 44,
              "end_idx": 55,
              "entity_en": "≥16.7mmol/L"
            },
            {
              "entity_id": "T153",
              "entity": "脱水体征",
              "entity_type": "Symptom",
              "start_idx": 60,
              "end_idx": 64,
              "entity_en": "Signs of dehydration"
            },
            {
              "entity_id": "T154",
              "entity": "血pH",
              "entity_type": "Test_items",
              "start_idx": 65,
              "end_idx": 68,
              "entity_en": "Blood pH"
            },
            {
              "entity_id": "T155",
              "entity": "正常",
              "entity_type": "Test_Value",
              "start_idx": 68,
              "end_idx": 70,
              "entity_en": "normal"
            },
            {
              "entity_id": "T156",
              "entity": "尿酮",
              "entity_type": "Test_items",
              "start_idx": 71,
              "end_idx": 73,
              "entity_en": "Urine Ketones"
            },
            {
              "entity_id": "T157",
              "entity": "阴性",
              "entity_type": "Test_Value",
              "start_idx": 73,
              "end_idx": 75,
              "entity_en": "Negative"
            },
            {
              "entity_id": "T158",
              "entity": "弱阳性",
              "entity_type": "Test_Value",
              "start_idx": 76,
              "end_idx": 79,
              "entity_en": "Weak positive"
            },
            {
              "entity_id": "T159",
              "entity": "血酮",
              "entity_type": "Test_items",
              "start_idx": 81,
              "end_idx": 83,
              "entity_en": "Blood ketones"
            },
            {
              "entity_id": "T160",
              "entity": "≥1.0mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 83,
              "end_idx": 93,
              "entity_en": "≥1.0mmol/L"
            },
            {
              "entity_id": "T161",
              "entity": "<3.0mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 94,
              "end_idx": 104,
              "entity_en": "<3.0mmol/L"
            },
            {
              "entity_id": "T162",
              "entity": "有效血浆渗透压",
              "entity_type": "Test_items",
              "start_idx": 105,
              "end_idx": 112,
              "entity_en": "Effective plasma osmotic pressure"
            },
            {
              "entity_id": "T163",
              "entity": "<320.0mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 112,
              "end_idx": 124,
              "entity_en": "<320.0mmol/L"
            },
            {
              "entity_id": "T164",
              "entity": "较高血糖水平",
              "entity_type": "Symptom",
              "start_idx": 135,
              "end_idx": 141,
              "entity_en": "Higher blood sugar levels"
            },
            {
              "entity_id": "T165",
              "entity": "尿酮",
              "entity_type": "Test_items",
              "start_idx": 142,
              "end_idx": 144,
              "entity_en": "Urine Ketones"
            },
            {
              "entity_id": "T166",
              "entity": "血酮",
              "entity_type": "Test_items",
              "start_idx": 147,
              "end_idx": 149,
              "entity_en": "Blood ketones"
            },
            {
              "entity_id": "T167",
              "entity": "空腹血糖(FPG)",
              "entity_type": "Test_items",
              "start_idx": 169,
              "end_idx": 178,
              "entity_en": "Fasting blood glucose (FPG)"
            },
            {
              "entity_id": "T168",
              "entity": "随机血糖",
              "entity_type": "Test_items",
              "start_idx": 190,
              "end_idx": 194,
              "entity_en": "Random blood sugar"
            },
            {
              "entity_id": "T169",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 208,
              "end_idx": 213,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T170",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 235,
              "end_idx": 238,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T171",
              "entity": "随机血糖",
              "entity_type": "Test_items",
              "start_idx": 251,
              "end_idx": 255,
              "entity_en": "Random blood sugar"
            },
            {
              "entity_id": "T172",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 267,
              "end_idx": 272,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T173",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 333,
              "end_idx": 336,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T174",
              "entity": "随机血糖",
              "entity_type": "Test_items",
              "start_idx": 349,
              "end_idx": 353,
              "entity_en": "Random blood sugar"
            },
            {
              "entity_id": "T175",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 366,
              "end_idx": 371,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T176",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 395,
              "end_idx": 397,
              "entity_en": "oral"
            },
            {
              "entity_id": "T177",
              "entity": "阴性",
              "entity_type": "Test_Value",
              "start_idx": 144,
              "end_idx": 146,
              "entity_en": "Negative"
            },
            {
              "entity_id": "T178",
              "entity": "<1.0mmo/L",
              "entity_type": "Test_Value",
              "start_idx": 149,
              "end_idx": 158,
              "entity_en": "<1.0mmo/L"
            },
            {
              "entity_id": "T179",
              "entity": "≥11.1mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 178,
              "end_idx": 189,
              "entity_en": "≥11.1mmol/L"
            },
            {
              "entity_id": "T180",
              "entity": "≥13.9mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 194,
              "end_idx": 205,
              "entity_en": "≥13.9mmol/L"
            },
            {
              "entity_id": "T181",
              "entity": "≥9.0%",
              "entity_type": "Test_Value",
              "start_idx": 213,
              "end_idx": 218,
              "entity_en": "≥9.0%"
            },
            {
              "entity_id": "T182",
              "entity": "<11.1mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 238,
              "end_idx": 249,
              "entity_en": "<11.1mmol/L"
            },
            {
              "entity_id": "T183",
              "entity": "<13.9mmo/L",
              "entity_type": "Test_Value",
              "start_idx": 255,
              "end_idx": 265,
              "entity_en": "<13.9mmo/L"
            },
            {
              "entity_id": "T184",
              "entity": "<9.0%",
              "entity_type": "Test_Value",
              "start_idx": 272,
              "end_idx": 277,
              "entity_en": "<9.0%"
            },
            {
              "entity_id": "T185",
              "entity": "<11.1mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 336,
              "end_idx": 347,
              "entity_en": "<11.1mmol/L"
            },
            {
              "entity_id": "T186",
              "entity": "<13.9mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 353,
              "end_idx": 364,
              "entity_en": "<13.9mmol/L"
            },
            {
              "entity_id": "T187",
              "entity": "<9.0%",
              "entity_type": "Test_Value",
              "start_idx": 371,
              "end_idx": 376,
              "entity_en": "<9.0%"
            },
            {
              "entity_id": "T188",
              "entity": "高血糖水平",
              "entity_type": "Symptom",
              "start_idx": 229,
              "end_idx": 234,
              "entity_en": "High blood sugar levels"
            },
            {
              "entity_id": "T189",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 292,
              "end_idx": 295,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T190",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 308,
              "end_idx": 310,
              "entity_en": "oral"
            },
            {
              "entity_id": "T191",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 317,
              "end_idx": 320,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T192",
              "entity": "高血糖水平",
              "entity_type": "Symptom",
              "start_idx": 327,
              "end_idx": 332,
              "entity_en": "High blood sugar levels"
            },
            {
              "entity_id": "T193",
              "entity": "脱水体征",
              "entity_type": "Symptom",
              "start_idx": 162,
              "end_idx": 166,
              "entity_en": "Signs of dehydration"
            },
            {
              "entity_id": "T194",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 1,
              "end_idx": 3,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T195",
              "entity": "控制差",
              "entity_type": "Test_Value",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "Poor control"
            }
          ],
          "relations": [],
          "sentence_en": "② Patients with poor blood sugar control and non-critical conditions: (a) Severe disorder of glucose metabolism with the following characteristics: random blood sugar ≥16.7mmol/L measured intermittently and multiple times; mild signs of dehydration; normal blood pH, negative or weakly positive urine ketones, or blood ketones ≥1.0mmol/L and <3.0mmol/L; effective plasma osmotic pressure <320.0mmol/L; (b) Higher blood sugar levels with the following characteristics: negative urine ketones or blood ketones <1.0mmo/L, no obvious signs of dehydration and fasting blood sugar (FPG) ≥11.1mmol/L or random blood sugar ≥13.9mmol/L or Recent HbA1c ≥ 9.0%; (c) High blood sugar level that meets the following characteristics: FPG < 11.1mmol/L, or random blood sugar < 13.9mmo/L, or HbA1c < 9.0%; accompanied by severe chronic complications or comorbidities, or risk of hypoglycemia, or long-term disease course, or more than 2 oral hypoglycemic drugs or use of insulin; (d) Simple high blood sugar level: FPG < 11.1mmol/L, or random blood sugar < 13.9mmol/L, or HbA1c < 9.0%; without obvious chronic complications or comorbidities, or 2 oral hypoglycemic drugs, or irregular diet medication."
        }
      ],
      "paragraph_en": "(3) Classification after the above evaluation: ① Patients with acute and critical illness: (a) Acute complications: including diabetic ketoacidosis, DKA, hyperglycemic hyperosmolar state, lactic acidosis with hyperglycemia; (b) Hypoglycemic coma: (c) Concurrent infection: including diabetic foot or fever of unknown cause. ② Patients with poor blood sugar control and non-acute and critical illness: (a) Severe disorder of glucose metabolism with the following characteristics: random blood sugar ≥16.7mmol/L measured intermittently and multiple times; there may be mild signs of dehydration; normal blood pH, negative or weakly positive urine ketones, or blood ketones ≥1.0mmol/L and <3.0mmol/L; effective plasma osmotic pressure <320.0mmol/L; (b) Higher blood sugar levels with the following characteristics: negative urine ketones or blood ketones <1.0mmo/L, no obvious signs of dehydration and fasting blood glucose (FPG) ≥11.1mmol/L or random blood glucose ≥13.9mmol/L or Recent HbA1c ≥ 9.0%; (c) High blood sugar level that meets the following characteristics: FPG < 11.1mmol/L, or random blood sugar < 13.9mmo/L, or HbA1c < 9.0%; accompanied by severe chronic complications or comorbidities, or risk of hypoglycemia, or long-term disease course, or more than 2 oral hypoglycemic drugs or use of insulin; (d) Simple high blood sugar level: FPG < 11.1mmol/L, or random blood sugar < 13.9mmol/L, or HbA1c < 9.0%; without obvious chronic complications or comorbidities, or 2 oral hypoglycemic drugs, or irregular diet medication."
    },
    {
      "paragraph_id": "33",
      "paragraph": "(4)血糖管理：①合并急危重症：(a)合并急性并发症：DKA、高血糖高渗状态、乳酸酸中毒伴高血糖。严重糖代谢紊乱伴水、电解质、酸碱平衡紊乱时的降糖治疗：此时患者处于急性糖代谢严重紊乱状态，合并脱水、电解质絮乱甚至酸中毒，危及生命。补液和胰岛素的应用有利于最大限度地逆转病情。在积极补液，有效改善组织灌注的同时，给予小剂量短效胰岛素静脉滴注，开始时按每小时每千克体重计算胰岛素的剂量0.1U·kg-1·h-1，每1小时监测血糖。之后根据血糖下降速度调整胰岛素剂量，血糖下降速度一般控制在每小时降低3.9~6.1mmol/L为宜。如第1个小时血糖下降不明显，且脱水已基本纠正，胰岛素剂量可加倍。当血糖降至13.9mmol/L.时，胰岛素剂量减至0.05~0.1U·kg-1·h-1，使血糖稳定在8.0~13.9mmol/L。观察病情，临床症状缓解，消化道症状基本消失，能少量进食后，需皮下注射基胰岛素(即中效胰岛素或长效胰岛素类似物)1~2h后，方可停止胰岛素静脉滴注。静脉输注胰岛素转皮下胰岛素注射时，可选择每日多次胰岛素皮下注射(MDI)或持续皮下胰岛素输注(CSH)。不能正常进食者，可仅给予基础胰岛素，或CSⅡ的基础量，每4~6h监测血糖。基础胰岛素剂量可参照患者院外基础胰岛素剂量，如果院外没有使用胰岛素者，可按0.2U·kg-1·h-1计算。进食主食量不足25g时，可暂时不给予餐前胰岛素，但要观察餐后血糖变化。进食量增加且能规律，或进食后血糖明显增加时，可在三顿主餐前加用短效胰岛素或速效胰岛素类似物，或CSII的餐前大剂量。使用剂量视者进餐情况并参照院外胰岛素剂量，同时监测7次血糖，每2~3天调整1次胰岛素剂量，逐渐控制血糖达到住院糖尿病患者控制目标。患者病情稳定，血糖控制满意后，调整为院外降糖方案，并至少监测1天的7次血糖。院外降糖方案可依据患者具体情况，选择MDI、CSII、预混胰岛素或预混胰岛素类似物2~3次皮下注射，加用或不加用二甲双胍、α-糖苷酶抑制剂。院外血糖控制目标可参照2011年《中国成人2型糖尿病HbA1c控制目标的专家共识》，血糖监测计",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)血糖管理：①合并急危重症：(a)合并急性并发症：DKA、高血糖高渗状态、乳酸酸中毒伴高血糖。严重糖代谢紊乱伴水、电解质、酸碱平衡紊乱时的降糖治疗：此时患者处于急性糖代谢严重紊乱状态，合并脱水、电解质絮乱甚至酸中毒，危及生命。补液和胰岛素的应用有利于最大限度地逆转病情。在积极补液，有效改善组织灌注的同时，给予小剂量短效胰岛素静脉滴注，开始时按每小时每千克体重计算胰岛素的剂量0.1U·kg-1·h-1，每1小时监测血糖。之后根据血糖下降速度调整胰岛素剂量，血糖下降速度一般控制在每小时降低3.9~6.1mmol/L为宜。如第1个小时血糖下降不明显，且脱水已基本纠正，胰岛素剂量可加倍。当血糖降至13.9mmol/L.时，胰岛素剂量减至0.05~0.1U·kg-1·h-1，使血糖稳定在8.0~13.9mmol/L。观察病情，临床症状缓解，消化道症状基本消失，能少量进食后，需皮下注射基胰岛素(即中效胰岛素或长效胰岛素类似物)1~2h后，方可停止胰岛素静脉滴注。静脉输注胰岛素转皮下胰岛素注射时，可选择每日多次胰岛素皮下注射(MDI)或持续皮下胰岛素输注(CSH)。不能正常进食者，可仅给予基础胰岛素，或CSⅡ的基础量，每4~6h监测血糖。基础胰岛素剂量可参照患者院外基础胰岛素剂量，如果院外没有使用胰岛素者，可按0.2U·kg-1·h-1计算。进食主食量不足25g时，可暂时不给予餐前胰岛素，但要观察餐后血糖变化。进食量增加且能规律，或进食后血糖明显增加时，可在三顿主餐前加用短效胰岛素或速效胰岛素类似物，或CSII的餐前大剂量。使用剂量视者进餐情况并参照院外胰岛素剂量，同时监测7次血糖，每2~3天调整1次胰岛素剂量，逐渐控制血糖达到住院糖尿病患者控制目标。患者病情稳定，血糖控制满意后，调整为院外降糖方案，并至少监测1天的7次血糖。院外降糖方案可依据患者具体情况，选择MDI、CSII、预混胰岛素或预混胰岛素类似物2~3次皮下注射，加用或不加用二甲双胍、α-糖苷酶抑制剂。院外血糖控制目标可参照2011年《中国成人2型糖尿病HbA1c控制目标的专家共识》，血糖监测计",
          "start_idx": 0,
          "end_idx": 888,
          "entities": [
            {
              "entity_id": "T196",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 30,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T197",
              "entity": "高血糖高渗状态",
              "entity_type": "Disease",
              "start_idx": 31,
              "end_idx": 38,
              "entity_en": "Hyperglycemic hyperosmolar state"
            },
            {
              "entity_id": "T198",
              "entity": "乳酸酸中毒",
              "entity_type": "Disease",
              "start_idx": 39,
              "end_idx": 44,
              "entity_en": "Lactic acidosis"
            },
            {
              "entity_id": "T199",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 48,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T200",
              "entity": "糖代谢紊乱",
              "entity_type": "Disease",
              "start_idx": 51,
              "end_idx": 56,
              "entity_en": "Disorders of glucose metabolism"
            },
            {
              "entity_id": "T201",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 49,
              "end_idx": 51,
              "entity_en": "serious"
            },
            {
              "entity_id": "T202",
              "entity": "水、电解质、酸碱平衡紊乱",
              "entity_type": "Disease",
              "start_idx": 57,
              "end_idx": 69,
              "entity_en": "Disorders of water, electrolytes, and acid-base balance"
            },
            {
              "entity_id": "T203",
              "entity": "急性",
              "entity_type": "Level",
              "start_idx": 82,
              "end_idx": 84,
              "entity_en": "acute"
            },
            {
              "entity_id": "T204",
              "entity": "糖代谢严重紊乱状态",
              "entity_type": "Disease",
              "start_idx": 84,
              "end_idx": 93,
              "entity_en": "Severe disorder of sugar metabolism"
            },
            {
              "entity_id": "T205",
              "entity": "脱水",
              "entity_type": "Disease",
              "start_idx": 96,
              "end_idx": 98,
              "entity_en": "Dehydration"
            },
            {
              "entity_id": "T206",
              "entity": "电解质絮乱",
              "entity_type": "Disease",
              "start_idx": 99,
              "end_idx": 104,
              "entity_en": "Electrolyte Disorders"
            },
            {
              "entity_id": "T207",
              "entity": "酸中毒",
              "entity_type": "Disease",
              "start_idx": 106,
              "end_idx": 109,
              "entity_en": "Acidosis"
            },
            {
              "entity_id": "T208",
              "entity": "补液",
              "entity_type": "Treatment",
              "start_idx": 115,
              "end_idx": 117,
              "entity_en": "Fluid replacement"
            },
            {
              "entity_id": "T209",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 118,
              "end_idx": 121,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T210",
              "entity": "补液",
              "entity_type": "Treatment",
              "start_idx": 140,
              "end_idx": 142,
              "entity_en": "Fluid replacement"
            },
            {
              "entity_id": "T211",
              "entity": "改善组织灌注",
              "entity_type": "Treatment",
              "start_idx": 145,
              "end_idx": 151,
              "entity_en": "Improve tissue perfusion"
            },
            {
              "entity_id": "T212",
              "entity": "静脉滴注",
              "entity_type": "Method",
              "start_idx": 165,
              "end_idx": 169,
              "entity_en": "Intravenous drip"
            },
            {
              "entity_id": "T213",
              "entity": "短效胰岛素",
              "entity_type": "Drug",
              "start_idx": 160,
              "end_idx": 165,
              "entity_en": "Short-acting insulin"
            },
            {
              "entity_id": "T214",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 184,
              "end_idx": 187,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T215",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 210,
              "end_idx": 212,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T216",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 217,
              "end_idx": 219,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T217",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 225,
              "end_idx": 228,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T218",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 231,
              "end_idx": 233,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T219",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 269,
              "end_idx": 271,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T220",
              "entity": "下降不明显",
              "entity_type": "Test_Value",
              "start_idx": 271,
              "end_idx": 276,
              "entity_en": "No significant decrease"
            },
            {
              "entity_id": "T221",
              "entity": "每小时降低3.9~6.1mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 242,
              "end_idx": 260,
              "entity_en": "Decrease by 3.9~6.1mmol/L per hour"
            },
            {
              "entity_id": "T222",
              "entity": "脱水",
              "entity_type": "Symptom",
              "start_idx": 278,
              "end_idx": 280,
              "entity_en": "Dehydration"
            },
            {
              "entity_id": "T223",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 286,
              "end_idx": 289,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T224",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 296,
              "end_idx": 298,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T225",
              "entity": "13.9mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 300,
              "end_idx": 310,
              "entity_en": "13.9mmol/L"
            },
            {
              "entity_id": "T226",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 313,
              "end_idx": 316,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T227",
              "entity": "0.05~0.1U·kg-1·h-1",
              "entity_type": "Amount",
              "start_idx": 320,
              "end_idx": 338,
              "entity_en": "0.05~0.1U·kg-1·h-1"
            },
            {
              "entity_id": "T228",
              "entity": "0.1U·kg-1·h-1",
              "entity_type": "Amount",
              "start_idx": 190,
              "end_idx": 203,
              "entity_en": "0.1U·kg-1·h-1"
            },
            {
              "entity_id": "T229",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 340,
              "end_idx": 342,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T230",
              "entity": "8.0~13.9mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 345,
              "end_idx": 359,
              "entity_en": "8.0~13.9mmol/L"
            },
            {
              "entity_id": "T231",
              "entity": "皮下注射",
              "entity_type": "Method",
              "start_idx": 390,
              "end_idx": 394,
              "entity_en": "Subcutaneous injection"
            },
            {
              "entity_id": "T232",
              "entity": "基胰岛素",
              "entity_type": "Drug",
              "start_idx": 394,
              "end_idx": 398,
              "entity_en": "Basal insulin"
            },
            {
              "entity_id": "T233",
              "entity": "中效胰岛素",
              "entity_type": "Drug",
              "start_idx": 400,
              "end_idx": 405,
              "entity_en": "Intermediate-acting insulin"
            },
            {
              "entity_id": "T234",
              "entity": "长效胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 406,
              "end_idx": 414,
              "entity_en": "Long-acting insulin analogs"
            },
            {
              "entity_id": "T235",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 425,
              "end_idx": 428,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T236",
              "entity": "静脉滴注",
              "entity_type": "Method",
              "start_idx": 428,
              "end_idx": 432,
              "entity_en": "Intravenous drip"
            },
            {
              "entity_id": "T237",
              "entity": "静脉输注",
              "entity_type": "Method",
              "start_idx": 433,
              "end_idx": 437,
              "entity_en": "Intravenous infusion"
            },
            {
              "entity_id": "T238",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 437,
              "end_idx": 440,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T239",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 443,
              "end_idx": 446,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T240",
              "entity": "注射",
              "entity_type": "Method",
              "start_idx": 446,
              "end_idx": 448,
              "entity_en": "injection"
            },
            {
              "entity_id": "T241",
              "entity": "持续皮下胰岛素输注(CSH)",
              "entity_type": "Method",
              "start_idx": 470,
              "end_idx": 484,
              "entity_en": "Continuous subcutaneous insulin infusion (CSH)"
            },
            {
              "entity_id": "T242",
              "entity": "每日多次胰岛素皮下注射(MDI)",
              "entity_type": "Method",
              "start_idx": 453,
              "end_idx": 469,
              "entity_en": "Multiple daily subcutaneous insulin injections (MDI)"
            },
            {
              "entity_id": "T243",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 499,
              "end_idx": 502,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T244",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 524,
              "end_idx": 527,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T245",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 538,
              "end_idx": 541,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T246",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 552,
              "end_idx": 555,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T247",
              "entity": "0.2U·kg-1·h-1",
              "entity_type": "Amount",
              "start_idx": 559,
              "end_idx": 572,
              "entity_en": "0.2U·kg-1·h-1"
            },
            {
              "entity_id": "T248",
              "entity": "餐前胰岛素",
              "entity_type": "Drug",
              "start_idx": 593,
              "end_idx": 598,
              "entity_en": "Pre-meal insulin"
            },
            {
              "entity_id": "T249",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 603,
              "end_idx": 607,
              "entity_en": "Postprandial blood sugar"
            },
            {
              "entity_id": "T250",
              "entity": "进食后血糖",
              "entity_type": "Test_items",
              "start_idx": 621,
              "end_idx": 626,
              "entity_en": "Blood sugar after eating"
            },
            {
              "entity_id": "T251",
              "entity": "明显增加",
              "entity_type": "Test_Value",
              "start_idx": 626,
              "end_idx": 630,
              "entity_en": "Significant increase"
            },
            {
              "entity_id": "T252",
              "entity": "短效胰岛素",
              "entity_type": "Drug",
              "start_idx": 641,
              "end_idx": 646,
              "entity_en": "Short-acting insulin"
            },
            {
              "entity_id": "T253",
              "entity": "速效胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 647,
              "end_idx": 655,
              "entity_en": "Rapid-acting insulin analogs"
            },
            {
              "entity_id": "T254",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 683,
              "end_idx": 686,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T255",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 695,
              "end_idx": 697,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T256",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 707,
              "end_idx": 710,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T257",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 717,
              "end_idx": 719,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T258",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 723,
              "end_idx": 726,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T259",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 768,
              "end_idx": 770,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T260",
              "entity": "MDI",
              "entity_type": "Method",
              "start_idx": 789,
              "end_idx": 792,
              "entity_en": "MDI"
            },
            {
              "entity_id": "T261",
              "entity": "CSII",
              "entity_type": "Method",
              "start_idx": 793,
              "end_idx": 797,
              "entity_en": "CSII"
            },
            {
              "entity_id": "T262",
              "entity": "皮下注射",
              "entity_type": "Method",
              "start_idx": 816,
              "end_idx": 820,
              "entity_en": "Subcutaneous injection"
            },
            {
              "entity_id": "T263",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 800,
              "end_idx": 803,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T264",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 806,
              "end_idx": 812,
              "entity_en": "Insulin analogs"
            },
            {
              "entity_id": "T265",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 827,
              "end_idx": 831,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T266",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 832,
              "end_idx": 840,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T267",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 862,
              "end_idx": 867,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T268",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 867,
              "end_idx": 872,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T269",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 862,
              "end_idx": 864,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T270",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 457,
              "end_idx": 460,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T271",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 474,
              "end_idx": 477,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T272",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 3,
              "end_idx": 5,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T273",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 843,
              "end_idx": 845,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T274",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 519,
              "end_idx": 521,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T275",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 740,
              "end_idx": 742,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R43",
              "head_entity_id": "T212",
              "tail_entity_id": "T213"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R44",
              "head_entity_id": "T228",
              "tail_entity_id": "T214"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R45",
              "head_entity_id": "T227",
              "tail_entity_id": "T226"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R46",
              "head_entity_id": "T231",
              "tail_entity_id": "T232"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R47",
              "head_entity_id": "T236",
              "tail_entity_id": "T235"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R48",
              "head_entity_id": "T237",
              "tail_entity_id": "T238"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R49",
              "head_entity_id": "T240",
              "tail_entity_id": "T239"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R50",
              "head_entity_id": "T241",
              "tail_entity_id": "T271"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R51",
              "head_entity_id": "T242",
              "tail_entity_id": "T270"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R52",
              "head_entity_id": "T257",
              "tail_entity_id": "T258"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R53",
              "head_entity_id": "T269",
              "tail_entity_id": "T267"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R54",
              "head_entity_id": "T268",
              "tail_entity_id": "T267"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R55",
              "head_entity_id": "T273",
              "tail_entity_id": "T267"
            }
          ],
          "sentence_en": "(4) Blood sugar management: ① Combined acute and critical illness: (a) Combined acute complications: DKA, hyperglycemic hyperosmolar state, lactic acidosis with hyperglycemia. Hypoglycemic treatment for severe glucose metabolism disorder with water, electrolyte, and acid-base balance disorder: At this time, the patient is in a state of acute severe glucose metabolism disorder, combined with dehydration, electrolyte disorder and even acidosis, which is life-threatening. The use of fluid replacement and insulin is conducive to reversing the condition to the greatest extent. While actively rehydrating and effectively improving tissue perfusion, a small dose of short-acting insulin is given by intravenous drip. At the beginning, the insulin dose is calculated as 0.1U·kg-1·h-1 per kilogram of body weight per hour, and blood sugar is monitored every hour. After that, the insulin dose is adjusted according to the rate of blood sugar decline. The rate of blood sugar decline is generally controlled to decrease by 3.9~6.1mmol/L per hour. If the blood sugar drop is not obvious in the first hour and the dehydration has been basically corrected, the insulin dose can be doubled. When blood sugar drops to 13.9mmol/L, the insulin dose is reduced to 0.05~0.1U·kg-1·h-1, so that blood sugar stabilizes at 8.0~13.9mmol/L. Observe the condition, clinical symptoms are relieved, gastrointestinal symptoms basically disappear, and after being able to eat a small amount, basal insulin (i.e., intermediate-acting insulin or long-acting insulin analogs) needs to be injected subcutaneously for 1~2 hours before the insulin intravenous drip can be stopped. When converting intravenous insulin infusion to subcutaneous insulin injection, multiple daily subcutaneous insulin injections (MDI) or continuous subcutaneous insulin infusion (CSH) can be selected. For those who cannot eat normally, only basal insulin or the basal amount of CSⅡ can be given, and blood sugar is monitored every 4~6 hours. The basal insulin dose can refer to the patient's basal insulin dose outside the hospital. If the patient does not use insulin outside the hospital, it can be calculated as 0.2U·kg-1·h-1. When the amount of staple food eaten is less than 25g, pre-meal insulin can be temporarily not given, but the changes in post-meal blood sugar should be observed. When the amount of food intake increases and becomes regular, or when blood sugar increases significantly after eating, short-acting insulin or rapid-acting insulin analogs, or a large pre-meal dose of CSII can be added before the three main meals. The dosage used depends on the patient's meal situation and refers to the out-of-hospital insulin dosage. At the same time, blood sugar is monitored 7 times, and the insulin dosage is adjusted every 2 to 3 days to gradually control blood sugar to achieve the control target for hospitalized diabetic patients. After the patient's condition stabilizes and blood sugar is satisfactorily controlled, the out-of-hospital glucose-lowering plan is adjusted, and blood sugar is monitored at least 7 times a day. The out-of-hospital glucose-lowering plan can be selected according to the patient's specific situation, including 2 to 3 subcutaneous injections of MDI, CSII, premixed insulin or premixed insulin analogs, with or without metformin and α-glucosidase inhibitors. The out-of-hospital blood sugar control target can refer to the 2011 \"Expert Consensus on HbA1c Control Targets for Adults with Type 2 Diabetes in China\", and the blood sugar monitoring meter"
        }
      ],
      "paragraph_en": "(4) Blood sugar management: ① Combined acute and critical illness: (a) Combined acute complications: DKA, hyperglycemic hyperosmolar state, lactic acidosis with hyperglycemia. Hypoglycemic treatment for severe glucose metabolism disorder with water, electrolyte, and acid-base balance disorder: At this time, the patient is in a state of acute severe glucose metabolism disorder, combined with dehydration, electrolyte disorder and even acidosis, which is life-threatening. The use of fluid replacement and insulin is conducive to reversing the condition to the greatest extent. While actively rehydrating and effectively improving tissue perfusion, a small dose of short-acting insulin is given by intravenous drip. At the beginning, the insulin dose is calculated as 0.1U·kg-1·h-1 per kilogram of body weight per hour, and blood sugar is monitored every hour. After that, the insulin dose is adjusted according to the rate of blood sugar decline. The rate of blood sugar decline is generally controlled to decrease by 3.9~6.1mmol/L per hour. If the blood sugar drop is not obvious in the first hour and the dehydration has been basically corrected, the insulin dose can be doubled. When blood sugar drops to 13.9mmol/L, the insulin dose is reduced to 0.05~0.1U·kg-1·h-1, so that blood sugar stabilizes at 8.0~13.9mmol/L. Observe the condition, clinical symptoms are relieved, gastrointestinal symptoms basically disappear, and after being able to eat a small amount, basal insulin (i.e., intermediate-acting insulin or long-acting insulin analogs) needs to be injected subcutaneously for 1~2 hours before the insulin intravenous drip can be stopped. When converting intravenous insulin infusion to subcutaneous insulin injection, multiple daily subcutaneous insulin injections (MDI) or continuous subcutaneous insulin infusion (CSH) can be selected. For those who cannot eat normally, only basal insulin or the basal amount of CSⅡ can be given, and blood sugar is monitored every 4~6 hours. The basal insulin dose can refer to the patient's basal insulin dose outside the hospital. If the patient does not use insulin outside the hospital, it can be calculated as 0.2U·kg-1·h-1. When the amount of staple food eaten is less than 25g, pre-meal insulin can be temporarily not given, but the changes in post-meal blood sugar should be observed. When the amount of food intake increases and becomes regular, or when blood sugar increases significantly after eating, short-acting insulin or rapid-acting insulin analogs, or a large pre-meal dose of CSII can be added before the three main meals. The dosage used depends on the patient's meal situation and refers to the out-of-hospital insulin dosage. At the same time, blood sugar is monitored 7 times, and the insulin dosage is adjusted every 2 to 3 days to gradually control blood sugar to achieve the control target for hospitalized diabetic patients. After the patient's condition stabilizes and blood sugar is satisfactorily controlled, the out-of-hospital glucose-lowering plan is adjusted, and blood sugar is monitored at least 7 times a day. The out-of-hospital glucose-lowering plan can be selected according to the patient's specific situation, including 2 to 3 subcutaneous injections of MDI, CSII, premixed insulin or premixed insulin analogs, with or without metformin and α-glucosidase inhibitors. The out-of-hospital blood sugar control target can refer to the 2011 \"Expert Consensus on HbA1c Control Targets for Adults with Type 2 Diabetes in China\", and the blood sugar monitoring meter"
    },
    {
      "paragraph_id": "34",
      "paragraph": "(b)低血糖昏迷：停止全部降糖治疗药物。静脉推注50%葡萄糖液60ml，继而5%~10%葡萄糖液持续静脉滴注，至意识恢复并保持。监测血糖，至少观察3d。抢救参照《内科学》第八版，以及2013年《中国2型糖尿病防治指南》、2012年《中国糖尿病患者低血糖管理的专家共识》。通常血糖在3~7d后逐渐增高，依据血糖水平和病情及本次低血糖昏迷的诱发因素综合分析，重新选择较为安全的降糖策略。(c)合并感染：包括糖尿病足或不明原因发热。感染可导致难以控制的高血糖，高血糖不利于感染的控制，如患者存在糖尿病足或不明原因发热，严格控制血糖为首要措施，胰岛素治疗为首选，如无严重糖代谢紊乱伴水、电解质酸碱平衡紊乱，应采用CSII或MDI治疗。基础胰岛素剂量可参照患者院外基础胰岛素剂量，如果院外没有使用胰岛素者，可按0.2U·kg1·d1计算。三餐前餐时胰岛素或餐前大剂量视患者进餐情况并参照院外胰岛素剂量，同时监测7次血糖，每2~3天调整1次胰岛素剂量，逐渐控制血糖达到住院糖尿病患者控制目标。如存在严重糖代谢紊乱伴水、电解质酸碱平衡紊乱，应积极补液及静脉胰岛素治疗，具体静脉使用胰岛素的方法与前述“(a)合并急性并发症”部分相同，使血糖稳定在8.0~13.9mmol/L。观察病情，临床症状缓解，过渡至皮下胰岛素注射，应避免低血糖发生。存在严重感染时禁用二甲双胍治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(b)低血糖昏迷：停止全部降糖治疗药物。静脉推注50%葡萄糖液60ml，继而5%~10%葡萄糖液持续静脉滴注，至意识恢复并保持。监测血糖，至少观察3d。抢救参照《内科学》第八版，以及2013年《中国2型糖尿病防治指南》、2012年《中国糖尿病患者低血糖管理的专家共识》。通常血糖在3~7d后逐渐增高，依据血糖水平和病情及本次低血糖昏迷的诱发因素综合分析，重新选择较为安全的降糖策略。(c)合并感染：包括糖尿病足或不明原因发热。感染可导致难以控制的高血糖，高血糖不利于感染的控制，如患者存在糖尿病足或不明原因发热，严格控制血糖为首要措施，胰岛素治疗为首选，如无严重糖代谢紊乱伴水、电解质酸碱平衡紊乱，应采用CSII或MDI治疗。基础胰岛素剂量可参照患者院外基础胰岛素剂量，如果院外没有使用胰岛素者，可按0.2U·kg1·d1计算。三餐前餐时胰岛素或餐前大剂量视患者进餐情况并参照院外胰岛素剂量，同时监测7次血糖，每2~3天调整1次胰岛素剂量，逐渐控制血糖达到住院糖尿病患者控制目标。如存在严重糖代谢紊乱伴水、电解质酸碱平衡紊乱，应积极补液及静脉胰岛素治疗，具体静脉使用胰岛素的方法与前述“(a)合并急性并发症”部分相同，使血糖稳定在8.0~13.9mmol/L。",
          "start_idx": 0,
          "end_idx": 530,
          "entities": [
            {
              "entity_id": "T276",
              "entity": "低血糖昏迷",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Hypoglycemia coma"
            },
            {
              "entity_id": "T277",
              "entity": "静脉推注",
              "entity_type": "Method",
              "start_idx": 20,
              "end_idx": 24,
              "entity_en": "IV push"
            },
            {
              "entity_id": "T278",
              "entity": "50%葡萄糖液",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 31,
              "entity_en": "50% glucose solution"
            },
            {
              "entity_id": "T279",
              "entity": "60ml",
              "entity_type": "Amount",
              "start_idx": 31,
              "end_idx": 35,
              "entity_en": "60ml"
            },
            {
              "entity_id": "T280",
              "entity": "5%~10%葡萄糖液",
              "entity_type": "Drug",
              "start_idx": 38,
              "end_idx": 48,
              "entity_en": "5%~10% glucose solution"
            },
            {
              "entity_id": "T281",
              "entity": "持续静脉滴注",
              "entity_type": "Method",
              "start_idx": 48,
              "end_idx": 54,
              "entity_en": "Continuous intravenous drip"
            },
            {
              "entity_id": "T282",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 99,
              "end_idx": 104,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T283",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 99,
              "end_idx": 101,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T284",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 118,
              "end_idx": 121,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T285",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 123,
              "end_idx": 126,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T286",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 137,
              "end_idx": 139,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T287",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 152,
              "end_idx": 154,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T288",
              "entity": "低血糖昏迷",
              "entity_type": "Disease",
              "start_idx": 162,
              "end_idx": 167,
              "entity_en": "Hypoglycemia coma"
            },
            {
              "entity_id": "T289",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 196,
              "end_idx": 198,
              "entity_en": "Infect"
            },
            {
              "entity_id": "T290",
              "entity": "糖尿病足",
              "entity_type": "Disease",
              "start_idx": 201,
              "end_idx": 205,
              "entity_en": "Diabetic foot"
            },
            {
              "entity_id": "T291",
              "entity": "足",
              "entity_type": "Anatomy",
              "start_idx": 204,
              "end_idx": 205,
              "entity_en": "foot"
            },
            {
              "entity_id": "T292",
              "entity": "发热",
              "entity_type": "Disease",
              "start_idx": 210,
              "end_idx": 212,
              "entity_en": "fever"
            },
            {
              "entity_id": "T293",
              "entity": "感染",
              "entity_type": "Reason",
              "start_idx": 213,
              "end_idx": 215,
              "entity_en": "Infect"
            },
            {
              "entity_id": "T294",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 223,
              "end_idx": 226,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T295",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 227,
              "end_idx": 230,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T296",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 233,
              "end_idx": 235,
              "entity_en": "Infect"
            },
            {
              "entity_id": "T297",
              "entity": "糖尿病足",
              "entity_type": "Disease",
              "start_idx": 244,
              "end_idx": 248,
              "entity_en": "Diabetic foot"
            },
            {
              "entity_id": "T298",
              "entity": "足",
              "entity_type": "Anatomy",
              "start_idx": 247,
              "end_idx": 248,
              "entity_en": "foot"
            },
            {
              "entity_id": "T299",
              "entity": "发热",
              "entity_type": "Disease",
              "start_idx": 253,
              "end_idx": 255,
              "entity_en": "fever"
            },
            {
              "entity_id": "T300",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 268,
              "end_idx": 271,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T301",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 279,
              "end_idx": 281,
              "entity_en": "serious"
            },
            {
              "entity_id": "T302",
              "entity": "糖代谢紊乱",
              "entity_type": "Disease",
              "start_idx": 281,
              "end_idx": 286,
              "entity_en": "Disorders of glucose metabolism"
            },
            {
              "entity_id": "T303",
              "entity": "水、电解质酸碱平衡紊乱",
              "entity_type": "Disease",
              "start_idx": 287,
              "end_idx": 298,
              "entity_en": "Disturbance of water, electrolyte and acid-base balance"
            },
            {
              "entity_id": "T304",
              "entity": "CSII",
              "entity_type": "Method",
              "start_idx": 302,
              "end_idx": 306,
              "entity_en": "CSII"
            },
            {
              "entity_id": "T305",
              "entity": "MDI",
              "entity_type": "Method",
              "start_idx": 307,
              "end_idx": 310,
              "entity_en": "MDI"
            },
            {
              "entity_id": "T306",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 315,
              "end_idx": 318,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T307",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 329,
              "end_idx": 332,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T308",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 343,
              "end_idx": 346,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T309",
              "entity": "0.2U·kg1·d1",
              "entity_type": "Amount",
              "start_idx": 350,
              "end_idx": 361,
              "entity_en": "0.2U·kg1·d1"
            },
            {
              "entity_id": "T310",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 369,
              "end_idx": 372,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T311",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 390,
              "end_idx": 393,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T312",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 402,
              "end_idx": 404,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T313",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 414,
              "end_idx": 417,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T314",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 424,
              "end_idx": 426,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T315",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 430,
              "end_idx": 433,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T316",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 443,
              "end_idx": 445,
              "entity_en": "serious"
            },
            {
              "entity_id": "T317",
              "entity": "糖代谢紊乱",
              "entity_type": "Disease",
              "start_idx": 445,
              "end_idx": 450,
              "entity_en": "Disorders of glucose metabolism"
            },
            {
              "entity_id": "T318",
              "entity": "水、电解质酸碱平衡紊乱",
              "entity_type": "Disease",
              "start_idx": 451,
              "end_idx": 462,
              "entity_en": "Disturbance of water, electrolyte and acid-base balance"
            },
            {
              "entity_id": "T319",
              "entity": "补液",
              "entity_type": "Treatment",
              "start_idx": 466,
              "end_idx": 468,
              "entity_en": "Fluid replacement"
            },
            {
              "entity_id": "T320",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 471,
              "end_idx": 474,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T321",
              "entity": "静脉",
              "entity_type": "Method",
              "start_idx": 469,
              "end_idx": 471,
              "entity_en": "vein"
            },
            {
              "entity_id": "T322",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 483,
              "end_idx": 486,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T323",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 510,
              "end_idx": 512,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T324",
              "entity": "8.0~13.9mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 515,
              "end_idx": 529,
              "entity_en": "8.0~13.9mmol/L"
            },
            {
              "entity_id": "T329",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 66,
              "end_idx": 68,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T330",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 260,
              "end_idx": 262,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R56",
              "head_entity_id": "T277",
              "tail_entity_id": "T278"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R57",
              "head_entity_id": "T279",
              "tail_entity_id": "T278"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R58",
              "head_entity_id": "T281",
              "tail_entity_id": "T280"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R59",
              "head_entity_id": "T283",
              "tail_entity_id": "T282"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R60",
              "head_entity_id": "T287",
              "tail_entity_id": "T288"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R61",
              "head_entity_id": "T291",
              "tail_entity_id": "T290"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R62",
              "head_entity_id": "T293",
              "tail_entity_id": "T294"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R63",
              "head_entity_id": "T298",
              "tail_entity_id": "T297"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R64",
              "head_entity_id": "T300",
              "tail_entity_id": "T297"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R65",
              "head_entity_id": "T330",
              "tail_entity_id": "T297"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R66",
              "head_entity_id": "T300",
              "tail_entity_id": "T299"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R67",
              "head_entity_id": "T330",
              "tail_entity_id": "T299"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R68",
              "head_entity_id": "T304",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R69",
              "head_entity_id": "T305",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R70",
              "head_entity_id": "T309",
              "tail_entity_id": "T306"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R71",
              "head_entity_id": "T314",
              "tail_entity_id": "T315"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R72",
              "head_entity_id": "T319",
              "tail_entity_id": "T317"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R73",
              "head_entity_id": "T320",
              "tail_entity_id": "T317"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R74",
              "head_entity_id": "T319",
              "tail_entity_id": "T318"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R75",
              "head_entity_id": "T320",
              "tail_entity_id": "T318"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R76",
              "head_entity_id": "T321",
              "tail_entity_id": "T320"
            }
          ],
          "sentence_en": "(b) Hypoglycemic coma: Stop all hypoglycemic drugs. Intravenous injection of 60 ml of 50% glucose solution, followed by continuous intravenous drip of 5%-10% glucose solution until consciousness is restored and maintained. Monitor blood sugar and observe for at least 3 days. Rescue refers to the eighth edition of \"Internal Medicine\", the 2013 \"Guidelines for the Prevention and Treatment of Type 2 Diabetes in China\", and the 2012 \"Expert Consensus on the Management of Hypoglycemia in Chinese Diabetic Patients\". Usually, blood sugar gradually increases after 3-7 days. Based on a comprehensive analysis of blood sugar levels, the condition and the inducing factors of this hypoglycemic coma, a safer blood sugar-lowering strategy should be re-selected. (c) Combined infection: including diabetic foot or unexplained fever. Infection can lead to uncontrollable hyperglycemia, which is not conducive to the control of infection. If the patient has diabetic foot or unexplained fever, strict blood sugar control is the primary measure, and insulin treatment is the first choice. If there is no severe glucose metabolism disorder accompanied by water, electrolyte and acid-base balance disorder, CSII or MDI treatment should be used. The basal insulin dose can refer to the patient's out-of-hospital basal insulin dose. If insulin is not used outside the hospital, it can be calculated as 0.2U·kg1·d1. Insulin before three meals or large doses before meals should be used according to the patient's meal situation and refer to the out-of-hospital insulin dose. Monitor blood sugar 7 times at the same time, adjust the insulin dose once every 2 to 3 days, and gradually control blood sugar to achieve the control target for hospitalized diabetic patients. If there is a severe glucose metabolism disorder accompanied by water, electrolyte and acid-base balance disorders, active fluid replacement and intravenous insulin treatment should be given. The specific method of intravenous insulin is the same as the aforementioned \"(a) Combined acute complications\" section to stabilize blood sugar at 8.0~13.9mmol/L."
        },
        {
          "sentence_id": "1",
          "sentence": "观察病情，临床症状缓解，过渡至皮下胰岛素注射，应避免低血糖发生。",
          "start_idx": 530,
          "end_idx": 562,
          "entities": [
            {
              "entity_id": "T325",
              "entity": "皮下胰岛素注射",
              "entity_type": "Method",
              "start_idx": 15,
              "end_idx": 22,
              "entity_en": "Subcutaneous insulin injection"
            },
            {
              "entity_id": "T326",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 20,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T327",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 26,
              "end_idx": 29,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R77",
              "head_entity_id": "T325",
              "tail_entity_id": "T326"
            }
          ],
          "sentence_en": "Observe the condition, and when clinical symptoms are relieved, transition to subcutaneous insulin injection to avoid hypoglycemia."
        },
        {
          "sentence_id": "2",
          "sentence": "存在严重感染时禁用二甲双胍治疗。",
          "start_idx": 562,
          "end_idx": 578,
          "entities": [
            {
              "entity_id": "T328",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 13,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "Metformin treatment is contraindicated in the presence of severe infection."
        }
      ],
      "paragraph_en": "(b) Hypoglycemic coma: Stop all hypoglycemic drugs. Intravenous injection of 60 ml of 50% glucose solution, followed by continuous intravenous drip of 5%-10% glucose solution until consciousness is restored and maintained. Monitor blood sugar and observe for at least 3 days. Rescue refers to the eighth edition of \"Internal Medicine\", the 2013 \"Guidelines for the Prevention and Treatment of Type 2 Diabetes in China\", and the 2012 \"Expert Consensus on the Management of Hypoglycemia in Chinese Diabetic Patients\". Usually, blood sugar gradually increases after 3-7 days. Based on a comprehensive analysis of blood sugar levels, the condition and the inducing factors of this hypoglycemic coma, a safer blood sugar-lowering strategy should be re-selected. (c) Combined infection: including diabetic foot or unexplained fever. Infection can lead to uncontrollable hyperglycemia, which is not conducive to the control of infection. If the patient has diabetic foot or unexplained fever, strict blood sugar control is the primary measure, and insulin treatment is the first choice. If there is no severe glucose metabolism disorder accompanied by water, electrolyte and acid-base balance disorder, CSII or MDI treatment should be used. The basal insulin dose can refer to the patient's out-of-hospital basal insulin dose. If insulin is not used outside the hospital, it can be calculated as 0.2U·kg1·d1. Insulin before three meals or large doses before meals should be used according to the patient's meal situation and refer to the out-of-hospital insulin dose. At the same time, blood sugar should be monitored 7 times, and the insulin dose should be adjusted once every 2 to 3 days to gradually control blood sugar to achieve the control target for hospitalized diabetic patients. If there is a severe glucose metabolism disorder accompanied by water, electrolyte and acid-base balance disorders, fluid replacement and intravenous insulin treatment should be actively performed. The specific method of intravenous insulin use is the same as the aforementioned \"(a) Combined acute complications\" section to stabilize blood sugar at 8.0~13.9mmol/L. Observe the condition, and transition to subcutaneous insulin injection after clinical symptoms are relieved. Hypoglycemia should be avoided. Metformin treatment is prohibited in the presence of severe infection."
    },
    {
      "paragraph_id": "35",
      "paragraph": "②血糖控制差且非急危重症：(a)第1类患者糖代谢紊乱严重，尚未危及生命，但持续高血糖状态可促使病情进展，应积极逆转，是胰岛素治疗的指征。降糖治疗需应用胰岛素，可相对短的时间静脉输注改善高糖毒性，缓解临床症状后改皮下注射。与前述“①合并急危重症者”中“(a)合并急性并发症“部分静脉胰岛素使用原则相同，不同的是开始时胰岛素剂量0.05U·kg-1·d-1，且静脉滴注时间相对短。患者血糖稳定在8.0~11.1mmol/L后2~4h，可改为多次胰岛素(基础一餐时)皮下注射或胰岛素泵治疗。同时改每小时监测血糖为每天检测7次血糖或4~6个监测点，必要时加测夜间血糖。依据血糖调整胰岛素剂量，逐渐控制血糖达到住院糖尿病患者控制目标后调整为院外降糖方案。(b)第2、3类患者均为胰岛素治疗的指征。降糖治疗亦应用胰岛素，最好采用胰岛素强化治疗方案，包括：基础加餐时胰岛素的MDI、CSⅡ、预混胰岛素类似物每日3次皮下注射，优选前两种。胰岛素强化治疗时，胰岛素起始剂量选择可按0.4~0.5U·kg-1·d-1。对于院外已用胰岛素血糖较高且无低血糖者，可直接采用原剂量；对于院外已用胰岛素血糖接近达标或有低血糖者，可采用原剂量的70%~80%。监测7次血糖，必要时加测夜间血糖。依据血糖调整胰岛素用量，逐渐控制血糖达到住院糖尿病患者控制目标后调整为院外降糖方案根据病情可选择加用或不加用口服降糖药及胰升糖素样肽1(GLP-1)受体激动剂。需要关注患者心肝肾功能，尤其是否存在慢性肾脏疾病，以及评估患者的估算肾小球滤过率(eGFR)。二甲双胍、α-糖苷酶抑制剂、噻唑烷二酮类药物等的应用有利于减少胰岛素的用量与血糖的波动(对于肥胖且胰岛素用量较大，已联合上述药物治疗效果不满意者，可试用GLP-1受体激动剂)。因采用胰岛素强化治疗方案，原则上不联用胰岛素促泌剂。(c)第4类患者相对病情轻。对于胰岛素缺乏为主的患者仍应胰岛素治疗，可以基础胰岛素联合口服降糖药治疗，或预混胰岛素2次皮下注射，必要时也可胰岛素强化治疗。每天1次基础或预混胰岛素注射时，胰岛素起始剂量选择0.2U·kg-1·d-1。每天2次预混胰岛素注射时，胰岛素起始剂量选择可按0.2~0.4U·kg-1·d-1，按照1：1比例分配于早晚餐前。对于院外已用胰岛素血糖较高且无低血糖者，可直接采用原剂量；对于院外已用胰岛素血糖接近达标或有低血糖者，可采用原剂量的70%~80%。与前述相同，需要关注患者心肝肾功能，尤其是否存在慢性肾脏疾病，要估算eGFR。二甲双胍、α-糖苷酶抑制剂、噻唑烷二酮类药物等的应用有利于减少胰岛素的用量与血糖的波动。每天2次以上胰岛素注射时原则上不联用胰岛素促泌剂(对于肥胖且胰岛素用量较大，已联合上述药物治疗效果不满意者，可试用GLP-1受体激动剂)。监测7次血糖，或监测FPG、早餐后2h血糖、晚餐前及餐后2h血糖和睡前血糖。必要时加测夜间血糖。(d)对所有患者都应进行生活方式教育和管理及对症治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "②血糖控制差且非急危重症：(a)第1类患者糖代谢紊乱严重，尚未危及生命，但持续高血糖状态可促使病情进展，应积极逆转，是胰岛素治疗的指征。降糖治疗需应用胰岛素，可相对短的时间静脉输注改善高糖毒性，缓解临床症状后改皮下注射。与前述“①合并急危重症者”中“(a)合并急性并发症“部分静脉胰岛素使用原则相同，不同的是开始时胰岛素剂量0.05U·kg-1·d-1，且静脉滴注时间相对短。患者血糖稳定在8.0~11.1mmol/L后2~4h，可改为多次胰岛素(基础一餐时)皮下注射或胰岛素泵治疗。同时改每小时监测血糖为每天检测7次血糖或4~6个监测点，必要时加测夜间血糖。依据血糖调整胰岛素剂量，逐渐控制血糖达到住院糖尿病患者控制目标后调整为院外降糖方案。(b)第2、3类患者均为胰岛素治疗的指征。降糖治疗亦应用胰岛素，最好采用胰岛素强化治疗方案，包括：基础加餐时胰岛素的MDI、CSⅡ、预混胰岛素类似物每日3次皮下注射，优选前两种。胰岛素强化治疗时，胰岛素起始剂量选择可按0.4~0.5U·kg-1·d-1。对于院外已用胰岛素血糖较高且无低血糖者，可直接采用原剂量；对于院外已用胰岛素血糖接近达标或有低血糖者，可采用原剂量的70%~80%。监测7次血糖，必要时加测夜间血糖。依据血糖调整胰岛素用量，逐渐控制血糖达到住院糖尿病患者控制目标后调整为院外降糖方案根据病情可选择加用或不加用口服降糖药及胰升糖素样肽1(GLP-1)受体激动剂。需要关注患者心肝肾功能，尤其是否存在慢性肾脏疾病，以及评估患者的估算肾小球滤过率(eGFR)。二甲双胍、α-糖苷酶抑制剂、噻唑烷二酮类药物等的应用有利于减少胰岛素的用量与血糖的波动(对于肥胖且胰岛素用量较大，已联合上述药物治疗效果不满意者，可试用GLP-1受体激动剂)。因采用胰岛素强化治疗方案，原则上不联用胰岛素促泌剂。(c)第4类患者相对病情轻。对于胰岛素缺乏为主的患者仍应胰岛素治疗，可以基础胰岛素联合口服降糖药治疗，或预混胰岛素2次皮下注射，必要时也可胰岛素强化治疗。每天1次基础或预混胰岛素注射时，胰岛素起始剂量选择0.2U·kg-1·d-1。每天2次预混胰岛素注射时，胰岛素起始剂量选择可按0.2~0.4U·kg-1·d-1，按照1：1比例分配于早晚餐前。对于院外已用胰岛素血糖较高且无低血糖者，可直接采用原剂量；对于院外已用胰岛素血糖接近达标或有低血糖者，可采用原剂量的70%~80%。与前述相同，需要关注患者心肝肾功能，尤其是否存在慢性肾脏疾病，要估算eGFR。",
          "start_idx": 0,
          "end_idx": 1051,
          "entities": [
            {
              "entity_id": "T331",
              "entity": "糖代谢紊乱",
              "entity_type": "Disease",
              "start_idx": 21,
              "end_idx": 26,
              "entity_en": "Disorders of glucose metabolism"
            },
            {
              "entity_id": "T332",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 26,
              "end_idx": 28,
              "entity_en": "serious"
            },
            {
              "entity_id": "T333",
              "entity": "持续高血糖状态",
              "entity_type": "Symptom",
              "start_idx": 37,
              "end_idx": 44,
              "entity_en": "Persistent hyperglycemia"
            },
            {
              "entity_id": "T334",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 62,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T335",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 75,
              "end_idx": 78,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T336",
              "entity": "静脉输注",
              "entity_type": "Method",
              "start_idx": 86,
              "end_idx": 90,
              "entity_en": "Intravenous infusion"
            },
            {
              "entity_id": "T337",
              "entity": "皮下注射",
              "entity_type": "Method",
              "start_idx": 105,
              "end_idx": 109,
              "entity_en": "Subcutaneous injection"
            },
            {
              "entity_id": "T338",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 140,
              "end_idx": 143,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T339",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 157,
              "end_idx": 160,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T340",
              "entity": "0.05U·kg-1·d-1",
              "entity_type": "Amount",
              "start_idx": 162,
              "end_idx": 176,
              "entity_en": "0.05U·kg-1·d-1"
            },
            {
              "entity_id": "T341",
              "entity": "静脉滴注",
              "entity_type": "Method",
              "start_idx": 178,
              "end_idx": 182,
              "entity_en": "Intravenous drip"
            },
            {
              "entity_id": "T342",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 190,
              "end_idx": 192,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T343",
              "entity": "8.0~11.1mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 195,
              "end_idx": 209,
              "entity_en": "8.0~11.1mmol/L"
            },
            {
              "entity_id": "T344",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 220,
              "end_idx": 223,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T345",
              "entity": "皮下注射",
              "entity_type": "Method",
              "start_idx": 230,
              "end_idx": 234,
              "entity_en": "Subcutaneous injection"
            },
            {
              "entity_id": "T346",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 259,
              "end_idx": 261,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T347",
              "entity": "夜间血糖",
              "entity_type": "Test_items",
              "start_idx": 275,
              "end_idx": 279,
              "entity_en": "Nighttime blood sugar"
            },
            {
              "entity_id": "T348",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 282,
              "end_idx": 284,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T349",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 286,
              "end_idx": 289,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T350",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 302,
              "end_idx": 305,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T351",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 334,
              "end_idx": 337,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T352",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 350,
              "end_idx": 353,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T353",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 358,
              "end_idx": 361,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T354",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 376,
              "end_idx": 379,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T355",
              "entity": "MDI",
              "entity_type": "Method",
              "start_idx": 380,
              "end_idx": 383,
              "entity_en": "MDI"
            },
            {
              "entity_id": "T356",
              "entity": "CSⅡ",
              "entity_type": "Method",
              "start_idx": 384,
              "end_idx": 387,
              "entity_en": "CSⅡ"
            },
            {
              "entity_id": "T357",
              "entity": "皮下注射",
              "entity_type": "Method",
              "start_idx": 400,
              "end_idx": 404,
              "entity_en": "Subcutaneous injection"
            },
            {
              "entity_id": "T358",
              "entity": "每日3次",
              "entity_type": "Frequency",
              "start_idx": 396,
              "end_idx": 400,
              "entity_en": "3 times a day"
            },
            {
              "entity_id": "T359",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 411,
              "end_idx": 414,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T360",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 420,
              "end_idx": 423,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T361",
              "entity": "0.4~0.5U·kg-1·d-1",
              "entity_type": "Amount",
              "start_idx": 431,
              "end_idx": 448,
              "entity_en": "0.4~0.5U·kg-1·d-1"
            },
            {
              "entity_id": "T362",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 455,
              "end_idx": 458,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T363",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 458,
              "end_idx": 460,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T364",
              "entity": "较高",
              "entity_type": "Test_Value",
              "start_idx": 460,
              "end_idx": 462,
              "entity_en": "Higher"
            },
            {
              "entity_id": "T365",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 464,
              "end_idx": 467,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T366",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 484,
              "end_idx": 487,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T367",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 487,
              "end_idx": 489,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T368",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 495,
              "end_idx": 498,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T369",
              "entity": "接近达标",
              "entity_type": "Test_Value",
              "start_idx": 489,
              "end_idx": 493,
              "entity_en": "Close to reaching the target"
            },
            {
              "entity_id": "T370",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 519,
              "end_idx": 521,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T371",
              "entity": "夜间血糖",
              "entity_type": "Test_items",
              "start_idx": 527,
              "end_idx": 531,
              "entity_en": "Nighttime blood sugar"
            },
            {
              "entity_id": "T372",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 534,
              "end_idx": 536,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T373",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 538,
              "end_idx": 541,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T374",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 554,
              "end_idx": 557,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T375",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 586,
              "end_idx": 588,
              "entity_en": "oral"
            },
            {
              "entity_id": "T376",
              "entity": "胰升糖素样肽1(GLP-1)受体激动剂",
              "entity_type": "Drug",
              "start_idx": 592,
              "end_idx": 611,
              "entity_en": "Glucagon-like peptide-1 (GLP-1) receptor agonists"
            },
            {
              "entity_id": "T377",
              "entity": "估算肾小球滤过率(eGFR)",
              "entity_type": "Test_items",
              "start_idx": 644,
              "end_idx": 658,
              "entity_en": "Estimated glomerular filtration rate (eGFR)"
            },
            {
              "entity_id": "T378",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 659,
              "end_idx": 663,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T379",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 664,
              "end_idx": 672,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T380",
              "entity": "噻唑烷二酮类药物",
              "entity_type": "Drug",
              "start_idx": 673,
              "end_idx": 681,
              "entity_en": "Thiazolidinediones"
            },
            {
              "entity_id": "T381",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 690,
              "end_idx": 693,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T382",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 697,
              "end_idx": 699,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T383",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 705,
              "end_idx": 707,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T384",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 708,
              "end_idx": 711,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T385",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 735,
              "end_idx": 745,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T386",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 750,
              "end_idx": 753,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T387",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 766,
              "end_idx": 772,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T388",
              "entity": "胰岛素缺乏",
              "entity_type": "Pathogenesis",
              "start_idx": 789,
              "end_idx": 794,
              "entity_en": "Insulin deficiency"
            },
            {
              "entity_id": "T389",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 801,
              "end_idx": 804,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T390",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 811,
              "end_idx": 814,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T391",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 816,
              "end_idx": 818,
              "entity_en": "oral"
            },
            {
              "entity_id": "T392",
              "entity": "2次",
              "entity_type": "Frequency",
              "start_idx": 830,
              "end_idx": 832,
              "entity_en": "2 times"
            },
            {
              "entity_id": "T393",
              "entity": "皮下注射",
              "entity_type": "Method",
              "start_idx": 832,
              "end_idx": 836,
              "entity_en": "Subcutaneous injection"
            },
            {
              "entity_id": "T394",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 842,
              "end_idx": 845,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T395",
              "entity": "每天1次",
              "entity_type": "Frequency",
              "start_idx": 850,
              "end_idx": 854,
              "entity_en": "1 time per day"
            },
            {
              "entity_id": "T396",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 866,
              "end_idx": 869,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T397",
              "entity": "0.2U·kg-1·d-1",
              "entity_type": "Amount",
              "start_idx": 875,
              "end_idx": 888,
              "entity_en": "0.2U·kg-1·d-1"
            },
            {
              "entity_id": "T398",
              "entity": "每天2次",
              "entity_type": "Frequency",
              "start_idx": 889,
              "end_idx": 893,
              "entity_en": "2 times a day"
            },
            {
              "entity_id": "T399",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 825,
              "end_idx": 830,
              "entity_en": "Premixed insulin"
            },
            {
              "entity_id": "T400",
              "entity": "预混胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 388,
              "end_idx": 396,
              "entity_en": "Premixed insulin analogs"
            },
            {
              "entity_id": "T401",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 857,
              "end_idx": 862,
              "entity_en": "Premixed insulin"
            },
            {
              "entity_id": "T402",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 893,
              "end_idx": 898,
              "entity_en": "Premixed insulin"
            },
            {
              "entity_id": "T403",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 902,
              "end_idx": 905,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T404",
              "entity": "0.2~0.4U·kg-1·d-1",
              "entity_type": "Amount",
              "start_idx": 913,
              "end_idx": 930,
              "entity_en": "0.2~0.4U·kg-1·d-1"
            },
            {
              "entity_id": "T405",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 952,
              "end_idx": 955,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T406",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 955,
              "end_idx": 957,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T407",
              "entity": "较高",
              "entity_type": "Test_Value",
              "start_idx": 957,
              "end_idx": 959,
              "entity_en": "Higher"
            },
            {
              "entity_id": "T408",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 961,
              "end_idx": 964,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T409",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 981,
              "end_idx": 984,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T410",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 984,
              "end_idx": 986,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T411",
              "entity": "接近达标",
              "entity_type": "Test_Value",
              "start_idx": 986,
              "end_idx": 990,
              "entity_en": "Close to reaching the target"
            },
            {
              "entity_id": "T412",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 992,
              "end_idx": 995,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T413",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 1046,
              "end_idx": 1050,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T431",
              "entity": "慢性肾脏疾病",
              "entity_type": "Disease",
              "start_idx": 630,
              "end_idx": 636,
              "entity_en": "Chronic kidney disease"
            },
            {
              "entity_id": "T432",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 632,
              "end_idx": 634,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T433",
              "entity": "慢性肾脏疾病",
              "entity_type": "Disease",
              "start_idx": 1036,
              "end_idx": 1042,
              "entity_en": "Chronic kidney disease"
            },
            {
              "entity_id": "T434",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 1038,
              "end_idx": 1040,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T435",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 1,
              "end_idx": 3,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T436",
              "entity": "控制差",
              "entity_type": "Test_Value",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T437",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 296,
              "end_idx": 298,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T438",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 250,
              "end_idx": 252,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T439",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 548,
              "end_idx": 550,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R78",
              "head_entity_id": "T334",
              "tail_entity_id": "T331"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R79",
              "head_entity_id": "T333",
              "tail_entity_id": "T331"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R80",
              "head_entity_id": "T336",
              "tail_entity_id": "T335"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R81",
              "head_entity_id": "T337",
              "tail_entity_id": "T335"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R82",
              "head_entity_id": "T340",
              "tail_entity_id": "T339"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R83",
              "head_entity_id": "T341",
              "tail_entity_id": "T339"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R84",
              "head_entity_id": "T345",
              "tail_entity_id": "T344"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R85",
              "head_entity_id": "T437",
              "tail_entity_id": "T350"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R86",
              "head_entity_id": "T355",
              "tail_entity_id": "T354"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R87",
              "head_entity_id": "T356",
              "tail_entity_id": "T354"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R88",
              "head_entity_id": "T357",
              "tail_entity_id": "T354"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R89",
              "head_entity_id": "T358",
              "tail_entity_id": "T354"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R90",
              "head_entity_id": "T361",
              "tail_entity_id": "T360"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R91",
              "head_entity_id": "T439",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R92",
              "head_entity_id": "T384",
              "tail_entity_id": "T383"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R93",
              "head_entity_id": "T392",
              "tail_entity_id": "T399"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R94",
              "head_entity_id": "T393",
              "tail_entity_id": "T399"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R95",
              "head_entity_id": "T395",
              "tail_entity_id": "T401"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R96",
              "head_entity_id": "T397",
              "tail_entity_id": "T396"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R97",
              "head_entity_id": "T398",
              "tail_entity_id": "T402"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R98",
              "head_entity_id": "T404",
              "tail_entity_id": "T403"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R99",
              "head_entity_id": "T413",
              "tail_entity_id": "T433"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R102",
              "head_entity_id": "T432",
              "tail_entity_id": "T431"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R103",
              "head_entity_id": "T434",
              "tail_entity_id": "T433"
            }
          ],
          "sentence_en": "② Poor blood sugar control and non-critical illness: (a) Category 1 patients have severe glucose metabolism disorders that are not life-threatening, but persistent hyperglycemia can promote disease progression and should be actively reversed, which is an indication for insulin treatment. Insulin is required for hypoglycemic treatment, which can be intravenously infused for a relatively short time to improve hyperglycemia toxicity, and then switched to subcutaneous injection after clinical symptoms are relieved. The principle of using intravenous insulin is the same as that of the \"(a) combined with acute complications\" section of the aforementioned \"① combined with critical illness\", except that the initial insulin dose is 0.05U·kg-1·d-1, and the intravenous infusion time is relatively short. After the patient's blood sugar stabilizes at 8.0~11.1mmol/L for 2~4h, multiple insulin (basic mealtime) subcutaneous injections or insulin pump treatment can be switched. At the same time, blood sugar monitoring is changed from hourly to 7 times a day or 4~6 monitoring points, and nighttime blood sugar is added when necessary. The insulin dose is adjusted according to blood sugar, and blood sugar is gradually controlled to reach the control target for hospitalized diabetic patients, and then adjusted to an out-of-hospital hypoglycemic program. (b) Category 2 and 3 patients are both indications for insulin treatment. Insulin is also used for hypoglycemic treatment. It is best to use an insulin intensive treatment plan, including: MDI, CSⅡ, and premixed insulin analogs of basic mealtime insulin three times a day, preferably the first two. During insulin intensive treatment, the starting dose of insulin can be selected according to 0.4~0.5U·kg-1·d-1. For patients with high blood sugar and no hypoglycemia who have used insulin outside the hospital, the original dose can be used directly; for patients with blood sugar close to the standard or hypoglycemia who have used insulin outside the hospital, 70%~80% of the original dose can be used. Monitor blood sugar 7 times, and add night blood sugar if necessary. Adjust the insulin dosage according to blood sugar, gradually control blood sugar to achieve the control target for hospitalized diabetic patients, and then adjust to the out-of-hospital hypoglycemic plan. Oral hypoglycemic drugs and glucagon-like peptide 1 (GLP-1) receptor agonists can be added or not according to the condition. It is necessary to pay attention to the patient's heart, liver, and kidney function, especially whether there is chronic kidney disease, and evaluate the patient's estimated glomerular filtration rate (eGFR). The use of metformin, α-glucosidase inhibitors, thiazolidinediones, etc. is helpful to reduce the amount of insulin and blood sugar fluctuations (for obese patients with high insulin dosage, who have been treated with the above drugs but are not satisfied with the effect, GLP-1 receptor agonists can be tried). In principle, insulin secretagogues are not used in combination because of the use of insulin intensive treatment. (c) Patients in category 4 are relatively mild. For patients with insulin deficiency, insulin treatment should still be used. Basal insulin combined with oral hypoglycemic drugs can be used, or premixed insulin can be injected subcutaneously twice. If necessary, insulin intensive treatment can also be used. When basal or premixed insulin is injected once a day, the starting dose of insulin is 0.2U·kg-1·d-1. When premixed insulin is injected twice a day, the starting dose of insulin can be 0.2~0.4U·kg-1·d-1, distributed before breakfast and dinner in a 1:1 ratio. For patients who have used insulin outside the hospital and have high blood sugar and no hypoglycemia, the original dose can be used directly; for patients who have used insulin outside the hospital and their blood sugar is close to the standard or have hypoglycemia, 70%~80% of the original dose can be used. As mentioned above, attention should be paid to the patient's heart, liver and kidney function, especially whether there is chronic kidney disease, and eGFR should be estimated."
        },
        {
          "sentence_id": "1",
          "sentence": "二甲双胍、α-糖苷酶抑制剂、噻唑烷二酮类药物等的应用有利于减少胰岛素的用量与血糖的波动。",
          "start_idx": 1051,
          "end_idx": 1095,
          "entities": [
            {
              "entity_id": "T414",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T415",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 13,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T416",
              "entity": "噻唑烷二酮类药物",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 22,
              "entity_en": "Thiazolidinediones"
            },
            {
              "entity_id": "T417",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 31,
              "end_idx": 34,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T418",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 38,
              "end_idx": 40,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "The use of metformin, α-glucosidase inhibitors, thiazolidinediones, etc. is helpful in reducing insulin dosage and blood sugar fluctuations."
        },
        {
          "sentence_id": "2",
          "sentence": "每天2次以上胰岛素注射时原则上不联用胰岛素促泌剂(对于肥胖且胰岛素用量较大，已联合上述药物治疗效果不满意者，可试用GLP-1受体激动剂)。",
          "start_idx": 1095,
          "end_idx": 1164,
          "entities": [
            {
              "entity_id": "T419",
              "entity": "每天2次",
              "entity_type": "Frequency",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "2 times a day"
            },
            {
              "entity_id": "T420",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T421",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 24,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T422",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 29,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T423",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 33,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T424",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 67,
              "entity_en": "GLP-1 receptor agonists"
            }
          ],
          "relations": [
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R100",
              "head_entity_id": "T419",
              "tail_entity_id": "T420"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R101",
              "head_entity_id": "T423",
              "tail_entity_id": "T422"
            }
          ],
          "sentence_en": "In principle, insulin secretagogues should not be used in combination with insulin injections more than twice a day (for those who are obese and require large amounts of insulin, and who have not been satisfied with the results of combined treatment with the above-mentioned drugs, GLP-1 receptor agonists can be tried)."
        },
        {
          "sentence_id": "3",
          "sentence": "监测7次血糖，或监测FPG、早餐后2h血糖、晚餐前及餐后2h血糖和睡前血糖。",
          "start_idx": 1164,
          "end_idx": 1202,
          "entities": [
            {
              "entity_id": "T425",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T426",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 10,
              "end_idx": 13,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T427",
              "entity": "早餐后2h血糖",
              "entity_type": "Test_items",
              "start_idx": 14,
              "end_idx": 21,
              "entity_en": "Blood sugar 2 hours after breakfast"
            },
            {
              "entity_id": "T428",
              "entity": "晚餐前及餐后2h血糖",
              "entity_type": "Test_items",
              "start_idx": 22,
              "end_idx": 32,
              "entity_en": "Blood sugar before and 2 hours after dinner"
            },
            {
              "entity_id": "T429",
              "entity": "睡前血糖",
              "entity_type": "Test_items",
              "start_idx": 33,
              "end_idx": 37,
              "entity_en": "Blood sugar before bed"
            }
          ],
          "relations": [],
          "sentence_en": "Monitor blood sugar 7 times, or monitor FPG, blood sugar 2 hours after breakfast, blood sugar before dinner and 2 hours after meal, and blood sugar before bedtime."
        },
        {
          "sentence_id": "4",
          "sentence": "必要时加测夜间血糖。",
          "start_idx": 1202,
          "end_idx": 1212,
          "entities": [
            {
              "entity_id": "T440",
              "entity": "夜间血糖",
              "entity_type": "Test_items",
              "start_idx": 5,
              "end_idx": 9,
              "entity_en": "Nighttime blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "If necessary, measure blood sugar at night."
        },
        {
          "sentence_id": "5",
          "sentence": "(d)对所有患者都应进行生活方式教育和管理及对症治疗",
          "start_idx": 1212,
          "end_idx": 1238,
          "entities": [
            {
              "entity_id": "T430",
              "entity": "生活方式教育和管理",
              "entity_type": "Treatment",
              "start_idx": 12,
              "end_idx": 21,
              "entity_en": "Lifestyle Education and Management"
            }
          ],
          "relations": [],
          "sentence_en": "(d) All patients should receive lifestyle education and management as well as symptomatic treatment"
        }
      ],
      "paragraph_en": "② Poor blood sugar control and non-critical illness: (a) Category 1 patients have severe glucose metabolism disorders that are not life-threatening, but persistent hyperglycemia can promote disease progression and should be actively reversed, which is an indication for insulin treatment. Insulin is required for hypoglycemic treatment, which can be intravenously infused for a relatively short time to improve hyperglycemia toxicity, and then switched to subcutaneous injection after clinical symptoms are relieved. The principle of using intravenous insulin is the same as that of the \"(a) combined with acute complications\" section of the aforementioned \"① combined with critical illness\", except that the initial insulin dose is 0.05U·kg-1·d-1, and the intravenous infusion time is relatively short. After the patient's blood sugar stabilizes at 8.0~11.1mmol/L for 2~4h, multiple insulin (basic mealtime) subcutaneous injections or insulin pump treatment can be switched. At the same time, blood sugar monitoring is changed from hourly to 7 times a day or 4~6 monitoring points, and nighttime blood sugar is added when necessary. The insulin dose is adjusted according to blood sugar, and blood sugar is gradually controlled to reach the control target for hospitalized diabetic patients, and then adjusted to an out-of-hospital hypoglycemic program. (b) Category 2 and 3 patients are both indications for insulin treatment. Insulin is also used for hypoglycemic treatment. It is best to use an insulin intensive treatment plan, including: MDI, CSⅡ, and premixed insulin analogs of basic mealtime insulin three times a day, preferably the first two. During insulin intensive treatment, the starting dose of insulin can be selected according to 0.4~0.5U·kg-1·d-1. For patients with high blood sugar and no hypoglycemia who have used insulin outside the hospital, the original dose can be used directly; for patients with blood sugar close to the standard or hypoglycemia who have used insulin outside the hospital, 70%~80% of the original dose can be used. Monitor blood sugar 7 times, and add night blood sugar if necessary. Adjust the insulin dosage according to blood sugar, gradually control blood sugar to achieve the control target for hospitalized diabetic patients, and then adjust to the out-of-hospital hypoglycemic plan. Oral hypoglycemic drugs and glucagon-like peptide 1 (GLP-1) receptor agonists can be added or not according to the condition. It is necessary to pay attention to the patient's heart, liver, and kidney function, especially whether there is chronic kidney disease, and evaluate the patient's estimated glomerular filtration rate (eGFR). The use of metformin, α-glucosidase inhibitors, thiazolidinediones, etc. is helpful to reduce the amount of insulin and blood sugar fluctuations (for obese patients with high insulin dosage, who have been treated with the above drugs but are not satisfied with the effect, GLP-1 receptor agonists can be tried). In principle, insulin secretagogues are not used in combination because of the use of insulin intensive treatment. (c) Patients in category 4 are relatively mild. For patients with insulin deficiency, insulin treatment should still be used. Basal insulin combined with oral hypoglycemic drugs can be used, or premixed insulin can be injected subcutaneously twice. If necessary, insulin intensive treatment can also be used. When basal or premixed insulin is injected once a day, the starting dose of insulin is 0.2U·kg-1·d-1. When premixed insulin is injected twice a day, the starting dose of insulin can be 0.2~0.4U·kg-1·d-1, distributed before breakfast and dinner in a 1:1 ratio. For patients who have used insulin outside the hospital and have high blood sugar and no hypoglycemia, the original dose can be used directly; for patients who have used insulin outside the hospital and their blood sugar is close to the standard or have hypoglycemia, 70%~80% of the original dose can be used. As mentioned above, attention should be paid to the patient's heart, liver and kidney function, especially whether there is chronic kidney disease, and eGFR should be estimated. The use of metformin, α-glucosidase inhibitors, thiazolidinediones, etc. is helpful in reducing insulin dosage and blood sugar fluctuations. In principle, insulin secretagogues are not used in combination with more than 2 insulin injections a day (for those who are obese and have a large insulin dosage and are unsatisfied with the combined treatment with the above-mentioned drugs, GLP-1 receptor agonists can be tried). Monitor blood sugar 7 times, or monitor FPG, blood sugar 2 hours after breakfast, blood sugar before dinner and 2 hours after meals, and blood sugar before bedtime. If necessary, add nighttime blood sugar test. (d) All patients should receive lifestyle education, management and symptomatic treatment"
    },
    {
      "paragraph_id": "36",
      "paragraph": "(5)住院糖尿病患者控制目标：具体请见“二、住院患者的血糖控制目标”章节。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(5)住院糖尿病患者控制目标：具体请见“二、住院患者的血糖控制目标”章节。",
          "start_idx": 0,
          "end_idx": 37,
          "entities": [
            {
              "entity_id": "T441",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T442",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 27,
              "end_idx": 29,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R104",
              "head_entity_id": "T442",
              "tail_entity_id": "T441"
            }
          ],
          "sentence_en": "(5) Control targets for hospitalized diabetic patients: Please see the section “II. Blood glucose control targets for hospitalized patients” for details."
        }
      ],
      "paragraph_en": "(5) Control targets for hospitalized diabetic patients: Please see the section “II. Blood glucose control targets for hospitalized patients” for details."
    },
    {
      "paragraph_id": "37",
      "paragraph": "(6)住院期间：①根据院内血糖监测情况、年龄，及入院后完善的检查，包括HbA1c、胰岛功能及其相关抗体、肝肾功能、慢性并发症情况、心血管系统及其相关代谢指标等健康状态评估后确定院内血糖控制目标。2根据上述情况及糖尿病分型完善降糖及综合治疗方案。③制订并实施饮食、运动治疗方案。④全程糖尿病健康指导，包括：饮食、运动、血糖监测、胰岛素注射技术、预防低血糖和糖尿病急性并发症、足保护、体重管理等。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(6)住院期间：①根据院内血糖监测情况、年龄，及入院后完善的检查，包括HbA1c、胰岛功能及其相关抗体、肝肾功能、慢性并发症情况、心血管系统及其相关代谢指标等健康状态评估后确定院内血糖控制目标。2根据上述情况及糖尿病分型完善降糖及综合治疗方案。③制订并实施饮食、运动治疗方案。④全程糖尿病健康指导，包括：饮食、运动、血糖监测、胰岛素注射技术、预防低血糖和糖尿病急性并发症、足保护、体重管理等。",
          "start_idx": 0,
          "end_idx": 196,
          "entities": [
            {
              "entity_id": "T443",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 35,
              "end_idx": 40,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T444",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 105,
              "end_idx": 108,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T445",
              "entity": "饮食、运动治疗方案",
              "entity_type": "Treatment",
              "start_idx": 128,
              "end_idx": 137,
              "entity_en": "Diet and exercise treatment plan"
            },
            {
              "entity_id": "T446",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 141,
              "end_idx": 144,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T447",
              "entity": "健康指导",
              "entity_type": "Treatment",
              "start_idx": 144,
              "end_idx": 148,
              "entity_en": "Health Guidance"
            },
            {
              "entity_id": "T448",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 163,
              "end_idx": 166,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T449",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 173,
              "end_idx": 176,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T450",
              "entity": "糖尿病急性并发症",
              "entity_type": "Disease",
              "start_idx": 177,
              "end_idx": 185,
              "entity_en": "Acute complications of diabetes"
            },
            {
              "entity_id": "T451",
              "entity": "足保护",
              "entity_type": "Treatment",
              "start_idx": 186,
              "end_idx": 189,
              "entity_en": "Foot protection"
            },
            {
              "entity_id": "T452",
              "entity": "体重管理",
              "entity_type": "Treatment",
              "start_idx": 190,
              "end_idx": 194,
              "entity_en": "Weight Management"
            },
            {
              "entity_id": "T453",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 90,
              "end_idx": 92,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T454",
              "entity": "血糖监测",
              "entity_type": "Test_items",
              "start_idx": 158,
              "end_idx": 162,
              "entity_en": "Blood glucose monitoring"
            },
            {
              "entity_id": "T455",
              "entity": "血糖监测",
              "entity_type": "Test_items",
              "start_idx": 13,
              "end_idx": 17,
              "entity_en": "Blood glucose monitoring"
            }
          ],
          "relations": [
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R105",
              "head_entity_id": "T447",
              "tail_entity_id": "T446"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R106",
              "head_entity_id": "T451",
              "tail_entity_id": "T446"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R107",
              "head_entity_id": "T452",
              "tail_entity_id": "T446"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R108",
              "head_entity_id": "T454",
              "tail_entity_id": "T446"
            }
          ],
          "sentence_en": "(6) During hospitalization: ① Determine the in-hospital blood sugar control target based on the in-hospital blood sugar monitoring, age, and comprehensive examinations after admission, including HbA1c, pancreatic islet function and related antibodies, liver and kidney function, chronic complications, cardiovascular system and related metabolic indicators and other health status assessments. 2 Improve the hypoglycemic and comprehensive treatment plan based on the above conditions and diabetes classification. ③ Develop and implement a diet and exercise treatment plan. ④ Provide full diabetes health guidance, including: diet, exercise, blood sugar monitoring, insulin injection technology, prevention of hypoglycemia and acute complications of diabetes, foot protection, weight management, etc."
        }
      ],
      "paragraph_en": "(6) During hospitalization: ① Determine the in-hospital blood sugar control target based on the in-hospital blood sugar monitoring, age, and comprehensive examinations after admission, including HbA1c, pancreatic islet function and related antibodies, liver and kidney function, chronic complications, cardiovascular system and related metabolic indicators and other health status assessments. 2 Improve the hypoglycemic and comprehensive treatment plan based on the above conditions and diabetes classification. ③ Develop and implement a diet and exercise treatment plan. ④ Provide full diabetes health guidance, including: diet, exercise, blood sugar monitoring, insulin injection technology, prevention of hypoglycemia and acute complications of diabetes, foot protection, weight management, etc."
    },
    {
      "paragraph_id": "38",
      "paragraph": "(7)出院前准备：①制订院外降糖及综合治疗方案。院外降糖方案在住院期间逐步形成，或胰岛素强化治疗转为院外非胰岛素强化治疗方案时需要至少监测1天的7次血糖，以评估治疗方案的有效性和安全性。告知血糖监测频率和控制目标。③制订体重管理与生活方式计划。④告知随访时间和内容。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(7)出院前准备：①制订院外降糖及综合治疗方案。",
          "start_idx": 0,
          "end_idx": 24,
          "entities": [
            {
              "entity_id": "T461",
              "entity": "院外降糖及综合治疗方案",
              "entity_type": "Treatment",
              "start_idx": 12,
              "end_idx": 23,
              "entity_en": "Out-of-hospital hypoglycemic and comprehensive treatment plan"
            }
          ],
          "relations": [],
          "sentence_en": "(7) Preparation before discharge: ① Develop an outpatient hypoglycemic and comprehensive treatment plan."
        },
        {
          "sentence_id": "1",
          "sentence": "院外降糖方案在住院期间逐步形成，或胰岛素强化治疗转为院外非胰岛素强化治疗方案时需要至少监测1天的7次血糖，以评估治疗方案的有效性和安全性。",
          "start_idx": 24,
          "end_idx": 93,
          "entities": [
            {
              "entity_id": "T456",
              "entity": "7次血糖",
              "entity_type": "Test_items",
              "start_idx": 48,
              "end_idx": 52,
              "entity_en": "7 blood sugar"
            },
            {
              "entity_id": "T459",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 20,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T460",
              "entity": "院外非胰岛素强化治疗方案",
              "entity_type": "Treatment",
              "start_idx": 26,
              "end_idx": 38,
              "entity_en": "Out-of-hospital non-insulin intensive treatment regimen"
            }
          ],
          "relations": [],
          "sentence_en": "When an out-of-hospital glucose-lowering regimen is gradually formed during hospitalization, or when insulin-intensive therapy is converted to an out-of-hospital non-insulin-intensive therapy, blood glucose needs to be monitored at least seven times a day to evaluate the effectiveness and safety of the treatment regimen."
        },
        {
          "sentence_id": "2",
          "sentence": "告知血糖监测频率和控制目标。",
          "start_idx": 93,
          "end_idx": 107,
          "entities": [
            {
              "entity_id": "T462",
              "entity": "血糖监测",
              "entity_type": "Test_items",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Blood glucose monitoring"
            }
          ],
          "relations": [],
          "sentence_en": "Inform the frequency of blood glucose monitoring and control targets."
        },
        {
          "sentence_id": "3",
          "sentence": "③制订体重管理与生活方式计划。",
          "start_idx": 107,
          "end_idx": 122,
          "entities": [
            {
              "entity_id": "T457",
              "entity": "体重管理",
              "entity_type": "Treatment",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Weight Management"
            },
            {
              "entity_id": "T458",
              "entity": "生活方式计划",
              "entity_type": "Treatment",
              "start_idx": 8,
              "end_idx": 14,
              "entity_en": "Lifestyle Plan"
            }
          ],
          "relations": [],
          "sentence_en": "③Develop a weight management and lifestyle plan."
        },
        {
          "sentence_id": "4",
          "sentence": "④告知随访时间和内容。",
          "start_idx": 122,
          "end_idx": 133,
          "entities": [],
          "relations": [],
          "sentence_en": "④Inform the follow-up time and content."
        }
      ],
      "paragraph_en": "(7) Preparation before discharge: ① Develop an outpatient glucose-lowering and comprehensive treatment plan. The outpatient glucose-lowering plan is gradually formed during hospitalization, or when the insulin-intensive treatment is converted to an outpatient non-insulin-intensive treatment plan, blood sugar needs to be monitored at least 7 times a day to evaluate the effectiveness and safety of the treatment plan. Inform the patient of the frequency of blood sugar monitoring and control targets. ③ Develop a weight management and lifestyle plan. ④ Inform the follow-up time and content."
    },
    {
      "paragraph_id": "39",
      "paragraph": "(二)非内分泌科住院的糖尿病或高血糖患者的血糖管理",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(二)非内分泌科住院的糖尿病或高血糖患者的血糖管理",
          "start_idx": 0,
          "end_idx": 25,
          "entities": [
            {
              "entity_id": "T463",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 14,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T464",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T465",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 21,
              "end_idx": 23,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R109",
              "head_entity_id": "T465",
              "tail_entity_id": "T463"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R110",
              "head_entity_id": "T465",
              "tail_entity_id": "T464"
            }
          ],
          "sentence_en": "2. Blood glucose management for non-endocrinology hospitalized patients with diabetes or hyperglycemia"
        }
      ],
      "paragraph_en": "2. Blood glucose management for non-endocrinology hospitalized patients with diabetes or hyperglycemia"
    },
    {
      "paragraph_id": "40",
      "paragraph": "对非内分泌科住院的糖尿病或高血糖患者的管理流程同样参见图1，如下详细阐述了其中血糖管理部分。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对非内分泌科住院的糖尿病或高血糖患者的管理流程同样参见图1，如下详细阐述了其中血糖管理部分。",
          "start_idx": 0,
          "end_idx": 46,
          "entities": [
            {
              "entity_id": "T466",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T467",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 16,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T468",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 39,
              "end_idx": 41,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R111",
              "head_entity_id": "T468",
              "tail_entity_id": "T466"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R112",
              "head_entity_id": "T468",
              "tail_entity_id": "T467"
            }
          ],
          "sentence_en": "The management process for non-endocrinology hospitalized patients with diabetes or hyperglycemia is also shown in Figure 1, and the blood glucose management part is explained in detail below."
        }
      ],
      "paragraph_en": "The management process for non-endocrinology hospitalized patients with diabetes or hyperglycemia is also shown in Figure 1, and the blood glucose management part is explained in detail below."
    },
    {
      "paragraph_id": "41",
      "paragraph": "1.管理对象",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.管理对象",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "1. Management Objects"
        }
      ],
      "paragraph_en": "1. Management Objects"
    },
    {
      "paragraph_id": "42",
      "paragraph": "非内分泌科住院的成人糖尿病或高血糖患者。包括既往明确诊断的糖尿病患者和既往无糖尿病史，在住院期间出现高血糖的患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "非内分泌科住院的成人糖尿病或高血糖患者。",
          "start_idx": 0,
          "end_idx": 20,
          "entities": [
            {
              "entity_id": "T469",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 13,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T470",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 17,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "Adult patients with diabetes or hyperglycemia who are hospitalized in non-endocrinology departments."
        },
        {
          "sentence_id": "1",
          "sentence": "包括既往明确诊断的糖尿病患者和既往无糖尿病史，在住院期间出现高血糖的患者。",
          "start_idx": 20,
          "end_idx": 57,
          "entities": [
            {
              "entity_id": "T471",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T472",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 21,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T473",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 30,
              "end_idx": 33,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "This includes patients with previously diagnosed diabetes and patients with no history of diabetes who develop hyperglycemia during hospitalization."
        }
      ],
      "paragraph_en": "Adult patients with diabetes or hyperglycemia who are hospitalized in non-endocrinology departments. This includes patients with previously diagnosed diabetes and patients with no history of diabetes who develop hyperglycemia during hospitalization."
    },
    {
      "paragraph_id": "43",
      "paragraph": "2.入院时病情评估",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.入院时病情评估",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [],
          "relations": [],
          "sentence_en": "2. Assessment of condition upon admission"
        }
      ],
      "paragraph_en": "2. Assessment of condition upon admission"
    },
    {
      "paragraph_id": "44",
      "paragraph": "(1)既往无糖尿病史患者，入院后出现血糖水平持续并显著高于7.8mmo/L，则需重新评估，制订诊治方案；HbA1c≥6.5%，提示入院前已存在高糖状态。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)既往无糖尿病史患者，入院后出现血糖水平持续并显著高于7.8mmo/L，则需重新评估，制订诊治方案；HbA1c≥6.5%，提示入院前已存在高糖状态。",
          "start_idx": 0,
          "end_idx": 76,
          "entities": [
            {
              "entity_id": "T474",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T475",
              "entity": "血糖水平",
              "entity_type": "Test_items",
              "start_idx": 18,
              "end_idx": 22,
              "entity_en": "Blood sugar levels"
            },
            {
              "entity_id": "T476",
              "entity": "高于7.8mmo/L",
              "entity_type": "Test_Value",
              "start_idx": 27,
              "end_idx": 37,
              "entity_en": "Higher than 7.8mmo/L"
            },
            {
              "entity_id": "T477",
              "entity": "HbA1",
              "entity_type": "Test_items",
              "start_idx": 52,
              "end_idx": 56,
              "entity_en": "HbA1"
            },
            {
              "entity_id": "T478",
              "entity": "c≥6.5%",
              "entity_type": "Test_Value",
              "start_idx": 56,
              "end_idx": 62,
              "entity_en": "c≥6.5%"
            },
            {
              "entity_id": "T479",
              "entity": "高糖状态",
              "entity_type": "Symptom",
              "start_idx": 71,
              "end_idx": 75,
              "entity_en": "High sugar state"
            }
          ],
          "relations": [],
          "sentence_en": "(1) Patients with no history of diabetes who have persistent and significantly higher blood sugar levels than 7.8 mmol/L after admission require re-evaluation and a treatment plan; HbA1c ≥ 6.5% indicates that hyperglycemia existed before admission."
        }
      ],
      "paragraph_en": "(1) Patients with no history of diabetes who have persistent and significantly higher blood sugar levels than 7.8 mmol/L after admission require re-evaluation and a treatment plan; HbA1c ≥ 6.5% indicates that hyperglycemia existed before admission."
    },
    {
      "paragraph_id": "45",
      "paragraph": "(2)既往有糖尿病史患者，既往3个月内如未行HbA1c检测，入院后则需进行HbA1c检测；",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)既往有糖尿病史患者，既往3个月内如未行HbA1c检测，入院后则需进行HbA1c检测；",
          "start_idx": 0,
          "end_idx": 45,
          "entities": [
            {
              "entity_id": "T480",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T481",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 22,
              "end_idx": 27,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T482",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 37,
              "end_idx": 42,
              "entity_en": "HbA1c"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R113",
              "head_entity_id": "T482",
              "tail_entity_id": "T480"
            }
          ],
          "sentence_en": "(2) Patients with a history of diabetes who have not undergone HbA1c testing within the past 3 months are required to undergo HbA1c testing upon admission;"
        }
      ],
      "paragraph_en": "(2) Patients with a history of diabetes who have not undergone HbA1c testing within the past 3 months are required to undergo HbA1c testing upon admission;"
    },
    {
      "paragraph_id": "46",
      "paragraph": "(3)糖尿病患者，询问既往有无低血糖事件，评判发生低血糖的风险程度。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)糖尿病患者，询问既往有无低血糖事件，评判发生低血糖的风险程度。",
          "start_idx": 0,
          "end_idx": 34,
          "entities": [
            {
              "entity_id": "T483",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T484",
              "entity": "低血糖事件",
              "entity_type": "Symptom",
              "start_idx": 15,
              "end_idx": 20,
              "entity_en": "Hypoglycemic events"
            },
            {
              "entity_id": "T485",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 28,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R114",
              "head_entity_id": "T484",
              "tail_entity_id": "T483"
            }
          ],
          "sentence_en": "(3) For diabetic patients, ask whether they have had any hypoglycemia events in the past and assess the risk of hypoglycemia."
        }
      ],
      "paragraph_en": "(3) For diabetic patients, ask whether they have had any hypoglycemia events in the past and assess the risk of hypoglycemia."
    },
    {
      "paragraph_id": "47",
      "paragraph": "(4)原发疾病的病情评估：年龄、预期寿命、是否存在器官功能不全、精神或智力障碍、心脑血管疾病既往史和(或)风险程度、是否需重症监护、是否需进行手术、手术的类型(急症、择期、整形等精细手术、或器官移植手术)；患者的营养状态、进食情况(禁食、正常摄食,或胃肠外营养)等。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)原发疾病的病情评估：年龄、预期寿命、是否存在器官功能不全、精神或智力障碍、心脑血管疾病既往史和(或)风险程度、是否需重症监护、是否需进行手术、手术的类型(急症、择期、整形等精细手术、或器官移植手术)；患者的营养状态、进食情况(禁食、正常摄食,或胃肠外营养)等。",
          "start_idx": 0,
          "end_idx": 133,
          "entities": [
            {
              "entity_id": "T486",
              "entity": "器官移植手术",
              "entity_type": "Operation",
              "start_idx": 95,
              "end_idx": 101,
              "entity_en": "Organ transplant surgery"
            },
            {
              "entity_id": "T487",
              "entity": "急症、择期、整形等精细手术",
              "entity_type": "Operation",
              "start_idx": 80,
              "end_idx": 93,
              "entity_en": "Emergency, elective, plastic surgery and other delicate surgeries"
            },
            {
              "entity_id": "T488",
              "entity": "心脑血管疾病",
              "entity_type": "Disease",
              "start_idx": 40,
              "end_idx": 46,
              "entity_en": "Cardiovascular and cerebrovascular diseases"
            },
            {
              "entity_id": "T489",
              "entity": "精神或智力障碍",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 39,
              "entity_en": "Mental or intellectual disability"
            },
            {
              "entity_id": "T490",
              "entity": "心脑血管",
              "entity_type": "Anatomy",
              "start_idx": 40,
              "end_idx": 44,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R115",
              "head_entity_id": "T490",
              "tail_entity_id": "T488"
            }
          ],
          "sentence_en": "(4) Assessment of the primary disease: age, life expectancy, presence of organ dysfunction, mental or intellectual disability, history of cardiovascular and cerebrovascular disease and/or risk level, need for intensive care, need for surgery, type of surgery (emergency, elective, delicate surgery such as plastic surgery, or organ transplantation); nutritional status and eating habits of the patient (fasting, normal food intake, or parenteral nutrition), etc."
        }
      ],
      "paragraph_en": "(4) Assessment of the primary disease: age, life expectancy, presence of organ dysfunction, mental or intellectual disability, history of cardiovascular and cerebrovascular disease and/or risk level, need for intensive care, need for surgery, type of surgery (emergency, elective, delicate surgery such as plastic surgery, or organ transplantation); nutritional status and eating habits of the patient (fasting, normal food intake, or parenteral nutrition), etc."
    },
    {
      "paragraph_id": "48",
      "paragraph": "3.血糖管理目标",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.血糖管理目标",
          "start_idx": 0,
          "end_idx": 8,
          "entities": [
            {
              "entity_id": "T491",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "3. Blood sugar management goals"
        }
      ],
      "paragraph_en": "3. Blood sugar management goals"
    },
    {
      "paragraph_id": "49",
      "paragraph": "经上述评估后，对血糖管理目标进行分类：",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "经上述评估后，对血糖管理目标进行分类：",
          "start_idx": 0,
          "end_idx": 19,
          "entities": [
            {
              "entity_id": "T492",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 8,
              "end_idx": 10,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "After the above assessment, blood sugar management goals are classified as follows:"
        }
      ],
      "paragraph_en": "After the above assessment, blood sugar management goals are classified as follows:"
    },
    {
      "paragraph_id": "50",
      "paragraph": "(1)如年轻的新诊断糖尿病患者和低血糖低危人群，在接受内科治疗的同时需严格控制血糖；其他内科疾病患者，若是高龄、或无法耐受低血糖、或存在器官功能不全，或预期寿命<5年、存在精神或智力障碍、本身是心脑血管疾病患者或心脑血管疾病高危人群,仅需宽松或一般控制血糖。对于重症监护患者、或拟进行急症和择期大中小手术的患者，在术前、术中和术后建议宽松控制血糖；对于精细手术(如整形手术)，血糖需严格控制;对于器官移植手术需一般控制血糖。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)如年轻的新诊断糖尿病患者和低血糖低危人群，在接受内科治疗的同时需严格控制血糖；其他内科疾病患者，若是高龄、或无法耐受低血糖、或存在器官功能不全，或预期寿命<5年、存在精神或智力障碍、本身是心脑血管疾病患者或心脑血管疾病高危人群,仅需宽松或一般控制血糖。",
          "start_idx": 0,
          "end_idx": 129,
          "entities": [
            {
              "entity_id": "T493",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 13,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T494",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 19,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T495",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 61,
              "end_idx": 64,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T496",
              "entity": "器官功能不全",
              "entity_type": "Disease",
              "start_idx": 68,
              "end_idx": 74,
              "entity_en": "Organ dysfunction"
            },
            {
              "entity_id": "T497",
              "entity": "精神或智力障碍",
              "entity_type": "Disease",
              "start_idx": 86,
              "end_idx": 93,
              "entity_en": "Mental or intellectual disability"
            },
            {
              "entity_id": "T501",
              "entity": "心脑血管疾病",
              "entity_type": "Disease",
              "start_idx": 97,
              "end_idx": 103,
              "entity_en": "Cardiovascular and cerebrovascular diseases"
            },
            {
              "entity_id": "T502",
              "entity": "心脑血管疾病",
              "entity_type": "Disease",
              "start_idx": 106,
              "end_idx": 112,
              "entity_en": "Cardiovascular and cerebrovascular diseases"
            },
            {
              "entity_id": "T503",
              "entity": "心脑血管",
              "entity_type": "Anatomy",
              "start_idx": 97,
              "end_idx": 101,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T504",
              "entity": "心脑血管",
              "entity_type": "Anatomy",
              "start_idx": 106,
              "end_idx": 110,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T505",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 126,
              "end_idx": 128,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T506",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 39,
              "end_idx": 41,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R116",
              "head_entity_id": "T506",
              "tail_entity_id": "T493"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R117",
              "head_entity_id": "T506",
              "tail_entity_id": "T494"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R118",
              "head_entity_id": "T503",
              "tail_entity_id": "T501"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R119",
              "head_entity_id": "T504",
              "tail_entity_id": "T502"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R120",
              "head_entity_id": "T505",
              "tail_entity_id": "T502"
            }
          ],
          "sentence_en": "(1) Young patients with newly diagnosed diabetes and people at low risk of hypoglycemia need to strictly control their blood sugar while receiving medical treatment. Patients with other medical diseases, such as those who are elderly, cannot tolerate hypoglycemia, have organ dysfunction, have a life expectancy of less than 5 years, have mental or intellectual disabilities, or are patients with cardiovascular and cerebrovascular diseases or people at high risk of cardiovascular and cerebrovascular diseases, only need loose or general blood sugar control."
        },
        {
          "sentence_id": "1",
          "sentence": "对于重症监护患者、或拟进行急症和择期大中小手术的患者，在术前、术中和术后建议宽松控制血糖；对于精细手术(如整形手术)，血糖需严格控制;对于器官移植手术需一般控制血糖。",
          "start_idx": 129,
          "end_idx": 212,
          "entities": [
            {
              "entity_id": "T498",
              "entity": "整形手术",
              "entity_type": "Operation",
              "start_idx": 53,
              "end_idx": 57,
              "entity_en": "Plastic surgery"
            },
            {
              "entity_id": "T499",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 59,
              "end_idx": 61,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T500",
              "entity": "器官移植手术",
              "entity_type": "Operation",
              "start_idx": 69,
              "end_idx": 75,
              "entity_en": "Organ transplant surgery"
            },
            {
              "entity_id": "T507",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 80,
              "end_idx": 82,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T508",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 42,
              "end_idx": 44,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "For patients in intensive care, or those who are scheduled to undergo emergency or elective major, medium or minor surgery, loose blood sugar control is recommended before, during and after surgery; for delicate surgery (such as plastic surgery), blood sugar needs to be strictly controlled; for organ transplant surgery, general blood sugar control is required."
        }
      ],
      "paragraph_en": "(1) For young newly diagnosed diabetic patients and people at low risk of hypoglycemia, strict blood sugar control is required while receiving medical treatment; for other patients with medical diseases, if they are elderly, cannot tolerate hypoglycemia, have organ dysfunction, or have a life expectancy of less than 5 years, have mental or intellectual disabilities, are patients with cardiovascular and cerebrovascular diseases or are at high risk of cardiovascular and cerebrovascular diseases, only loose or general blood sugar control is required. For patients in intensive care or patients who are scheduled for emergency and elective major, medium or small surgery, loose blood sugar control is recommended before, during and after surgery; for delicate surgery (such as plastic surgery), blood sugar needs to be strictly controlled; for organ transplant surgery, blood sugar needs to be generally controlled."
    },
    {
      "paragraph_id": "51",
      "paragraph": "(2)严格、一般和宽松血糖控制目标的定义详见本共识“二、住院患者的血糖控制目标“部分。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)严格、一般和宽松血糖控制目标的定义详见本共识“二、住院患者的血糖控制目标“部分。",
          "start_idx": 0,
          "end_idx": 43,
          "entities": [
            {
              "entity_id": "T509",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 11,
              "end_idx": 13,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T510",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 33,
              "end_idx": 35,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "(2) The definitions of strict, general, and loose blood glucose control targets are detailed in section “II. Blood glucose control targets for hospitalized patients” of this consensus."
        }
      ],
      "paragraph_en": "(2) The definitions of strict, general, and loose blood glucose control targets are detailed in section “II. Blood glucose control targets for hospitalized patients” of this consensus."
    },
    {
      "paragraph_id": "52",
      "paragraph": "4.血糖管理措施",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.血糖管理措施",
          "start_idx": 0,
          "end_idx": 8,
          "entities": [
            {
              "entity_id": "T511",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "4. Blood sugar management measures"
        }
      ],
      "paragraph_en": "4. Blood sugar management measures"
    },
    {
      "paragraph_id": "53",
      "paragraph": "(1)对血糖控制未达标的非内分泌科住院高血糖患者，尤其在合并有糖尿病酮症、DKA和糖尿病高渗状态等急性并发症的患者，建议邀请内分泌专科医生协同诊治。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)对血糖控制未达标的非内分泌科住院高血糖患者，尤其在合并有糖尿病酮症、DKA和糖尿病高渗状态等急性并发症的患者，建议邀请内分泌专科医生协同诊治。",
          "start_idx": 0,
          "end_idx": 74,
          "entities": [
            {
              "entity_id": "T512",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 22,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T513",
              "entity": "糖尿病酮症",
              "entity_type": "Disease",
              "start_idx": 31,
              "end_idx": 36,
              "entity_en": "Diabetic ketoacidosis"
            },
            {
              "entity_id": "T514",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 40,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T515",
              "entity": "糖尿病高渗状态",
              "entity_type": "Disease",
              "start_idx": 41,
              "end_idx": 48,
              "entity_en": "Diabetic hyperosmolar state"
            },
            {
              "entity_id": "T516",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R121",
              "head_entity_id": "T516",
              "tail_entity_id": "T512"
            }
          ],
          "sentence_en": "(1) For non-endocrinology hospitalized patients with hyperglycemia whose blood sugar control is not up to standard, especially those with acute complications such as diabetic ketoacidosis, DKA, and diabetic hyperosmolar state, it is recommended to invite an endocrinologist for collaborative diagnosis and treatment."
        }
      ],
      "paragraph_en": "(1) For non-endocrinology hospitalized patients with hyperglycemia whose blood sugar control is not up to standard, especially those with acute complications such as diabetic ketoacidosis, DKA, and diabetic hyperosmolar state, it is recommended to invite an endocrinologist for collaborative diagnosis and treatment."
    },
    {
      "paragraph_id": "54",
      "paragraph": "(2)对于大多数的非内分泌科住院高血糖患者而言，胰岛素是控制血糖的首选治疗方法。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)对于大多数的非内分泌科住院高血糖患者而言，胰岛素是控制血糖的首选治疗方法。",
          "start_idx": 0,
          "end_idx": 40,
          "entities": [
            {
              "entity_id": "T517",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 19,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T518",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 27,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T519",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 32,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R122",
              "head_entity_id": "T518",
              "tail_entity_id": "T517"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R123",
              "head_entity_id": "T519",
              "tail_entity_id": "T517"
            }
          ],
          "sentence_en": "(2) For most non-endocrinology hospitalized patients with hyperglycemia, insulin is the treatment of choice for controlling blood sugar."
        }
      ],
      "paragraph_en": "(2) For most non-endocrinology hospitalized patients with hyperglycemia, insulin is the treatment of choice for controlling blood sugar."
    },
    {
      "paragraph_id": "55",
      "paragraph": "(3)对于急危重症患者，推荐采用持续静脉岛素输注，根据血糖波动情况随时调整胰岛素剂量；在打算改用胰岛素皮下注射时，需在停止胰岛素静脉输注前1~2h接受皮下注射。同时，每日减少大约20%~40%的胰岛素总量。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)对于急危重症患者，推荐采用持续静脉岛素输注，根据血糖波动情况随时调整胰岛素剂量；在打算改用胰岛素皮下注射时，需在停止胰岛素静脉输注前1~2h接受皮下注射。",
          "start_idx": 0,
          "end_idx": 80,
          "entities": [
            {
              "entity_id": "T520",
              "entity": "持续静脉岛素输注",
              "entity_type": "Method",
              "start_idx": 16,
              "end_idx": 24,
              "entity_en": "Continuous intravenous insulin infusion"
            },
            {
              "entity_id": "T521",
              "entity": "脉岛素",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 22,
              "entity_en": "Insulin"
            },
            {
              "entity_id": "T522",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 27,
              "end_idx": 29,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T523",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 40,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T524",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 48,
              "end_idx": 51,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T525",
              "entity": "皮下注射",
              "entity_type": "Method",
              "start_idx": 51,
              "end_idx": 55,
              "entity_en": "Subcutaneous injection"
            },
            {
              "entity_id": "T526",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 61,
              "end_idx": 64,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T527",
              "entity": "静脉输注",
              "entity_type": "Method",
              "start_idx": 64,
              "end_idx": 68,
              "entity_en": "Intravenous infusion"
            },
            {
              "entity_id": "T528",
              "entity": "皮下注射",
              "entity_type": "Method",
              "start_idx": 75,
              "end_idx": 79,
              "entity_en": "Subcutaneous injection"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R124",
              "head_entity_id": "T520",
              "tail_entity_id": "T521"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R125",
              "head_entity_id": "T525",
              "tail_entity_id": "T524"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R126",
              "head_entity_id": "T527",
              "tail_entity_id": "T526"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R127",
              "head_entity_id": "T528",
              "tail_entity_id": "T526"
            }
          ],
          "sentence_en": "(3) For critically ill patients, continuous intravenous insulin infusion is recommended, and the insulin dose should be adjusted at any time according to blood sugar fluctuations. When switching to subcutaneous insulin injection, subcutaneous injection should be given 1 to 2 hours before stopping intravenous insulin infusion."
        },
        {
          "sentence_id": "1",
          "sentence": "同时，每日减少大约20%~40%的胰岛素总量。",
          "start_idx": 80,
          "end_idx": 103,
          "entities": [
            {
              "entity_id": "T529",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 20,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "At the same time, the total daily insulin intake is reduced by approximately 20% to 40%."
        }
      ],
      "paragraph_en": "(3) For critically ill patients, continuous intravenous insulin infusion is recommended, and the insulin dose should be adjusted at any time according to blood sugar fluctuations; when switching to subcutaneous insulin injection, subcutaneous injection should be performed 1 to 2 hours before stopping intravenous insulin infusion. At the same time, the total amount of insulin per day should be reduced by approximately 20% to 40%."
    },
    {
      "paragraph_id": "56",
      "paragraph": "(4)对于非急危重症患者，可考虑皮下胰岛素注射。胰岛素注射剂量根据进餐和睡眠时间进行设定；如未进食或有持续肠内或肠外营养，每4~6h皮下注射短效或速效胰岛素。对于进食差，或无法正常进食的患者，可考虑以基础胰岛素为主，辅以临时短效或速效胰岛素注射；营养摄入充足患者，则推荐基础一餐时胰岛素治疗方案以及必要时临时补充短效或速效胰岛素，有条件的也可考虑胰岛素泵治疗。推荐餐前进行床旁血糖监测。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)对于非急危重症患者，可考虑皮下胰岛素注射。胰岛素注射剂量根据进餐和睡眠时间进行设定；如未进食或有持续肠内或肠外营养，每4~6h皮下注射短效或速效胰岛素。",
          "start_idx": 0,
          "end_idx": 79,
          "entities": [
            {
              "entity_id": "T530",
              "entity": "皮下胰岛素注射",
              "entity_type": "Method",
              "start_idx": 16,
              "end_idx": 23,
              "entity_en": "Subcutaneous insulin injection"
            },
            {
              "entity_id": "T531",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 21,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T532",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 27,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T533",
              "entity": "持续肠内或肠外营养",
              "entity_type": "Treatment",
              "start_idx": 51,
              "end_idx": 60,
              "entity_en": "Continuous enteral or parenteral nutrition"
            },
            {
              "entity_id": "T534",
              "entity": "皮下注射",
              "entity_type": "Method",
              "start_idx": 66,
              "end_idx": 70,
              "entity_en": "Subcutaneous injection"
            },
            {
              "entity_id": "T535",
              "entity": "短效或速效胰岛素",
              "entity_type": "Drug",
              "start_idx": 70,
              "end_idx": 78,
              "entity_en": "Short-acting or rapid-acting insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R128",
              "head_entity_id": "T530",
              "tail_entity_id": "T531"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R129",
              "head_entity_id": "T534",
              "tail_entity_id": "T535"
            }
          ],
          "sentence_en": "(4) For non-critically ill patients, subcutaneous insulin injection can be considered. The insulin injection dose is set according to meal and sleep time; if not eating or with continuous enteral or parenteral nutrition, short-acting or rapid-acting insulin is injected subcutaneously every 4 to 6 hours."
        },
        {
          "sentence_id": "1",
          "sentence": "对于进食差，或无法正常进食的患者，可考虑以基础胰岛素为主，辅以临时短效或速效胰岛素注射；营养摄入充足患者，则推荐基础一餐时胰岛素治疗方案以及必要时临时补充短效或速效胰岛素，有条件的也可考虑胰岛素泵治疗。",
          "start_idx": 79,
          "end_idx": 180,
          "entities": [
            {
              "entity_id": "T536",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 26,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T537",
              "entity": "短效或速效胰岛素",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 41,
              "entity_en": "Short-acting or rapid-acting insulin"
            },
            {
              "entity_id": "T538",
              "entity": "注射",
              "entity_type": "Method",
              "start_idx": 41,
              "end_idx": 43,
              "entity_en": "injection"
            },
            {
              "entity_id": "T539",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 61,
              "end_idx": 64,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T540",
              "entity": "短效或速效胰岛素",
              "entity_type": "Drug",
              "start_idx": 77,
              "end_idx": 85,
              "entity_en": "Short-acting or rapid-acting insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R130",
              "head_entity_id": "T538",
              "tail_entity_id": "T537"
            }
          ],
          "sentence_en": "For patients with poor appetite or inability to eat normally, basal insulin can be considered as the main treatment, supplemented by temporary short-acting or rapid-acting insulin injections. For patients with adequate nutritional intake, a basic mealtime insulin treatment plan is recommended, as well as temporary supplementation with short-acting or rapid-acting insulin when necessary. Insulin pump therapy can also be considered if conditions permit."
        },
        {
          "sentence_id": "2",
          "sentence": "推荐餐前进行床旁血糖监测。",
          "start_idx": 180,
          "end_idx": 193,
          "entities": [
            {
              "entity_id": "T541",
              "entity": "血糖监测",
              "entity_type": "Test_items",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "Blood glucose monitoring"
            }
          ],
          "relations": [],
          "sentence_en": "Bedside blood glucose monitoring before meals is recommended."
        }
      ],
      "paragraph_en": "(4) For patients who are not critically ill, subcutaneous insulin injection can be considered. The insulin injection dose is set according to meal and sleep time; if not eating or with continuous enteral or parenteral nutrition, short-acting or rapid-acting insulin is injected subcutaneously every 4 to 6 hours. For patients with poor eating or unable to eat normally, basal insulin can be considered as the main treatment, supplemented by temporary short-acting or rapid-acting insulin injection; for patients with adequate nutritional intake, a basic mealtime insulin treatment plan is recommended, as well as temporary supplementation of short-acting or rapid-acting insulin when necessary. Insulin pump therapy can also be considered if conditions permit. Bedside blood glucose monitoring before meals is recommended."
    },
    {
      "paragraph_id": "57",
      "paragraph": "(5)在胰岛素制剂的选择上，有短效或速效胰岛素、预混胰岛素、中效或长效胰岛素。速效胰岛素类似物联合长效胰岛素类似物进行基础一餐时胰岛素治疗或者速效胰岛素类似物用于胰岛素泵治疗能够带来更好的血糖控制，降低低血糖的发生风险，血糖达标时间更短，有助于缩短手术前准备时间和住院时间。速效胰岛素类似物可以餐前即刻或餐后立即注射的灵活特点也使其能够更好地满足进食不规律的住院患者的治疗需求。而且，速效胰岛素类似物堵管的发生风险较低，更适合于胰岛素泵治疗。对于入院前应用预混胰岛素且血糖控制良好的患者，入院后可考虑继续应用预混胰岛素治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(5)在胰岛素制剂的选择上，有短效或速效胰岛素、预混胰岛素、中效或长效胰岛素。速效胰岛素类似物联合长效胰岛素类似物进行基础一餐时胰岛素治疗或者速效胰岛素类似物用于胰岛素泵治疗能够带来更好的血糖控制，降低低血糖的发生风险，血糖达标时间更短，有助于缩短手术前准备时间和住院时间。速效胰岛素类似物可以餐前即刻或餐后立即注射的灵活特点也使其能够更好地满足进食不规律的住院患者的治疗需求。而且，速效胰岛素类似物堵管的发生风险较低，更适合于胰岛素泵治疗。",
          "start_idx": 0,
          "end_idx": 221,
          "entities": [
            {
              "entity_id": "T542",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T543",
              "entity": "短效或速效胰岛素",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 23,
              "entity_en": "Short-acting or rapid-acting insulin"
            },
            {
              "entity_id": "T544",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 29,
              "entity_en": "Premixed insulin"
            },
            {
              "entity_id": "T545",
              "entity": "中效或长效胰岛素",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 38,
              "entity_en": "Intermediate-acting or long-acting insulin"
            },
            {
              "entity_id": "T546",
              "entity": "速效胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 39,
              "end_idx": 47,
              "entity_en": "Rapid-acting insulin analogs"
            },
            {
              "entity_id": "T547",
              "entity": "长效胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 57,
              "entity_en": "Long-acting insulin analogs"
            },
            {
              "entity_id": "T548",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 67,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T549",
              "entity": "速效胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 71,
              "end_idx": 79,
              "entity_en": "Rapid-acting insulin analogs"
            },
            {
              "entity_id": "T550",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 101,
              "end_idx": 104,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T551",
              "entity": "速效胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 137,
              "end_idx": 145,
              "entity_en": "Rapid-acting insulin analogs"
            },
            {
              "entity_id": "T552",
              "entity": "注射",
              "entity_type": "Method",
              "start_idx": 156,
              "end_idx": 158,
              "entity_en": "injection"
            },
            {
              "entity_id": "T553",
              "entity": "速效胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 192,
              "end_idx": 200,
              "entity_en": "Rapid-acting insulin analogs"
            },
            {
              "entity_id": "T554",
              "entity": "堵管",
              "entity_type": "ADE",
              "start_idx": 200,
              "end_idx": 202,
              "entity_en": "Pipe blocking"
            },
            {
              "entity_id": "T558",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 94,
              "end_idx": 96,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T559",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 110,
              "end_idx": 112,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R131",
              "head_entity_id": "T552",
              "tail_entity_id": "T551"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R132",
              "head_entity_id": "T554",
              "tail_entity_id": "T553"
            }
          ],
          "sentence_en": "(5) In terms of the choice of insulin preparations, there are short-acting or rapid-acting insulin, premixed insulin, intermediate-acting or long-acting insulin. Rapid-acting insulin analogs combined with long-acting insulin analogs for basal mealtime insulin therapy or rapid-acting insulin analogs for insulin pump therapy can bring better blood sugar control, reduce the risk of hypoglycemia, and shorten the time it takes for blood sugar to reach the target, which helps to shorten the preoperative preparation time and hospitalization time. The flexibility of rapid-acting insulin analogs, which can be injected immediately before or after meals, also enables them to better meet the treatment needs of hospitalized patients with irregular eating habits. In addition, rapid-acting insulin analogs have a lower risk of tube blockage and are more suitable for insulin pump therapy."
        },
        {
          "sentence_id": "1",
          "sentence": "对于入院前应用预混胰岛素且血糖控制良好的患者，入院后可考虑继续应用预混胰岛素治疗。",
          "start_idx": 221,
          "end_idx": 262,
          "entities": [
            {
              "entity_id": "T555",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 12,
              "entity_en": "Premixed insulin"
            },
            {
              "entity_id": "T556",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T557",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 38,
              "entity_en": "Premixed insulin"
            }
          ],
          "relations": [],
          "sentence_en": "For patients who use premixed insulin and have good blood sugar control before admission, continued use of premixed insulin treatment can be considered after admission."
        }
      ],
      "paragraph_en": "(5) In terms of the choice of insulin preparations, there are short-acting or rapid-acting insulin, premixed insulin, intermediate-acting or long-acting insulin. Rapid-acting insulin analogs combined with long-acting insulin analogs for basal mealtime insulin therapy or rapid-acting insulin analogs for insulin pump therapy can bring better blood sugar control, reduce the risk of hypoglycemia, and shorten the time it takes for blood sugar to reach the target, which helps to shorten the preoperative preparation time and hospitalization time. The flexibility of rapid-acting insulin analogs, which can be injected immediately before or after meals, also enables them to better meet the treatment needs of hospitalized patients with irregular eating habits. In addition, rapid-acting insulin analogs have a lower risk of tube blockage and are more suitable for insulin pump therapy. For patients who use premixed insulin before admission and have good blood sugar control, continued use of premixed insulin therapy can be considered after admission."
    },
    {
      "paragraph_id": "58",
      "paragraph": "(6)口服降糖药物，包括二肽基肽酶4(DPP-4)抑制剂和GLP-1受体激动剂在住院高血糖患者的使用证据较少。如果患者的临床状况比较稳定、进食规律并且没有使用这些药物的禁忌证，则在入院后可以考虑维续应用其入院前已经使用的口服降糖药物或GLP-1受体激动剂。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(6)口服降糖药物，包括二肽基肽酶4(DPP-4)抑制剂和GLP-1受体激动剂在住院高血糖患者的使用证据较少。如果患者的临床状况比较稳定、进食规律并且没有使用这些药物的禁忌证，则在入院后可以考虑维续应用其入院前已经使用的口服降糖药物或GLP-1受体激动剂。",
          "start_idx": 0,
          "end_idx": 128,
          "entities": [
            {
              "entity_id": "T560",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 3,
              "end_idx": 5,
              "entity_en": "oral"
            },
            {
              "entity_id": "T561",
              "entity": "二肽基肽酶4(DPP-4)抑制剂",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 28,
              "entity_en": "Dipeptidyl peptidase 4 (DPP-4) inhibitors"
            },
            {
              "entity_id": "T562",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 39,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T563",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 42,
              "end_idx": 45,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T564",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 110,
              "end_idx": 112,
              "entity_en": "oral"
            },
            {
              "entity_id": "T565",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 117,
              "end_idx": 127,
              "entity_en": "GLP-1 receptor agonists"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R133",
              "head_entity_id": "T560",
              "tail_entity_id": "T561"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R134",
              "head_entity_id": "T560",
              "tail_entity_id": "T562"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R135",
              "head_entity_id": "T561",
              "tail_entity_id": "T563"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R136",
              "head_entity_id": "T562",
              "tail_entity_id": "T563"
            }
          ],
          "sentence_en": "(6) There is little evidence for the use of oral hypoglycemic drugs, including dipeptidyl peptidase 4 (DPP-4) inhibitors and GLP-1 receptor agonists in hospitalized patients with hyperglycemia. If the patient's clinical condition is relatively stable, his/her diet is regular, and there are no contraindications to the use of these drugs, then the oral hypoglycemic drugs or GLP-1 receptor agonists that he/she has been using before admission can be considered for continued use after admission."
        }
      ],
      "paragraph_en": "(6) There is little evidence for the use of oral hypoglycemic drugs, including dipeptidyl peptidase 4 (DPP-4) inhibitors and GLP-1 receptor agonists in hospitalized patients with hyperglycemia. If the patient's clinical condition is relatively stable, his/her diet is regular, and there are no contraindications to the use of these drugs, then the oral hypoglycemic drugs or GLP-1 receptor agonists that he/she has been using before admission can be considered for continued use after admission."
    },
    {
      "paragraph_id": "59",
      "paragraph": "5.特殊情况的处理",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.特殊情况的处理",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [],
          "relations": [],
          "sentence_en": "5. Handling of special situations"
        }
      ],
      "paragraph_en": "5. Handling of special situations"
    },
    {
      "paragraph_id": "60",
      "paragraph": "(1)肠内或肠外营养：①持续肠内营养，每日1次或2次基础胰岛素；同时，每4h给予短效或速效胰岛素皮下注射；分次肠内营养，维持原基胰岛素治疗方案；如初始治疗，给予10U基础胰岛素。同时，在每次进行肠内营养时，给予短效或速效胰岛素皮下注射；③肠外营养，全胃肠外静脉营养液中添加短效或速效胰岛素；同时，每4h给予短效或速效胰岛素皮下注射。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)肠内或肠外营养：①持续肠内营养，每日1次或2次基础胰岛素；同时，每4h给予短效或速效胰岛素皮下注射；分次肠内营养，维持原基胰岛素治疗方案；如初始治疗，给予10U基础胰岛素。",
          "start_idx": 0,
          "end_idx": 89,
          "entities": [
            {
              "entity_id": "T566",
              "entity": "肠内或肠外营养",
              "entity_type": "Treatment",
              "start_idx": 3,
              "end_idx": 10,
              "entity_en": "Enteral or parenteral nutrition"
            },
            {
              "entity_id": "T567",
              "entity": "持续肠内营养",
              "entity_type": "Treatment",
              "start_idx": 12,
              "end_idx": 18,
              "entity_en": "Continuous enteral nutrition"
            },
            {
              "entity_id": "T568",
              "entity": "每日1次或2次",
              "entity_type": "Frequency",
              "start_idx": 19,
              "end_idx": 26,
              "entity_en": "1 or 2 times a day"
            },
            {
              "entity_id": "T569",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 28,
              "end_idx": 31,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T570",
              "entity": "每4h",
              "entity_type": "Frequency",
              "start_idx": 35,
              "end_idx": 38,
              "entity_en": "Every 4 hours"
            },
            {
              "entity_id": "T571",
              "entity": "短效或速效胰岛素",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 48,
              "entity_en": "Short-acting or rapid-acting insulin"
            },
            {
              "entity_id": "T572",
              "entity": "皮下注射",
              "entity_type": "Method",
              "start_idx": 48,
              "end_idx": 52,
              "entity_en": "Subcutaneous injection"
            },
            {
              "entity_id": "T573",
              "entity": "肠内营养",
              "entity_type": "Treatment",
              "start_idx": 55,
              "end_idx": 59,
              "entity_en": "Enteral nutrition"
            },
            {
              "entity_id": "T574",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 67,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T575",
              "entity": "10U",
              "entity_type": "Amount",
              "start_idx": 80,
              "end_idx": 83,
              "entity_en": "10U"
            },
            {
              "entity_id": "T576",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 85,
              "end_idx": 88,
              "entity_en": "insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R137",
              "head_entity_id": "T568",
              "tail_entity_id": "T569"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R138",
              "head_entity_id": "T570",
              "tail_entity_id": "T571"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R139",
              "head_entity_id": "T572",
              "tail_entity_id": "T571"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R140",
              "head_entity_id": "T575",
              "tail_entity_id": "T576"
            }
          ],
          "sentence_en": "(1) Enteral or parenteral nutrition: ① Continuous enteral nutrition, basal insulin once or twice a day; at the same time, short-acting or rapid-acting insulin is given subcutaneously every 4 hours; divided enteral nutrition, maintaining the original insulin treatment plan; if the initial treatment, give 10U basal insulin."
        },
        {
          "sentence_id": "1",
          "sentence": "同时，在每次进行肠内营养时，给予短效或速效胰岛素皮下注射；③肠外营养，全胃肠外静脉营养液中添加短效或速效胰岛素；同时，每4h给予短效或速效胰岛素皮下注射。",
          "start_idx": 89,
          "end_idx": 166,
          "entities": [
            {
              "entity_id": "T577",
              "entity": "肠内营养",
              "entity_type": "Treatment",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "Enteral nutrition"
            },
            {
              "entity_id": "T578",
              "entity": "短效或速效胰岛素",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 24,
              "entity_en": "Short-acting or rapid-acting insulin"
            },
            {
              "entity_id": "T579",
              "entity": "皮下注射",
              "entity_type": "Method",
              "start_idx": 24,
              "end_idx": 28,
              "entity_en": "Subcutaneous injection"
            },
            {
              "entity_id": "T580",
              "entity": "肠外营养",
              "entity_type": "Treatment",
              "start_idx": 30,
              "end_idx": 34,
              "entity_en": "Parenteral Nutrition"
            },
            {
              "entity_id": "T581",
              "entity": "全胃肠外静脉营养液",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 44,
              "entity_en": "Total parenteral nutrition solution"
            },
            {
              "entity_id": "T582",
              "entity": "短效或速效胰岛素",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 55,
              "entity_en": "Short-acting or rapid-acting insulin"
            },
            {
              "entity_id": "T583",
              "entity": "每4h",
              "entity_type": "Frequency",
              "start_idx": 59,
              "end_idx": 62,
              "entity_en": "Every 4 hours"
            },
            {
              "entity_id": "T584",
              "entity": "短效或速效胰岛素",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 72,
              "entity_en": "Short-acting or rapid-acting insulin"
            },
            {
              "entity_id": "T585",
              "entity": "皮下注射",
              "entity_type": "Method",
              "start_idx": 72,
              "end_idx": 76,
              "entity_en": "Subcutaneous injection"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R141",
              "head_entity_id": "T579",
              "tail_entity_id": "T578"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R142",
              "head_entity_id": "T583",
              "tail_entity_id": "T584"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R143",
              "head_entity_id": "T585",
              "tail_entity_id": "T584"
            }
          ],
          "sentence_en": "At the same time, short-acting or rapid-acting insulin is given subcutaneously every time enteral nutrition is performed; ③ For enteral nutrition, short-acting or rapid-acting insulin is added to the total parenteral intravenous nutrition solution; at the same time, short-acting or rapid-acting insulin is given subcutaneously every 4 hours."
        }
      ],
      "paragraph_en": "(1) Enteral or parenteral nutrition: ① Continuous enteral nutrition, basal insulin once or twice a day; at the same time, short-acting or rapid-acting insulin is given subcutaneously every 4 hours; divided enteral nutrition, maintain the original insulin treatment plan; if it is the initial treatment, 10U of basal insulin is given. At the same time, short-acting or rapid-acting insulin is given subcutaneously during each enteral nutrition; ③ Parenteral nutrition, short-acting or rapid-acting insulin is added to the total parenteral intravenous nutrition solution; at the same time, short-acting or rapid-acting insulin is given subcutaneously every 4 hours."
    },
    {
      "paragraph_id": "61",
      "paragraph": "(2)糖皮质激素的使用：糖皮质激素在使用时需考虑其在体内作用时间对高血糖的影响。可使用中效或长效胰岛素控制血糖。同样床旁血糖监测非常重要，根据血精监测结果调整胰岛素的使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)糖皮质激素的使用：糖皮质激素在使用时需考虑其在体内作用时间对高血糖的影响。可使用中效或长效胰岛素控制血糖。同样床旁血糖监测非常重要，根据血精监测结果调整胰岛素的使用。",
          "start_idx": 0,
          "end_idx": 86,
          "entities": [
            {
              "entity_id": "T586",
              "entity": "糖皮质激素",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Glucocorticoids"
            },
            {
              "entity_id": "T587",
              "entity": "糖皮质激素",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 17,
              "entity_en": "Glucocorticoids"
            },
            {
              "entity_id": "T588",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 36,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T589",
              "entity": "中效或长效胰岛素",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 51,
              "entity_en": "Intermediate-acting or long-acting insulin"
            },
            {
              "entity_id": "T590",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 79,
              "end_idx": 82,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T591",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 53,
              "end_idx": 55,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T592",
              "entity": "血糖监测",
              "entity_type": "Test_items",
              "start_idx": 60,
              "end_idx": 64,
              "entity_en": "Blood glucose monitoring"
            },
            {
              "entity_id": "T593",
              "entity": "血精监测",
              "entity_type": "Test_items",
              "start_idx": 71,
              "end_idx": 75,
              "entity_en": "Hematospermia monitoring"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R144",
              "head_entity_id": "T587",
              "tail_entity_id": "T588"
            }
          ],
          "sentence_en": "(2) Use of glucocorticoids: When using glucocorticoids, the effect of their duration of action in the body on hyperglycemia must be considered. Intermediate-acting or long-acting insulin can be used to control blood sugar. Similarly, bedside blood sugar monitoring is very important, and the use of insulin should be adjusted according to the results of blood-sperm monitoring."
        }
      ],
      "paragraph_en": "(2) Use of glucocorticoids: When using glucocorticoids, the effect of their duration of action in the body on hyperglycemia must be considered. Intermediate-acting or long-acting insulin can be used to control blood sugar. Similarly, bedside blood sugar monitoring is very important, and the use of insulin should be adjusted according to the results of blood-sperm monitoring."
    },
    {
      "paragraph_id": "62",
      "paragraph": "(3)围手术期：①围手术期血糖控制目标参见本共识“二、住院患者的血糖控制目标”部分；对于缺血性心脏病高风险患者，存在自主神经病变或肾功能衰竭患者需慎重评估围手术期低血糖风险；根据患者的血糖情况、一般状况及手术的类型决定是否需要停用之前的口服降糖药物以及是否需要胰岛素治疗。对于需要禁食的手术，在进行手术当日早上，停用口服降糖药物，给予半剂量中性低精蛋白锌胰岛素(NPH)，或全剂量长效胰岛素类似物，或全剂量胰岛素泵基础量。③在禁食期间，每4~6h进行血糖检测，超过血糖控制目标时给子短效或速效胰岛素。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)围手术期：①围手术期血糖控制目标参见本共识“二、住院患者的血糖控制目标”部分；对于缺血性心脏病高风险患者，存在自主神经病变或肾功能衰竭患者需慎重评估围手术期低血糖风险；根据患者的血糖情况、一般状况及手术的类型决定是否需要停用之前的口服降糖药物以及是否需要胰岛素治疗。",
          "start_idx": 0,
          "end_idx": 136,
          "entities": [
            {
              "entity_id": "T594",
              "entity": "缺血性心脏病",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 50,
              "entity_en": "Ischemic heart disease"
            },
            {
              "entity_id": "T595",
              "entity": "心脏",
              "entity_type": "Anatomy",
              "start_idx": 47,
              "end_idx": 49,
              "entity_en": "heart"
            },
            {
              "entity_id": "T596",
              "entity": "自主神经病变",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 64,
              "entity_en": "Autonomic neuropathy"
            },
            {
              "entity_id": "T597",
              "entity": "神经",
              "entity_type": "Anatomy",
              "start_idx": 60,
              "end_idx": 62,
              "entity_en": "nerve"
            },
            {
              "entity_id": "T598",
              "entity": "肾功能衰竭",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 70,
              "entity_en": "Renal failure"
            },
            {
              "entity_id": "T599",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 65,
              "end_idx": 66,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T600",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 81,
              "end_idx": 84,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T601",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 92,
              "end_idx": 94,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T602",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 118,
              "end_idx": 120,
              "entity_en": "oral"
            },
            {
              "entity_id": "T603",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 130,
              "end_idx": 133,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T608",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T609",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R145",
              "head_entity_id": "T595",
              "tail_entity_id": "T594"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R146",
              "head_entity_id": "T597",
              "tail_entity_id": "T596"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R147",
              "head_entity_id": "T599",
              "tail_entity_id": "T598"
            }
          ],
          "sentence_en": "(3) Perioperative period: ① For perioperative blood glucose control targets, please refer to the section “II. Blood glucose control targets for hospitalized patients” of this consensus; for patients at high risk of ischemic heart disease, patients with autonomic neuropathy or renal failure, the risk of perioperative hypoglycemia should be carefully assessed; whether to stop taking previous oral hypoglycemic drugs and whether insulin treatment is needed should be determined based on the patient’s blood glucose status, general condition and type of surgery."
        },
        {
          "sentence_id": "1",
          "sentence": "对于需要禁食的手术，在进行手术当日早上，停用口服降糖药物，给予半剂量中性低精蛋白锌胰岛素(NPH)，或全剂量长效胰岛素类似物，或全剂量胰岛素泵基础量。",
          "start_idx": 136,
          "end_idx": 211,
          "entities": [
            {
              "entity_id": "T604",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 22,
              "end_idx": 24,
              "entity_en": "oral"
            },
            {
              "entity_id": "T605",
              "entity": "半剂量中性低精蛋白锌胰岛素(NPH)",
              "entity_type": "Drug",
              "start_idx": 31,
              "end_idx": 49,
              "entity_en": "Half-dose neutral protamine phosphokinase (NPH) insulin"
            },
            {
              "entity_id": "T606",
              "entity": "全剂量长效胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 62,
              "entity_en": "Full-dose long-acting insulin analogs"
            }
          ],
          "relations": [],
          "sentence_en": "For surgeries that require fasting, oral hypoglycemic drugs are discontinued on the morning of the surgery, and half-dose neutral protamine phosphokinase (NPH) insulin, or full-dose long-acting insulin analogs, or full-dose insulin pump basal volume are given."
        },
        {
          "sentence_id": "2",
          "sentence": "③在禁食期间，每4~6h进行血糖检测，超过血糖控制目标时给子短效或速效胰岛素。",
          "start_idx": 211,
          "end_idx": 250,
          "entities": [
            {
              "entity_id": "T607",
              "entity": "短效或速效胰岛素",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 38,
              "entity_en": "Short-acting or rapid-acting insulin"
            },
            {
              "entity_id": "T610",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 21,
              "end_idx": 23,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T611",
              "entity": "血糖检测",
              "entity_type": "Test_items",
              "start_idx": 14,
              "end_idx": 18,
              "entity_en": "Blood glucose testing"
            }
          ],
          "relations": [],
          "sentence_en": "③During the fasting period, blood sugar levels should be tested every 4 to 6 hours, and short-acting or rapid-acting insulin should be administered if blood sugar levels exceed the target."
        }
      ],
      "paragraph_en": "(3) Perioperative period: ① For perioperative blood sugar control targets, please refer to the section “II. Blood sugar control targets for hospitalized patients” of this consensus; for patients at high risk of ischemic heart disease, patients with autonomic neuropathy or renal failure, the risk of perioperative hypoglycemia should be carefully assessed; whether to stop taking previous oral hypoglycemic drugs and whether insulin treatment is needed should be determined based on the patient’s blood sugar status, general condition and type of surgery. For surgeries that require fasting, oral hypoglycemic drugs should be stopped on the morning of the surgery, and half-dose neutral hypoglycemic insulin (NPH) or full-dose long-acting insulin analogs or full-dose insulin pump basal volume should be given. ③ During the fasting period, blood sugar should be tested every 4 to 6 hours, and short-acting or rapid-acting insulin should be given if the blood sugar control target is exceeded."
    },
    {
      "paragraph_id": "63",
      "paragraph": "(4)DKA和糖尿病高渗状态：处理目标包括：纠正血容量、改善组织灌注、纠正高血糖、血电解质紊乱和酮症等。寻找相关诱因非常重要。小剂量胰岛素静脉、肌肉或皮下注射是治疗DKA和高渗状态的安全有效措施。具体治疗方案详见本章节“(一)内分泌科住院糖尿病患者的血糖管理“中“2.内分泌科住院糖尿病患者的血糖管理”部分。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)DKA和糖尿病高渗状态：处理目标包括：纠正血容量、改善组织灌注、纠正高血糖、血电解质紊乱和酮症等。寻找相关诱因非常重要。小剂量胰岛素静脉、肌肉或皮下注射是治疗DKA和高渗状态的安全有效措施。具体治疗方案详见本章节“(一)内分泌科住院糖尿病患者的血糖管理“中“2.内分泌科住院糖尿病患者的血糖管理”部分。",
          "start_idx": 0,
          "end_idx": 154,
          "entities": [
            {
              "entity_id": "T612",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T613",
              "entity": "糖尿病高渗状态",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 14,
              "entity_en": "Diabetic hyperosmolar state"
            },
            {
              "entity_id": "T614",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 66,
              "end_idx": 69,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T615",
              "entity": "静脉、肌肉或皮下注射",
              "entity_type": "Method",
              "start_idx": 69,
              "end_idx": 79,
              "entity_en": "Intravenous, intramuscular, or subcutaneous injection"
            },
            {
              "entity_id": "T616",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 82,
              "end_idx": 85,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T617",
              "entity": "高渗状态",
              "entity_type": "Disease",
              "start_idx": 86,
              "end_idx": 90,
              "entity_en": "Hypertonic state"
            },
            {
              "entity_id": "T618",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 119,
              "end_idx": 122,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T619",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 140,
              "end_idx": 143,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T620",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 146,
              "end_idx": 148,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T621",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 125,
              "end_idx": 127,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R148",
              "head_entity_id": "T615",
              "tail_entity_id": "T614"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R149",
              "head_entity_id": "T614",
              "tail_entity_id": "T616"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R150",
              "head_entity_id": "T614",
              "tail_entity_id": "T617"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R151",
              "head_entity_id": "T621",
              "tail_entity_id": "T618"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R152",
              "head_entity_id": "T620",
              "tail_entity_id": "T619"
            }
          ],
          "sentence_en": "(4) DKA and diabetic hyperosmolar state: Treatment goals include: correcting blood volume, improving tissue perfusion, correcting hyperglycemia, blood electrolyte imbalance and ketosis, etc. It is very important to find the relevant triggers. Small doses of insulin injected intravenously, intramuscularly or subcutaneously are safe and effective measures for the treatment of DKA and hyperosmolar state. For specific treatment plans, please refer to the \"2. Blood sugar management of diabetic patients hospitalized in the endocrinology department\" section of this chapter \"(I) Blood sugar management of diabetic patients hospitalized in the endocrinology department\"."
        }
      ],
      "paragraph_en": "(4) DKA and diabetic hyperosmolar state: Treatment goals include: correcting blood volume, improving tissue perfusion, correcting hyperglycemia, blood electrolyte imbalance and ketosis, etc. It is very important to find the relevant triggers. Intravenous, intramuscular or subcutaneous injection of small doses of insulin is a safe and effective measure for the treatment of DKA and hyperosmolar state. For specific treatment plans, please refer to the \"2. Blood sugar management of diabetic patients hospitalized in the endocrinology department\" in this chapter \"(I) Blood sugar management of diabetic patients hospitalized in the endocrinology department\"."
    },
    {
      "paragraph_id": "64",
      "paragraph": "6.低血糖的治疗和预防：参见本章节”(一)内分泌科住院糖尿病患者的血糖管理”中“2.内分泌科住院糖尿病患者的血糖管理”中对低血糖的管理。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "6.低血糖的治疗和预防：参见本章节”(一)内分泌科住院糖尿病患者的血糖管理”中“2.内分泌科住院糖尿病患者的血糖管理”中对低血糖的管理。",
          "start_idx": 0,
          "end_idx": 68,
          "entities": [
            {
              "entity_id": "T622",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T623",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 30,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T624",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 51,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T625",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 61,
              "end_idx": 64,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T626",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 33,
              "end_idx": 35,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T627",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 54,
              "end_idx": 56,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R153",
              "head_entity_id": "T626",
              "tail_entity_id": "T623"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R154",
              "head_entity_id": "T627",
              "tail_entity_id": "T624"
            }
          ],
          "sentence_en": "6. Treatment and prevention of hypoglycemia: Refer to the management of hypoglycemia in \"2. Management of blood sugar in hospitalized diabetic patients in the endocrinology department\" in this chapter (I) Blood sugar management in hospitalized diabetic patients in the endocrinology department."
        }
      ],
      "paragraph_en": "6. Treatment and prevention of hypoglycemia: Refer to the management of hypoglycemia in \"2. Management of blood sugar in hospitalized diabetic patients in the endocrinology department\" in this chapter (I) Blood sugar management in hospitalized diabetic patients in the endocrinology department."
    },
    {
      "paragraph_id": "65",
      "paragraph": "7.出院随访",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "7.出院随访",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "7. Follow-up after discharge"
        }
      ],
      "paragraph_en": "7. Follow-up after discharge"
    },
    {
      "paragraph_id": "66",
      "paragraph": "(1)完整的出院小结信息有助于患者在出院后方便安全地在门诊随访或至当地或基层医疗机构就诊。相关信息包括高血糖的病因信息(或寻找病因的方案)相关并发症与合并症，推荐的后继治疗方案等。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)完整的出院小结信息有助于患者在出院后方便安全地在门诊随访或至当地或基层医疗机构就诊。",
          "start_idx": 0,
          "end_idx": 45,
          "entities": [],
          "relations": [],
          "sentence_en": "(1) Complete discharge summary information helps patients to conveniently and safely follow up in outpatient clinics or go to local or primary medical institutions for treatment after discharge."
        },
        {
          "sentence_id": "1",
          "sentence": "相关信息包括高血糖的病因信息(或寻找病因的方案)相关并发症与合并症，推荐的后继治疗方案等。",
          "start_idx": 45,
          "end_idx": 90,
          "entities": [
            {
              "entity_id": "T628",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "Relevant information includes the cause of hyperglycemia (or plans to find the cause), related complications and comorbidities, and recommended follow-up treatment plans."
        }
      ],
      "paragraph_en": "(1) Complete discharge summary information helps patients to conveniently and safely follow up in outpatient clinics or go to local or primary care institutions for treatment after discharge. Relevant information includes the cause of hyperglycemia (or plans to find the cause), related complications and comorbidities, and recommended follow-up treatment plans."
    },
    {
      "paragraph_id": "67",
      "paragraph": "(2)出院时向患者及家属交代清楚治疗方案，确保新处方的安全性；正确使用并处置胰岛素皮下注射针头和注射器；提供购买相关医疗设备或耗材的信息(如胰岛素笔、便携式血糖仪)；对药物的服用方法、药品的管理、血糖监测、高低血糖的识别、预防和应急处理进行宣传教育。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)出院时向患者及家属交代清楚治疗方案，确保新处方的安全性；正确使用并处置胰岛素皮下注射针头和注射器；提供购买相关医疗设备或耗材的信息(如胰岛素笔、便携式血糖仪)；对药物的服用方法、药品的管理、血糖监测、高低血糖的识别、预防和应急处理进行宣传教育。",
          "start_idx": 0,
          "end_idx": 125,
          "entities": [
            {
              "entity_id": "T629",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 38,
              "end_idx": 41,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T630",
              "entity": "皮下注射",
              "entity_type": "Method",
              "start_idx": 41,
              "end_idx": 45,
              "entity_en": "Subcutaneous injection"
            },
            {
              "entity_id": "T631",
              "entity": "高低血糖",
              "entity_type": "Disease",
              "start_idx": 103,
              "end_idx": 107,
              "entity_en": "High and low blood sugar"
            },
            {
              "entity_id": "T632",
              "entity": "血糖监测",
              "entity_type": "Test_items",
              "start_idx": 98,
              "end_idx": 102,
              "entity_en": "Blood glucose monitoring"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R155",
              "head_entity_id": "T630",
              "tail_entity_id": "T629"
            }
          ],
          "sentence_en": "(2) Upon discharge, the patient and family members should be informed of the treatment plan and ensure the safety of the new prescription; the patient should be instructed on the correct use and disposal of insulin hypodermic needles and syringes; information on the purchase of related medical equipment or consumables (such as insulin pens, portable blood glucose meters) should be provided; and education should be provided on the method of taking medications, the management of medications, blood glucose monitoring, the identification, prevention, and emergency treatment of high and low blood glucose."
        }
      ],
      "paragraph_en": "(2) Upon discharge, the patient and family members should be informed of the treatment plan and ensure the safety of the new prescription; the patient should be instructed on the correct use and disposal of insulin hypodermic needles and syringes; information on the purchase of related medical equipment or consumables (such as insulin pens, portable blood glucose meters) should be provided; and education should be provided on the method of taking medications, the management of medications, blood glucose monitoring, the identification, prevention, and emergency treatment of high and low blood glucose."
    },
    {
      "paragraph_id": "68",
      "paragraph": "(3)建议所有糖尿病或高血糖患者在出院1个月后接受内分泌专科医生的评估。糖尿病患者根据出院后的血糖水平，由内分泌专科医生进行降糖方案的调整并制订长期随访方案。对于住院新发现的高血糖患者更有必要在出院后重新进行糖代谢状态的评估。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)建议所有糖尿病或高血糖患者在出院1个月后接受内分泌专科医生的评估。糖尿病患者根据出院后的血糖水平，由内分泌专科医生进行降糖方案的调整并制订长期随访方案。对于住院新发现的高血糖患者更有必要在出院后重新进行糖代谢状态的评估。",
          "start_idx": 0,
          "end_idx": 113,
          "entities": [
            {
              "entity_id": "T633",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T634",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 14,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T635",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 39,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T636",
              "entity": "血糖水平",
              "entity_type": "Test_items",
              "start_idx": 47,
              "end_idx": 51,
              "entity_en": "Blood sugar levels"
            },
            {
              "entity_id": "T637",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 87,
              "end_idx": 90,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T638",
              "entity": "糖代谢状态的评估",
              "entity_type": "Test",
              "start_idx": 104,
              "end_idx": 112,
              "entity_en": "Assessment of glucose metabolism status"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R156",
              "head_entity_id": "T636",
              "tail_entity_id": "T635"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R157",
              "head_entity_id": "T638",
              "tail_entity_id": "T637"
            }
          ],
          "sentence_en": "(3) It is recommended that all patients with diabetes or hyperglycemia be evaluated by an endocrinologist one month after discharge. Based on the blood sugar level after discharge, the endocrinologist will adjust the glucose-lowering regimen of the diabetic patient and formulate a long-term follow-up plan. For patients with newly discovered hyperglycemia during hospitalization, it is even more necessary to re-evaluate their glucose metabolism status after discharge."
        }
      ],
      "paragraph_en": "(3) It is recommended that all patients with diabetes or hyperglycemia receive an evaluation by an endocrinologist one month after discharge. Based on the blood sugar level after discharge, the endocrinologist will adjust the glucose-lowering regimen of the diabetic patient and develop a long-term follow-up plan. For patients with newly discovered hyperglycemia during hospitalization, it is even more necessary to re-evaluate their glucose metabolism status after discharge."
    },
    {
      "paragraph_id": "69",
      "paragraph": "(三)糖尿病妊娠及妊娠糖尿病住院患者的管理",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(三)糖尿病妊娠及妊娠糖尿病住院患者的管理",
          "start_idx": 0,
          "end_idx": 21,
          "entities": [
            {
              "entity_id": "T639",
              "entity": "糖尿病妊娠",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Diabetic pregnancy"
            },
            {
              "entity_id": "T640",
              "entity": "妊娠糖尿病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "Gestational diabetes"
            }
          ],
          "relations": [],
          "sentence_en": "3. Management of diabetic pregnancy and hospitalized patients with gestational diabetes"
        }
      ],
      "paragraph_en": "3. Management of diabetic pregnancy and hospitalized patients with gestational diabetes"
    },
    {
      "paragraph_id": "70",
      "paragraph": "妊娠期间高血糖包括糖尿病妊娠与妊娠糖尿病(GDM)，不论是那种类型高血糖，均可能导致不良妊娠结局，其中需要进行住院血糖管理的患者包括：糖尿病患者计划妊娠或已妊娠时，或GDM患者，经门诊治疗血糖不达标者；合并严重急、慢性并发症者；妊娠期需启动胰岛素治疗者；另外，在产科住院的妊娠高血糖患者，依据血糖情况，必要时也应请内分泌科进行血糖管理。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "妊娠期间高血糖包括糖尿病妊娠与妊娠糖尿病(GDM)，不论是那种类型高血糖，均可能导致不良妊娠结局，其中需要进行住院血糖管理的患者包括：糖尿病患者计划妊娠或已妊娠时，或GDM患者，经门诊治疗血糖不达标者；合并严重急、慢性并发症者；妊娠期需启动胰岛素治疗者；另外，在产科住院的妊娠高血糖患者，依据血糖情况，必要时也应请内分泌科进行血糖管理。",
          "start_idx": 0,
          "end_idx": 168,
          "entities": [
            {
              "entity_id": "T641",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T642",
              "entity": "括糖尿病妊娠",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 14,
              "entity_en": "Diabetes in pregnancy"
            },
            {
              "entity_id": "T643",
              "entity": "妊娠糖尿病(GDM)",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 25,
              "entity_en": "Gestational diabetes mellitus (GDM)"
            },
            {
              "entity_id": "T644",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 36,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T645",
              "entity": "不良妊娠",
              "entity_type": "Symptom",
              "start_idx": 42,
              "end_idx": 46,
              "entity_en": "Adverse pregnancy"
            },
            {
              "entity_id": "T646",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 67,
              "end_idx": 70,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T647",
              "entity": "GDM",
              "entity_type": "Disease",
              "start_idx": 83,
              "end_idx": 86,
              "entity_en": "GDM"
            },
            {
              "entity_id": "T648",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 94,
              "end_idx": 96,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T649",
              "entity": "不达标",
              "entity_type": "Test_Value",
              "start_idx": 96,
              "end_idx": 99,
              "entity_en": "Not up to standard"
            },
            {
              "entity_id": "T650",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 120,
              "end_idx": 123,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T651",
              "entity": "妊娠高血糖",
              "entity_type": "Disease",
              "start_idx": 136,
              "end_idx": 141,
              "entity_en": "Hyperglycemia in pregnancy"
            },
            {
              "entity_id": "T652",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 146,
              "end_idx": 148,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T653",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 57,
              "end_idx": 59,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T654",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 163,
              "end_idx": 165,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R158",
              "head_entity_id": "T645",
              "tail_entity_id": "T644"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R159",
              "head_entity_id": "T653",
              "tail_entity_id": "T646"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R160",
              "head_entity_id": "T653",
              "tail_entity_id": "T647"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R161",
              "head_entity_id": "T654",
              "tail_entity_id": "T651"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R162",
              "head_entity_id": "T652",
              "tail_entity_id": "T651"
            }
          ],
          "sentence_en": "Hyperglycemia during pregnancy includes diabetic pregnancy and gestational diabetes mellitus (GDM). Regardless of the type of hyperglycemia, it may lead to adverse pregnancy outcomes. Patients who need hospitalization for blood sugar management include: diabetic patients planning pregnancy or already pregnant, or GDM patients whose blood sugar levels do not meet standard after outpatient treatment; those with severe acute and chronic complications; those who need to start insulin treatment during pregnancy; in addition, patients with gestational hyperglycemia who are hospitalized in the obstetrics department should also ask the endocrinology department to manage their blood sugar levels if necessary, depending on their blood sugar levels."
        }
      ],
      "paragraph_en": "Hyperglycemia during pregnancy includes diabetic pregnancy and gestational diabetes mellitus (GDM). Regardless of the type of hyperglycemia, it may lead to adverse pregnancy outcomes. Patients who need hospitalization for blood sugar management include: diabetic patients planning pregnancy or already pregnant, or GDM patients whose blood sugar levels do not meet standard after outpatient treatment; those with severe acute and chronic complications; those who need to start insulin treatment during pregnancy; in addition, patients with gestational hyperglycemia who are hospitalized in the obstetrics department should also ask the endocrinology department to manage their blood sugar levels if necessary, depending on their blood sugar levels."
    },
    {
      "paragraph_id": "71",
      "paragraph": "1.计划妊娠的糖尿病患者住院血糖管理",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.计划妊娠的糖尿病患者住院血糖管理",
          "start_idx": 0,
          "end_idx": 18,
          "entities": [
            {
              "entity_id": "T655",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T656",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 14,
              "end_idx": 16,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R163",
              "head_entity_id": "T656",
              "tail_entity_id": "T655"
            }
          ],
          "sentence_en": "1. Blood glucose management in hospitalized diabetic patients planning pregnancy"
        }
      ],
      "paragraph_en": "1. Blood glucose management in hospitalized diabetic patients planning pregnancy"
    },
    {
      "paragraph_id": "72",
      "paragraph": "糖尿病患者从计划妊娠至整个孕期，都应进行严格的血糖管理.以减少不良妊娠结局的发生。计划妊娠的糖尿病患者因血糖控制不良或合并严重急、慢性并发症入院时，需要进行以下管理：",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "糖尿病患者从计划妊娠至整个孕期，都应进行严格的血糖管理.以减少不良妊娠结局的发生。计划妊娠的糖尿病患者因血糖控制不良或合并严重急、慢性并发症入院时，需要进行以下管理：",
          "start_idx": 0,
          "end_idx": 83,
          "entities": [
            {
              "entity_id": "T657",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T658",
              "entity": "不良妊娠",
              "entity_type": "Symptom",
              "start_idx": 31,
              "end_idx": 35,
              "entity_en": "Adverse pregnancy"
            },
            {
              "entity_id": "T659",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 49,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T660",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 23,
              "end_idx": 25,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T661",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 52,
              "end_idx": 54,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T662",
              "entity": "控制不良",
              "entity_type": "Test_Value",
              "start_idx": 54,
              "end_idx": 58,
              "entity_en": "Poor control"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R164",
              "head_entity_id": "T660",
              "tail_entity_id": "T657"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R165",
              "head_entity_id": "T658",
              "tail_entity_id": "T657"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R166",
              "head_entity_id": "T661",
              "tail_entity_id": "T659"
            }
          ],
          "sentence_en": "Diabetic patients should strictly manage their blood sugar from the time of pregnancy planning to the entire pregnancy to reduce the occurrence of adverse pregnancy outcomes. When diabetic patients planning pregnancy are hospitalized due to poor blood sugar control or severe acute or chronic complications, the following management is required:"
        }
      ],
      "paragraph_en": "Diabetic patients should strictly manage their blood sugar from the time of pregnancy planning to the entire pregnancy to reduce the occurrence of adverse pregnancy outcomes. When diabetic patients planning pregnancy are hospitalized due to poor blood sugar control or severe acute or chronic complications, the following management is required:"
    },
    {
      "paragraph_id": "73",
      "paragraph": "(1)糖尿病病情评估：系统评价血糖控制状况，监测全天血糖谱(三餐前后、睡前血糖)及HbA1c，必要时可进行动态血糖监测系统(CGMS)；全面评估糖尿病慢性并发症状况如糖尿病视网膜病变(DR)、糖尿病肾脏病变(DKD)及糖尿病周围神经病变等，评估可能加重或促使DR、DKD进展的危险因素；根据White分级(表3)评估糖尿病病情与妊娠风险，White分级在F级以下的患者，妊娠后胎儿存活率不到5%，因而应避免妊娠。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)糖尿病病情评估：系统评价血糖控制状况，监测全天血糖谱(三餐前后、睡前血糖)及HbA1c，必要时可进行动态血糖监测系统(CGMS)；全面评估糖尿病慢性并发症状况如糖尿病视网膜病变(DR)、糖尿病肾脏病变(DKD)及糖尿病周围神经病变等，评估可能加重或促使DR、DKD进展的危险因素；根据White分级(表3)评估糖尿病病情与妊娠风险，White分级在F级以下的患者，妊娠后胎儿存活率不到5%，因而应避免妊娠。",
          "start_idx": 0,
          "end_idx": 206,
          "entities": [
            {
              "entity_id": "T663",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T664",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 41,
              "end_idx": 46,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T665",
              "entity": "糖尿病慢性并发症状况",
              "entity_type": "Disease",
              "start_idx": 72,
              "end_idx": 82,
              "entity_en": "Chronic complications of diabetes"
            },
            {
              "entity_id": "T666",
              "entity": "糖尿病视网膜病变(DR)",
              "entity_type": "Disease",
              "start_idx": 83,
              "end_idx": 95,
              "entity_en": "Diabetic Retinopathy (DR)"
            },
            {
              "entity_id": "T667",
              "entity": "糖尿病肾脏病变(DKD)",
              "entity_type": "Disease",
              "start_idx": 96,
              "end_idx": 108,
              "entity_en": "Diabetic Kidney Disease (DKD)"
            },
            {
              "entity_id": "T668",
              "entity": "糖尿病周围神经病变",
              "entity_type": "Disease",
              "start_idx": 109,
              "end_idx": 118,
              "entity_en": "Diabetic peripheral neuropathy"
            },
            {
              "entity_id": "T669",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 86,
              "end_idx": 89,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T670",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 99,
              "end_idx": 101,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T671",
              "entity": "周围神经",
              "entity_type": "Anatomy",
              "start_idx": 112,
              "end_idx": 116,
              "entity_en": "Peripheral nerves"
            },
            {
              "entity_id": "T672",
              "entity": "DR",
              "entity_type": "Disease",
              "start_idx": 129,
              "end_idx": 131,
              "entity_en": "DR"
            },
            {
              "entity_id": "T673",
              "entity": "DKD",
              "entity_type": "Disease",
              "start_idx": 132,
              "end_idx": 135,
              "entity_en": "DKD"
            },
            {
              "entity_id": "T674",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 158,
              "end_idx": 161,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T675",
              "entity": "避免妊娠",
              "entity_type": "Treatment",
              "start_idx": 201,
              "end_idx": 205,
              "entity_en": "Avoid pregnancy"
            },
            {
              "entity_id": "T676",
              "entity": "全天血糖谱",
              "entity_type": "Test_items",
              "start_idx": 24,
              "end_idx": 29,
              "entity_en": "All-day blood sugar profile"
            },
            {
              "entity_id": "T677",
              "entity": "三餐前后、睡前血糖",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 39,
              "entity_en": "Blood sugar levels before and after meals and before bedtime"
            },
            {
              "entity_id": "T678",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 15,
              "end_idx": 17,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T679",
              "entity": "动态血糖监测系统(CGMS)",
              "entity_type": "Test_items",
              "start_idx": 53,
              "end_idx": 67,
              "entity_en": "Continuous Glucose Monitoring System (CGMS)"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R167",
              "head_entity_id": "T678",
              "tail_entity_id": "T663"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R168",
              "head_entity_id": "T669",
              "tail_entity_id": "T666"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R169",
              "head_entity_id": "T670",
              "tail_entity_id": "T667"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R170",
              "head_entity_id": "T671",
              "tail_entity_id": "T668"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R171",
              "head_entity_id": "T675",
              "tail_entity_id": "T674"
            }
          ],
          "sentence_en": "(1) Assessment of diabetes: Systematically evaluate blood sugar control status, monitor blood sugar profile throughout the day (blood sugar levels before and after meals and before bedtime) and HbA1c, and use a continuous blood glucose monitoring system (CGMS) if necessary; comprehensively assess chronic complications of diabetes such as diabetic retinopathy (DR), diabetic nephropathy (DKD), and diabetic peripheral neuropathy, and assess risk factors that may aggravate or promote the progression of DR and DKD; assess diabetes status and pregnancy risk according to the White classification (Table 3). For patients with a White classification below F, the fetal survival rate after pregnancy is less than 5%, so pregnancy should be avoided."
        }
      ],
      "paragraph_en": "(1) Assessment of diabetes: Systematically evaluate blood sugar control status, monitor blood sugar profile throughout the day (blood sugar levels before and after meals and before bedtime) and HbA1c, and use a continuous blood glucose monitoring system (CGMS) if necessary; comprehensively assess chronic complications of diabetes such as diabetic retinopathy (DR), diabetic nephropathy (DKD), and diabetic peripheral neuropathy, and assess risk factors that may aggravate or promote the progression of DR and DKD; assess diabetes status and pregnancy risk according to the White classification (Table 3). For patients with a White classification below F, the fetal survival rate after pregnancy is less than 5%, so pregnancy should be avoided."
    },
    {
      "paragraph_id": "74",
      "paragraph": "(2)血糖控制目标和治疗方案：计划妊娠的糖尿病患者应严格控制血糖，餐前血糖控制在3.9-6.5mmol/L，餐后血糖<8.5mmol/L，在避免低血糖的情况下尽量控制HbA1c<6.5%，用胰岛素治疗者控制HbA1c<7.0%。目前我国口服降糖药物均未纳入妊娠期使用适应证，因此孕前正在使用口服降糖药物的2型糖尿病患者应适时停用，并转换为胰岛素控制血糖。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)血糖控制目标和治疗方案：计划妊娠的糖尿病患者应严格控制血糖，餐前血糖控制在3.9-6.5mmol/L，餐后血糖<8.5mmol/L，在避免低血糖的情况下尽量控制HbA1c<6.5%，用胰岛素治疗者控制HbA1c<7.0%。目前我国口服降糖药物均未纳入妊娠期使用适应证，因此孕前正在使用口服降糖药物的2型糖尿病患者应适时停用，并转换为胰岛素控制血糖。",
          "start_idx": 0,
          "end_idx": 177,
          "entities": [
            {
              "entity_id": "T680",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 23,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T681",
              "entity": "餐前血糖",
              "entity_type": "Test_items",
              "start_idx": 33,
              "end_idx": 37,
              "entity_en": "Pre-meal blood sugar"
            },
            {
              "entity_id": "T682",
              "entity": "3.9-6.5mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 40,
              "end_idx": 53,
              "entity_en": "3.9-6.5mmol/L"
            },
            {
              "entity_id": "T683",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 54,
              "end_idx": 58,
              "entity_en": "Postprandial blood sugar"
            },
            {
              "entity_id": "T684",
              "entity": "<8.5mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 58,
              "end_idx": 68,
              "entity_en": "<8.5mmol/L"
            },
            {
              "entity_id": "T685",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 72,
              "end_idx": 75,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T686",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 83,
              "end_idx": 88,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T687",
              "entity": "<6.5%",
              "entity_type": "Test_Value",
              "start_idx": 88,
              "end_idx": 93,
              "entity_en": "<6.5%"
            },
            {
              "entity_id": "T688",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 95,
              "end_idx": 98,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T689",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 103,
              "end_idx": 108,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T690",
              "entity": "<7.0%",
              "entity_type": "Test_Value",
              "start_idx": 108,
              "end_idx": 113,
              "entity_en": "<7.0%"
            },
            {
              "entity_id": "T691",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 118,
              "end_idx": 120,
              "entity_en": "oral"
            },
            {
              "entity_id": "T692",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 145,
              "end_idx": 147,
              "entity_en": "oral"
            },
            {
              "entity_id": "T693",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 152,
              "end_idx": 157,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T694",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 152,
              "end_idx": 154,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T695",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 172,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T696",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 3,
              "end_idx": 5,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T697",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 32,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T698",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 174,
              "end_idx": 176,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R172",
              "head_entity_id": "T697",
              "tail_entity_id": "T680"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R173",
              "head_entity_id": "T694",
              "tail_entity_id": "T693"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R174",
              "head_entity_id": "T695",
              "tail_entity_id": "T693"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R175",
              "head_entity_id": "T698",
              "tail_entity_id": "T693"
            }
          ],
          "sentence_en": "(2) Blood sugar control goals and treatment plans: Diabetic patients planning pregnancy should strictly control blood sugar, with pre-meal blood sugar controlled at 3.9-6.5mmol/L and post-meal blood sugar <8.5mmol/L. While avoiding hypoglycemia, try to control HbA1c <6.5%, and control HbA1c <7.0% for those treated with insulin. At present, oral hypoglycemic drugs in my country are not included in the indications for use during pregnancy. Therefore, patients with type 2 diabetes who are using oral hypoglycemic drugs before pregnancy should stop using them in a timely manner and switch to insulin to control blood sugar."
        }
      ],
      "paragraph_en": "(2) Blood sugar control goals and treatment plans: Diabetic patients planning pregnancy should strictly control blood sugar, with pre-meal blood sugar controlled at 3.9-6.5mmol/L and post-meal blood sugar <8.5mmol/L. While avoiding hypoglycemia, try to control HbA1c <6.5%, and control HbA1c <7.0% for those treated with insulin. At present, oral hypoglycemic drugs in my country are not included in the indications for use during pregnancy. Therefore, patients with type 2 diabetes who are using oral hypoglycemic drugs before pregnancy should stop using them in a timely manner and switch to insulin to control blood sugar."
    },
    {
      "paragraph_id": "75",
      "paragraph": "(3)制订妊娠计划与患者教育：住院期间，应对计划妊娠的糖尿病患者及其家属进行教育，帮助患者及其家属明确糖尿病与妊娠间的相互影响，帮助患者制订以家庭为单位的妊娠计划，并制定完善的孕期随访计划。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)制订妊娠计划与患者教育：住院期间，应对计划妊娠的糖尿病患者及其家属进行教育，帮助患者及其家属明确糖尿病与妊娠间的相互影响，帮助患者制订以家庭为单位的妊娠计划，并制定完善的孕期随访计划。",
          "start_idx": 0,
          "end_idx": 95,
          "entities": [
            {
              "entity_id": "T699",
              "entity": "制订妊娠计划",
              "entity_type": "Treatment",
              "start_idx": 3,
              "end_idx": 9,
              "entity_en": "Planning your pregnancy"
            },
            {
              "entity_id": "T700",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 30,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T701",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 51,
              "end_idx": 54,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T702",
              "entity": "制订以家庭为单位的妊娠计划",
              "entity_type": "Treatment",
              "start_idx": 68,
              "end_idx": 81,
              "entity_en": "Develop a pregnancy plan as a family unit"
            },
            {
              "entity_id": "T703",
              "entity": "制定完善的孕期随访计划",
              "entity_type": "Treatment",
              "start_idx": 83,
              "end_idx": 94,
              "entity_en": "Develop a comprehensive pregnancy follow-up plan"
            }
          ],
          "relations": [
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R176",
              "head_entity_id": "T702",
              "tail_entity_id": "T701"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R177",
              "head_entity_id": "T703",
              "tail_entity_id": "T701"
            }
          ],
          "sentence_en": "(3) Developing pregnancy plans and patient education: During hospitalization, diabetic patients who are planning pregnancy and their families should be educated to help them understand the mutual impact between diabetes and pregnancy, help patients develop a pregnancy plan as a family unit, and develop a comprehensive pregnancy follow-up plan."
        }
      ],
      "paragraph_en": "(3) Developing pregnancy plans and patient education: During hospitalization, diabetic patients who are planning pregnancy and their families should be educated to help them understand the mutual impact between diabetes and pregnancy, help patients develop a pregnancy plan as a family unit, and develop a comprehensive pregnancy follow-up plan."
    },
    {
      "paragraph_id": "76",
      "paragraph": "2.妊娠期间的住院血糖管理",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.妊娠期间的住院血糖管理",
          "start_idx": 0,
          "end_idx": 13,
          "entities": [
            {
              "entity_id": "T704",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 9,
              "end_idx": 11,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "2. Inpatient blood sugar management during pregnancy"
        }
      ],
      "paragraph_en": "2. Inpatient blood sugar management during pregnancy"
    },
    {
      "paragraph_id": "77",
      "paragraph": "对于血糖控制不良的孕妇而言，如何在较短的孕期内尽早实现良好血糖控制十分重要。妊娠期间进行住院血糖管理内容包括：",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于血糖控制不良的孕妇而言，如何在较短的孕期内尽早实现良好血糖控制十分重要。",
          "start_idx": 0,
          "end_idx": 38,
          "entities": [
            {
              "entity_id": "T705",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T706",
              "entity": "控制不良",
              "entity_type": "Test_Value",
              "start_idx": 4,
              "end_idx": 8,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T707",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 29,
              "end_idx": 31,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "For pregnant women with poor blood sugar control, it is very important to achieve good blood sugar control as early as possible during a shorter pregnancy."
        },
        {
          "sentence_id": "1",
          "sentence": "妊娠期间进行住院血糖管理内容包括：",
          "start_idx": 38,
          "end_idx": 55,
          "entities": [
            {
              "entity_id": "T708",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 8,
              "end_idx": 10,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "Inpatient blood sugar management during pregnancy includes:"
        }
      ],
      "paragraph_en": "For pregnant women with poor blood sugar control, it is very important to achieve good blood sugar control as early as possible during a shorter pregnancy. Inpatient blood sugar management during pregnancy includes:"
    },
    {
      "paragraph_id": "78",
      "paragraph": "(1)病情监测与控制目标：血糖控制不良或不稳定时，应每日监测全天血糖谱(三餐前后、睡前血糖)，必要时可进行CGMS。当孕妇出现不明原因恶心、呕吐、乏力等不适或者血糖控制不理想时还应及时监测尿酮体，必要时行血气分析。妊娠期间血糖控制目标根据糖尿病类型不同有所不同(表4)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)病情监测与控制目标：血糖控制不良或不稳定时，应每日监测全天血糖谱(三餐前后、睡前血糖)，必要时可进行CGMS。当孕妇出现不明原因恶心、呕吐、乏力等不适或者血糖控制不理想时还应及时监测尿酮体，必要时行血气分析。妊娠期间血糖控制目标根据糖尿病类型不同有所不同(表4)。",
          "start_idx": 0,
          "end_idx": 135,
          "entities": [
            {
              "entity_id": "T709",
              "entity": "CGMS",
              "entity_type": "Test",
              "start_idx": 53,
              "end_idx": 57,
              "entity_en": "CGMS"
            },
            {
              "entity_id": "T710",
              "entity": "恶心",
              "entity_type": "Symptom",
              "start_idx": 67,
              "end_idx": 69,
              "entity_en": "nausea"
            },
            {
              "entity_id": "T711",
              "entity": "呕吐",
              "entity_type": "Symptom",
              "start_idx": 70,
              "end_idx": 72,
              "entity_en": "Vomit"
            },
            {
              "entity_id": "T712",
              "entity": "乏力",
              "entity_type": "Symptom",
              "start_idx": 73,
              "end_idx": 75,
              "entity_en": "Fatigue"
            },
            {
              "entity_id": "T713",
              "entity": "尿酮体",
              "entity_type": "Test_items",
              "start_idx": 94,
              "end_idx": 97,
              "entity_en": "Urine ketone bodies"
            },
            {
              "entity_id": "T714",
              "entity": "血气分析",
              "entity_type": "Test",
              "start_idx": 102,
              "end_idx": 106,
              "entity_en": "Blood gas analysis"
            },
            {
              "entity_id": "T715",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 119,
              "end_idx": 122,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T716",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T717",
              "entity": "控制不良或不稳定",
              "entity_type": "Test_Value",
              "start_idx": 15,
              "end_idx": 23,
              "entity_en": "Poor or unstable control"
            },
            {
              "entity_id": "T718",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 80,
              "end_idx": 82,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T719",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 111,
              "end_idx": 113,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T720",
              "entity": "血糖谱",
              "entity_type": "Test_items",
              "start_idx": 32,
              "end_idx": 35,
              "entity_en": "Blood glucose profile"
            },
            {
              "entity_id": "T721",
              "entity": "三餐前后、睡前血糖",
              "entity_type": "Test_items",
              "start_idx": 36,
              "end_idx": 45,
              "entity_en": "Blood sugar levels before and after meals and before bedtime"
            },
            {
              "entity_id": "T722",
              "entity": "控制不理想",
              "entity_type": "Test_Value",
              "start_idx": 82,
              "end_idx": 87,
              "entity_en": "Poor control"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R178",
              "head_entity_id": "T719",
              "tail_entity_id": "T715"
            }
          ],
          "sentence_en": "(1) Disease monitoring and control goals: When blood sugar is poorly controlled or unstable, the blood sugar profile should be monitored daily (blood sugar before and after meals and before bedtime), and CGMS can be performed if necessary. When pregnant women experience unexplained nausea, vomiting, fatigue, or other discomfort or when blood sugar control is not ideal, urine ketone bodies should be monitored in a timely manner, and blood gas analysis should be performed if necessary. The blood sugar control goals during pregnancy vary depending on the type of diabetes (Table 4)."
        }
      ],
      "paragraph_en": "(1) Disease monitoring and control goals: When blood sugar is poorly controlled or unstable, the blood sugar profile should be monitored daily (blood sugar before and after meals and before bedtime), and CGMS can be performed if necessary. When pregnant women experience unexplained nausea, vomiting, fatigue, or other discomfort or when blood sugar control is not ideal, urine ketone bodies should be monitored in a timely manner, and blood gas analysis should be performed if necessary. The blood sugar control goals during pregnancy vary depending on the type of diabetes (Table 4)."
    },
    {
      "paragraph_id": "79",
      "paragraph": "(2)管理方案：①饮食与运动方案：饮食与运动干预是妊娠期高血糖管理的基础，在孕妇身体条件允许的情况下，住院期间也应进行合理的饮食、运动干预。饮食应控制总能量摄入，并保证营养均衡，可请营养科进行指导。②胰岛素治疗方案：糖尿病患者妊娠时，血糖水平波动较大，血糖较难控制，均需要使用胰岛素控制血糖。而通过生活方式干预血糖不能达标的GDM孕妇应首先推荐应用胰岛素控制血糖。虽然国外有研究证实了口服降糖药物二甲双胍等在GDM孕妇中应用的安全性和有效性，但我国尚缺乏相关研究，且口服降糖药在我国均无妊娠期间使用的适应证。对于孕前已使用二甲双胍的多囊卵巢综合征(PCOS)患者，应权衡药物的潜在风险和可能获益，在知情同意的基础上可以考虑妊娠期间继续使用。妊娠期常用的胰岛素制剂类型包括短效人胰岛素、中效人胰岛素，另外，胰岛素类似物如门冬胰岛素、地特胰岛素已获国家食品药品监督管理总局(CFDA)批准可以在妊娠期间使用(表5)。临床上最符合生理要求的胰岛素治疗方案为基础一餐时胰岛素治疗和CSII，两种方案均可根据血糖监测情况进行灵活的个体化调整。需要注意的是，妊娠中、晚期对胰岛素需要量有不同程度的增加，妊娠32~36周胰岛素需要量达高峰，妊娠36周后稍下降，应根据个体血糖监测结果，不断调整胰岛素用量。产后一旦患者恢复正常饮食，应及时进行血糖监测，根据血糖情况决定是否需要继续胰岛素治疗，通常产后胰岛素需要量较妊娠期会明显减少。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)管理方案：①饮食与运动方案：饮食与运动干预是妊娠期高血糖管理的基础，在孕妇身体条件允许的情况下，住院期间也应进行合理的饮食、运动干预。饮食应控制总能量摄入，并保证营养均衡，可请营养科进行指导。②胰岛素治疗方案：糖尿病患者妊娠时，血糖水平波动较大，血糖较难控制，均需要使用胰岛素控制血糖。而通过生活方式干预血糖不能达标的GDM孕妇应首先推荐应用胰岛素控制血糖。虽然国外有研究证实了口服降糖药物二甲双胍等在GDM孕妇中应用的安全性和有效性，但我国尚缺乏相关研究，且口服降糖药在我国均无妊娠期间使用的适应证。",
          "start_idx": 0,
          "end_idx": 254,
          "entities": [
            {
              "entity_id": "T723",
              "entity": "饮食与运动干预",
              "entity_type": "Treatment",
              "start_idx": 17,
              "end_idx": 24,
              "entity_en": "Diet and exercise intervention"
            },
            {
              "entity_id": "T724",
              "entity": "妊娠期高血糖",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 31,
              "entity_en": "Hyperglycemia during pregnancy"
            },
            {
              "entity_id": "T725",
              "entity": "饮食、运动干预",
              "entity_type": "Treatment",
              "start_idx": 62,
              "end_idx": 69,
              "entity_en": "Diet and exercise intervention"
            },
            {
              "entity_id": "T726",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 100,
              "end_idx": 103,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T727",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 108,
              "end_idx": 111,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T728",
              "entity": "血糖水平",
              "entity_type": "Test_items",
              "start_idx": 117,
              "end_idx": 121,
              "entity_en": "Blood sugar levels"
            },
            {
              "entity_id": "T729",
              "entity": "波动较大",
              "entity_type": "Test_Value",
              "start_idx": 121,
              "end_idx": 125,
              "entity_en": "Large fluctuations"
            },
            {
              "entity_id": "T730",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 126,
              "end_idx": 128,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T731",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 138,
              "end_idx": 141,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T732",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 149,
              "end_idx": 155,
              "entity_en": "Lifestyle interventions"
            },
            {
              "entity_id": "T733",
              "entity": "GDM",
              "entity_type": "Disease",
              "start_idx": 162,
              "end_idx": 165,
              "entity_en": "GDM"
            },
            {
              "entity_id": "T734",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 155,
              "end_idx": 157,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T735",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 174,
              "end_idx": 177,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T736",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 192,
              "end_idx": 194,
              "entity_en": "oral"
            },
            {
              "entity_id": "T737",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 198,
              "end_idx": 202,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T738",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 233,
              "end_idx": 235,
              "entity_en": "oral"
            },
            {
              "entity_id": "T758",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 143,
              "end_idx": 145,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T759",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 179,
              "end_idx": 181,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R179",
              "head_entity_id": "T723",
              "tail_entity_id": "T724"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R180",
              "head_entity_id": "T731",
              "tail_entity_id": "T727"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R181",
              "head_entity_id": "T728",
              "tail_entity_id": "T727"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R182",
              "head_entity_id": "T732",
              "tail_entity_id": "T733"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R183",
              "head_entity_id": "T734",
              "tail_entity_id": "T733"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R184",
              "head_entity_id": "T735",
              "tail_entity_id": "T733"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R185",
              "head_entity_id": "T736",
              "tail_entity_id": "T737"
            }
          ],
          "sentence_en": "(2) Management plan: ① Diet and exercise plan: Diet and exercise intervention is the basis for managing hyperglycemia during pregnancy. If the physical condition of the pregnant woman allows, reasonable diet and exercise intervention should also be carried out during hospitalization. The diet should control total energy intake and ensure balanced nutrition. You can ask the nutrition department for guidance. ② Insulin treatment plan: During pregnancy, the blood sugar level of diabetic patients fluctuates greatly and blood sugar is difficult to control. Insulin is required to control blood sugar. GDM pregnant women who cannot reach the blood sugar standard through lifestyle intervention should first be recommended to use insulin to control blood sugar. Although foreign studies have confirmed the safety and effectiveness of oral hypoglycemic drugs such as metformin in GDM pregnant women, there is still a lack of relevant research in my country, and oral hypoglycemic drugs have no indications for use during pregnancy in my country."
        },
        {
          "sentence_id": "1",
          "sentence": "对于孕前已使用二甲双胍的多囊卵巢综合征(PCOS)患者，应权衡药物的潜在风险和可能获益，在知情同意的基础上可以考虑妊娠期间继续使用。",
          "start_idx": 254,
          "end_idx": 320,
          "entities": [
            {
              "entity_id": "T739",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 11,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T740",
              "entity": "多囊卵巢综合征(PCOS)",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 25,
              "entity_en": "Polycystic Ovary Syndrome (PCOS)"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R186",
              "head_entity_id": "T739",
              "tail_entity_id": "T740"
            }
          ],
          "sentence_en": "For patients with polycystic ovary syndrome (PCOS) who have used metformin before pregnancy, the potential risks and possible benefits of the drug should be weighed, and continued use during pregnancy can be considered based on informed consent."
        },
        {
          "sentence_id": "2",
          "sentence": "妊娠期常用的胰岛素制剂类型包括短效人胰岛素、中效人胰岛素，另外，胰岛素类似物如门冬胰岛素、地特胰岛素已获国家食品药品监督管理总局(CFDA)批准可以在妊娠期间使用(表5)。",
          "start_idx": 320,
          "end_idx": 406,
          "entities": [
            {
              "entity_id": "T741",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T742",
              "entity": "短效人胰岛素",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 21,
              "entity_en": "Short-acting human insulin"
            },
            {
              "entity_id": "T743",
              "entity": "中效人胰岛素",
              "entity_type": "Drug",
              "start_idx": 22,
              "end_idx": 28,
              "entity_en": "Intermediate-acting human insulin"
            },
            {
              "entity_id": "T744",
              "entity": "胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 32,
              "end_idx": 38,
              "entity_en": "Insulin analogs"
            },
            {
              "entity_id": "T745",
              "entity": "门冬胰岛素",
              "entity_type": "Drug",
              "start_idx": 39,
              "end_idx": 44,
              "entity_en": "Insulin Aspart"
            },
            {
              "entity_id": "T746",
              "entity": "地特胰岛素",
              "entity_type": "Drug",
              "start_idx": 45,
              "end_idx": 50,
              "entity_en": "Insulin Detemir"
            }
          ],
          "relations": [],
          "sentence_en": "Commonly used types of insulin preparations during pregnancy include short-acting human insulin and intermediate-acting human insulin. In addition, insulin analogs such as aspart insulin and detemir insulin have been approved by the State Food and Drug Administration (CFDA) for use during pregnancy (Table 5)."
        },
        {
          "sentence_id": "3",
          "sentence": "临床上最符合生理要求的胰岛素治疗方案为基础一餐时胰岛素治疗和CSII，两种方案均可根据血糖监测情况进行灵活的个体化调整。",
          "start_idx": 406,
          "end_idx": 466,
          "entities": [
            {
              "entity_id": "T747",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 14,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T748",
              "entity": "血糖监测",
              "entity_type": "Test_items",
              "start_idx": 43,
              "end_idx": 47,
              "entity_en": "Blood glucose monitoring"
            },
            {
              "entity_id": "T749",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 27,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "The insulin treatment regimens that best meet physiological requirements clinically are meal-based insulin therapy and CSII. Both regimens can be flexibly adjusted individually based on blood glucose monitoring results."
        },
        {
          "sentence_id": "4",
          "sentence": "需要注意的是，妊娠中、晚期对胰岛素需要量有不同程度的增加，妊娠32~36周胰岛素需要量达高峰，妊娠36周后稍下降，应根据个体血糖监测结果，不断调整胰岛素用量。",
          "start_idx": 466,
          "end_idx": 545,
          "entities": [
            {
              "entity_id": "T750",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 17,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T751",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 40,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T752",
              "entity": "血糖监测",
              "entity_type": "Test_items",
              "start_idx": 62,
              "end_idx": 66,
              "entity_en": "Blood glucose monitoring"
            },
            {
              "entity_id": "T753",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 73,
              "end_idx": 76,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "It should be noted that the insulin requirement increases to varying degrees in the middle and late stages of pregnancy. The insulin requirement reaches a peak at 32 to 36 weeks of pregnancy and decreases slightly after 36 weeks of pregnancy. The insulin dosage should be continuously adjusted according to individual blood sugar monitoring results."
        },
        {
          "sentence_id": "5",
          "sentence": "产后一旦患者恢复正常饮食，应及时进行血糖监测，根据血糖情况决定是否需要继续胰岛素治疗，通常产后胰岛素需要量较妊娠期会明显减少。",
          "start_idx": 545,
          "end_idx": 608,
          "entities": [
            {
              "entity_id": "T754",
              "entity": "血糖监测",
              "entity_type": "Test_items",
              "start_idx": 18,
              "end_idx": 22,
              "entity_en": "Blood glucose monitoring"
            },
            {
              "entity_id": "T755",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 25,
              "end_idx": 27,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T756",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 40,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T757",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 50,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "Once the patient resumes a normal diet after delivery, blood sugar monitoring should be performed in a timely manner, and a decision should be made whether to continue insulin treatment based on the blood sugar level. Usually, the amount of insulin required after delivery is significantly reduced compared to pregnancy."
        }
      ],
      "paragraph_en": "(2) Management plan: ① Diet and exercise plan: Diet and exercise intervention is the basis for managing hyperglycemia during pregnancy. If the pregnant woman's physical condition allows, she should also undergo reasonable diet and exercise intervention during hospitalization. The diet should control total energy intake and ensure balanced nutrition. You can ask the nutrition department for guidance. ② Insulin treatment plan: During pregnancy, the blood sugar level of diabetic patients fluctuates greatly and is difficult to control. Insulin is required to control blood sugar. Pregnant women with GDM who cannot reach the target blood sugar level through lifestyle intervention should first be recommended to use insulin to control blood sugar. Although foreign studies have confirmed the safety and effectiveness of oral hypoglycemic drugs such as metformin in pregnant women with GDM, there is still a lack of relevant research in my country, and oral hypoglycemic drugs have no indications for use during pregnancy in my country. For patients with polycystic ovary syndrome (PCOS) who have used metformin before pregnancy, the potential risks and possible benefits of the drug should be weighed, and continued use during pregnancy can be considered on the basis of informed consent. Commonly used insulin preparations during pregnancy include short-acting human insulin and intermediate-acting human insulin. In addition, insulin analogs such as aspart insulin and detemir insulin have been approved by the State Food and Drug Administration (CFDA) for use during pregnancy (Table 5). The most clinically physiologically appropriate insulin treatment regimen is meal-based insulin therapy and CSII. Both regimens can be flexibly adjusted to individual needs based on blood glucose monitoring. It should be noted that the need for insulin increases to varying degrees during the middle and late stages of pregnancy. The need for insulin peaks at 32 to 36 weeks of pregnancy and decreases slightly after 36 weeks of pregnancy. The amount of insulin should be adjusted continuously based on individual blood glucose monitoring results. Once the patient resumes a normal diet after delivery, blood glucose monitoring should be performed in a timely manner to determine whether insulin treatment needs to be continued based on the blood glucose situation. Usually, the need for insulin after delivery is significantly reduced compared to that during pregnancy."
    },
    {
      "paragraph_id": "80",
      "paragraph": "(3)急、危重症的处理：①妊娠期低血糖：常见诱因包括：早孕反应(如晨起恶心)引起的摄食异常；运动量过大；胰岛素剂量过大；围产期能量清耗过大。治疗原则：迅速给予糖水或碳水化合物食物；重症者需用50%葡萄糖静脉注射；如需要，可为糖尿病孕妇提供胰升糖素；寻找诱因，及时调整药物治疗。②妊娠期DKA：孕期血糖控制不良容易并发酮症甚至DKA，常见诱因包括：妊娠期间漏诊、未及时诊断或治疗的糖尿病：胰岛素治疗不规范；饮食控制不合理；产程中和手术前后应激状态；合并感染；使用糖皮质激素等。治疗原则：给予胰岛素降低血糖、纠正代谢和电解质紊乱、改善血液循环、去除诱因。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)急、危重症的处理：①妊娠期低血糖：常见诱因包括：早孕反应(如晨起恶心)引起的摄食异常；运动量过大；胰岛素剂量过大；围产期能量清耗过大。治疗原则：迅速给予糖水或碳水化合物食物；重症者需用50%葡萄糖静脉注射；如需要，可为糖尿病孕妇提供胰升糖素；寻找诱因，及时调整药物治疗。②妊娠期DKA：孕期血糖控制不良容易并发酮症甚至DKA，常见诱因包括：妊娠期间漏诊、未及时诊断或治疗的糖尿病：胰岛素治疗不规范；饮食控制不合理；产程中和手术前后应激状态；合并感染；使用糖皮质激素等。",
          "start_idx": 0,
          "end_idx": 237,
          "entities": [
            {
              "entity_id": "T760",
              "entity": "妊娠期低血糖",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 19,
              "entity_en": "Hypoglycemia during pregnancy"
            },
            {
              "entity_id": "T761",
              "entity": "早孕反应(如晨起恶心)引起的摄食异常",
              "entity_type": "Reason",
              "start_idx": 27,
              "end_idx": 45,
              "entity_en": "Abnormal feeding due to early pregnancy symptoms (such as morning sickness)"
            },
            {
              "entity_id": "T762",
              "entity": "运动量过大",
              "entity_type": "Reason",
              "start_idx": 46,
              "end_idx": 51,
              "entity_en": "Excessive exercise"
            },
            {
              "entity_id": "T763",
              "entity": "胰岛素剂量过大",
              "entity_type": "Reason",
              "start_idx": 52,
              "end_idx": 59,
              "entity_en": "Excessive insulin dose"
            },
            {
              "entity_id": "T764",
              "entity": "围产期能量清耗过大",
              "entity_type": "Reason",
              "start_idx": 60,
              "end_idx": 69,
              "entity_en": "Excessive energy consumption during the peripartum period"
            },
            {
              "entity_id": "T765",
              "entity": "给予糖水或碳水化合物食物",
              "entity_type": "Treatment",
              "start_idx": 77,
              "end_idx": 89,
              "entity_en": "Give sugar water or carbohydrate food"
            },
            {
              "entity_id": "T766",
              "entity": "50%葡萄糖",
              "entity_type": "Drug",
              "start_idx": 95,
              "end_idx": 101,
              "entity_en": "50% Glucose"
            },
            {
              "entity_id": "T767",
              "entity": "静脉注射",
              "entity_type": "Method",
              "start_idx": 101,
              "end_idx": 105,
              "entity_en": "Intravenous injection"
            },
            {
              "entity_id": "T768",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 112,
              "end_idx": 115,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T769",
              "entity": "胰升糖素",
              "entity_type": "Drug",
              "start_idx": 119,
              "end_idx": 123,
              "entity_en": "Glucagon"
            },
            {
              "entity_id": "T770",
              "entity": "妊娠期DKA",
              "entity_type": "Disease",
              "start_idx": 139,
              "end_idx": 145,
              "entity_en": "DKA during pregnancy"
            },
            {
              "entity_id": "T771",
              "entity": "酮症",
              "entity_type": "Disease",
              "start_idx": 158,
              "end_idx": 160,
              "entity_en": "Ketosis"
            },
            {
              "entity_id": "T772",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 162,
              "end_idx": 165,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T773",
              "entity": "妊娠期间漏诊、未及时诊断或治疗的糖尿病",
              "entity_type": "Reason",
              "start_idx": 173,
              "end_idx": 192,
              "entity_en": "Diabetes that is missed, undiagnosed, or untreated during pregnancy"
            },
            {
              "entity_id": "T774",
              "entity": "胰岛素治疗不规范",
              "entity_type": "Reason",
              "start_idx": 193,
              "end_idx": 201,
              "entity_en": "Insulin therapy is not standardized"
            },
            {
              "entity_id": "T775",
              "entity": "饮食控制不合理",
              "entity_type": "Reason",
              "start_idx": 202,
              "end_idx": 209,
              "entity_en": "Improper diet control"
            },
            {
              "entity_id": "T776",
              "entity": "产程中和手术前后应激状态",
              "entity_type": "Reason",
              "start_idx": 210,
              "end_idx": 222,
              "entity_en": "Stress during labor and before and after surgery"
            },
            {
              "entity_id": "T777",
              "entity": "合并感染",
              "entity_type": "Reason",
              "start_idx": 223,
              "end_idx": 227,
              "entity_en": "Co-infection"
            },
            {
              "entity_id": "T778",
              "entity": "使用糖皮质激素",
              "entity_type": "Reason",
              "start_idx": 228,
              "end_idx": 235,
              "entity_en": "Use of glucocorticoids"
            },
            {
              "entity_id": "T781",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 148,
              "end_idx": 150,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R187",
              "head_entity_id": "T761",
              "tail_entity_id": "T760"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R188",
              "head_entity_id": "T762",
              "tail_entity_id": "T760"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R189",
              "head_entity_id": "T763",
              "tail_entity_id": "T760"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R190",
              "head_entity_id": "T764",
              "tail_entity_id": "T760"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R191",
              "head_entity_id": "T767",
              "tail_entity_id": "T766"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R192",
              "head_entity_id": "T769",
              "tail_entity_id": "T768"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R193",
              "head_entity_id": "T773",
              "tail_entity_id": "T770"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R194",
              "head_entity_id": "T774",
              "tail_entity_id": "T770"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R195",
              "head_entity_id": "T775",
              "tail_entity_id": "T770"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R196",
              "head_entity_id": "T776",
              "tail_entity_id": "T770"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R197",
              "head_entity_id": "T777",
              "tail_entity_id": "T770"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R198",
              "head_entity_id": "T778",
              "tail_entity_id": "T770"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R199",
              "head_entity_id": "T781",
              "tail_entity_id": "T771"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R200",
              "head_entity_id": "T781",
              "tail_entity_id": "T772"
            }
          ],
          "sentence_en": "(3) Treatment of acute and critical illnesses: ① Hypoglycemia during pregnancy: Common causes include: abnormal eating due to early pregnancy reactions (such as morning nausea); excessive exercise; excessive insulin doses; and excessive perinatal energy consumption. Treatment principles: Rapidly administer sugar water or carbohydrate foods; severe cases require intravenous injection of 50% glucose; if necessary, provide glucagon to pregnant women with diabetes; identify the causes and adjust drug treatment in a timely manner. ② DKA during pregnancy: Poor blood sugar control during pregnancy is prone to complications such as ketosis and even DKA. Common causes include: missed diagnosis, undiagnosed or untreated diabetes during pregnancy: irregular insulin treatment; unreasonable dietary control; stress during labor and before and after surgery; concurrent infection; use of glucocorticoids, etc."
        },
        {
          "sentence_id": "1",
          "sentence": "治疗原则：给予胰岛素降低血糖、纠正代谢和电解质紊乱、改善血液循环、去除诱因。",
          "start_idx": 237,
          "end_idx": 275,
          "entities": [
            {
              "entity_id": "T779",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T780",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 12,
              "end_idx": 14,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "Treatment principles: Give insulin to lower blood sugar, correct metabolic and electrolyte disorders, improve blood circulation, and remove inducements."
        }
      ],
      "paragraph_en": "(3) Treatment of acute and critical illnesses: ① Hypoglycemia during pregnancy: Common causes include: abnormal eating caused by early pregnancy reactions (such as morning nausea); excessive exercise; excessive insulin doses; excessive perinatal energy consumption. Treatment principles: Rapidly give sugar water or carbohydrate food; severe cases require intravenous injection of 50% glucose; if necessary, provide glucagon to pregnant women with diabetes; find the cause and adjust drug treatment in time. ② DKA during pregnancy: Poor blood sugar control during pregnancy is prone to complications such as ketosis and even DKA. Common causes include: missed diagnosis, undiagnosed or untreated diabetes during pregnancy: irregular insulin treatment; unreasonable diet control; stress during labor and before and after surgery; concurrent infection; use of glucocorticoids, etc. Treatment principles: Give insulin to lower blood sugar, correct metabolic and electrolyte disorders, improve blood circulation, and remove the cause."
    },
    {
      "paragraph_id": "81",
      "paragraph": "(4)分娩及产料、儿料处理：住院期间如出现母儿并发症，应及时联合产科进病情评估，根据病情决定终止妊娠时机及分娩方式。新生儿出生后易发生低血糖，严密监测其血糖变化及时发现低血糖，提早喂糖水、开奶，必要时进行静脉葡萄滴注。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)分娩及产料、儿料处理：住院期间如出现母儿并发症，应及时联合产科进病情评估，根据病情决定终止妊娠时机及分娩方式。新生儿出生后易发生低血糖，严密监测其血糖变化及时发现低血糖，提早喂糖水、开奶，必要时进行静脉葡萄滴注。",
          "start_idx": 0,
          "end_idx": 109,
          "entities": [
            {
              "entity_id": "T782",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 67,
              "end_idx": 70,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T783",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 76,
              "end_idx": 78,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T784",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 84,
              "end_idx": 87,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T785",
              "entity": "提早喂糖水、开奶",
              "entity_type": "Treatment",
              "start_idx": 88,
              "end_idx": 96,
              "entity_en": "Feed sugar water and milk early"
            },
            {
              "entity_id": "T786",
              "entity": "静脉葡萄滴注",
              "entity_type": "Method",
              "start_idx": 102,
              "end_idx": 108,
              "entity_en": "Intravenous grape drip"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R201",
              "head_entity_id": "T783",
              "tail_entity_id": "T784"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R202",
              "head_entity_id": "T785",
              "tail_entity_id": "T784"
            }
          ],
          "sentence_en": "(4) Delivery and handling of delivery and infant material: If maternal and fetal complications occur during hospitalization, the obstetric department should be consulted for timely assessment of the condition, and the timing of termination of pregnancy and method of delivery should be determined based on the condition. Newborns are prone to hypoglycemia after birth. Closely monitor their blood sugar changes to detect hypoglycemia in time, feed sugar water and milk early, and perform intravenous glucose drip if necessary."
        }
      ],
      "paragraph_en": "(4) Delivery and handling of delivery and infant material: If maternal and fetal complications occur during hospitalization, the obstetric department should be consulted for timely assessment of the condition, and the timing of termination of pregnancy and method of delivery should be determined based on the condition. Newborns are prone to hypoglycemia after birth. Closely monitor their blood sugar changes to detect hypoglycemia in time, feed sugar water and milk early, and perform intravenous glucose drip if necessary."
    },
    {
      "paragraph_id": "82",
      "paragraph": "档案建立及远期随访：所有因糖尿病住院的孕妇都应常规建立随访档案，制订随访计划，定期到内分泌门诊随访血糖状况。推荐所有GDM妇女在产后6~12周进行口服葡萄糖耐量试验(OGTT)检查，明确有无糖代谢异常，以后每3年随访1次。同时，建议对糖尿病患者的子代进行生长发育状况的随访，并进行健康生活方式的指导。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "档案建立及远期随访：所有因糖尿病住院的孕妇都应常规建立随访档案，制订随访计划，定期到内分泌门诊随访血糖状况。推荐所有GDM妇女在产后6~12周进行口服葡萄糖耐量试验(OGTT)检查，明确有无糖代谢异常，以后每3年随访1次。同时，建议对糖尿病患者的子代进行生长发育状况的随访，并进行健康生活方式的指导。",
          "start_idx": 0,
          "end_idx": 150,
          "entities": [
            {
              "entity_id": "T787",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 16,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T788",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 49,
              "end_idx": 51,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T789",
              "entity": "GDM",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 61,
              "entity_en": "GDM"
            },
            {
              "entity_id": "T790",
              "entity": "口服葡萄糖耐量试验(OGTT)检查",
              "entity_type": "Test",
              "start_idx": 73,
              "end_idx": 90,
              "entity_en": "Oral glucose tolerance test (OGTT)"
            },
            {
              "entity_id": "T791",
              "entity": "糖代谢异常",
              "entity_type": "Disease",
              "start_idx": 95,
              "end_idx": 100,
              "entity_en": "Abnormal glucose metabolism"
            },
            {
              "entity_id": "T792",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 117,
              "end_idx": 120,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T793",
              "entity": "健康生活方式的指导",
              "entity_type": "Treatment",
              "start_idx": 140,
              "end_idx": 149,
              "entity_en": "Healthy lifestyle guidance"
            },
            {
              "entity_id": "T794",
              "entity": "生长发育状况的随访",
              "entity_type": "Treatment",
              "start_idx": 127,
              "end_idx": 136,
              "entity_en": "Follow-up of growth and development"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R203",
              "head_entity_id": "T788",
              "tail_entity_id": "T787"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R204",
              "head_entity_id": "T790",
              "tail_entity_id": "T789"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R205",
              "head_entity_id": "T794",
              "tail_entity_id": "T792"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R206",
              "head_entity_id": "T793",
              "tail_entity_id": "T792"
            }
          ],
          "sentence_en": "File establishment and long-term follow-up: All pregnant women hospitalized for diabetes should have follow-up files established routinely, develop follow-up plans, and regularly visit the endocrine clinic to follow up on their blood sugar status. It is recommended that all women with GDM undergo an oral glucose tolerance test (OGTT) 6 to 12 weeks after delivery to determine whether they have abnormal glucose metabolism, and then follow up once every 3 years. At the same time, it is recommended to follow up the growth and development of the offspring of diabetic patients and provide guidance on a healthy lifestyle."
        }
      ],
      "paragraph_en": "File establishment and long-term follow-up: All pregnant women hospitalized for diabetes should have follow-up files established routinely, develop follow-up plans, and regularly visit the endocrine clinic to follow up on their blood sugar status. It is recommended that all women with GDM undergo an oral glucose tolerance test (OGTT) 6 to 12 weeks after delivery to determine whether they have abnormal glucose metabolism, and then follow up once every 3 years. At the same time, it is recommended to follow up the growth and development of the offspring of diabetic patients and provide guidance on a healthy lifestyle."
    },
    {
      "paragraph_id": "83",
      "paragraph": "四、住院患者血糖管理模式介绍",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "四、住院患者血糖管理模式介绍",
          "start_idx": 0,
          "end_idx": 14,
          "entities": [
            {
              "entity_id": "T795",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 6,
              "end_idx": 8,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "IV. Introduction to blood glucose management model for inpatients"
        }
      ],
      "paragraph_en": "IV. Introduction to blood glucose management model for inpatients"
    },
    {
      "paragraph_id": "84",
      "paragraph": "住院血糖管理模式是在管理理念指导下建构起来，由管理方法、管理制度、管理工具、管理程序组成的住院血糖管理行为体系结构。虽然我国糖尿病患病率逐年升高，但关于住院患者血糖管理模式的研究报道较少。由于各国医患关系、医院体制及医保制度的不同，住院患者管理模式存在差异。参照美国临床内分泌医师协会(AACE)住院患者血糖管理模式，结合我国住院患者及医院管理实情，对我国住院血糖管理模式进行以下推荐，以期为住院患者良好的血糖控制提供帮助。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "住院血糖管理模式是在管理理念指导下建构起来，由管理方法、管理制度、管理工具、管理程序组成的住院血糖管理行为体系结构。虽然我国糖尿病患病率逐年升高，但关于住院患者血糖管理模式的研究报道较少。",
          "start_idx": 0,
          "end_idx": 94,
          "entities": [
            {
              "entity_id": "T796",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 62,
              "end_idx": 65,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T797",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T798",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 47,
              "end_idx": 49,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T799",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 80,
              "end_idx": 82,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R207",
              "head_entity_id": "T799",
              "tail_entity_id": "T796"
            }
          ],
          "sentence_en": "The inpatient blood glucose management model is constructed under the guidance of management concepts and is composed of management methods, management systems, management tools, and management procedures. Although the prevalence of diabetes in my country has increased year by year, there are few research reports on the blood glucose management model for inpatients."
        },
        {
          "sentence_id": "1",
          "sentence": "由于各国医患关系、医院体制及医保制度的不同，住院患者管理模式存在差异。",
          "start_idx": 94,
          "end_idx": 129,
          "entities": [],
          "relations": [],
          "sentence_en": "Due to differences in doctor-patient relationships, hospital systems and medical insurance systems in different countries, there are differences in the management models of inpatients."
        },
        {
          "sentence_id": "2",
          "sentence": "参照美国临床内分泌医师协会(AACE)住院患者血糖管理模式，结合我国住院患者及医院管理实情，对我国住院血糖管理模式进行以下推荐，以期为住院患者良好的血糖控制提供帮助。",
          "start_idx": 129,
          "end_idx": 212,
          "entities": [
            {
              "entity_id": "T800",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 23,
              "end_idx": 25,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T801",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 51,
              "end_idx": 53,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T802",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 74,
              "end_idx": 76,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "Referring to the blood glucose management model of inpatients of the American Association of Clinical Endocrinologists (AACE) and combining the actual situation of inpatients and hospital management in my country, the following recommendations are made for the blood glucose management model of inpatients in my country, in order to help inpatients achieve good blood glucose control."
        }
      ],
      "paragraph_en": "The inpatient blood glucose management model is constructed under the guidance of management concepts. It is a behavioral system of inpatient blood glucose management composed of management methods, management systems, management tools, and management procedures. Although the prevalence of diabetes in my country has increased year by year, there are few research reports on the blood glucose management model of inpatients. Due to the differences in doctor-patient relationships, hospital systems, and medical insurance systems in different countries, there are differences in the management model of inpatients. Referring to the inpatient blood glucose management model of the American Association of Clinical Endocrinologists (AACE), combined with the actual situation of inpatients and hospital management in my country, the following recommendations are made for the inpatient blood glucose management model in my country, in order to provide help for good blood glucose control for inpatients."
    },
    {
      "paragraph_id": "85",
      "paragraph": "(一)住院血糖管理模式的分类",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(一)住院血糖管理模式的分类",
          "start_idx": 0,
          "end_idx": 14,
          "entities": [
            {
              "entity_id": "T803",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 5,
              "end_idx": 7,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "1. Classification of inpatient blood glucose management models"
        }
      ],
      "paragraph_en": "1. Classification of inpatient blood glucose management models"
    },
    {
      "paragraph_id": "86",
      "paragraph": "根据我国住院患者病情轻者比例较高，新诊断糖尿病患者入院治疗较多，住院期间新发现的糖尿病患者较多，住院患者病情差异性大等特点，推荐我国住院血糖管理分为以下3种：(1)科室自我管理模式：(2)会诊专业管理模式；(3)互联网系统管理模式。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "根据我国住院患者病情轻者比例较高，新诊断糖尿病患者入院治疗较多，住院期间新发现的糖尿病患者较多，住院患者病情差异性大等特点，推荐我国住院血糖管理分为以下3种：(1)科室自我管理模式：(2)会诊专业管理模式；(3)互联网系统管理模式。",
          "start_idx": 0,
          "end_idx": 116,
          "entities": [
            {
              "entity_id": "T804",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 23,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T805",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 40,
              "end_idx": 43,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T806",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 68,
              "end_idx": 70,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R208",
              "head_entity_id": "T806",
              "tail_entity_id": "T805"
            }
          ],
          "sentence_en": "Based on the characteristics of my country's hospitalized patients with mild conditions, a high proportion of newly diagnosed diabetic patients admitted to hospital for treatment, a large number of newly discovered diabetic patients during hospitalization, and great differences in the conditions of hospitalized patients, it is recommended that inpatient blood glucose management in my country be divided into the following three types: (1) departmental self-management model; (2) consultation professional management model; and (3) Internet system management model."
        }
      ],
      "paragraph_en": "Based on the characteristics of my country's hospitalized patients with mild conditions, a high proportion of newly diagnosed diabetic patients admitted to hospital for treatment, a large number of newly discovered diabetic patients during hospitalization, and great differences in the conditions of hospitalized patients, it is recommended that inpatient blood glucose management in my country be divided into the following three types: (1) departmental self-management model; (2) consultation professional management model; and (3) Internet system management model."
    },
    {
      "paragraph_id": "87",
      "paragraph": "(二)科室自我管理模式",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(二)科室自我管理模式",
          "start_idx": 0,
          "end_idx": 11,
          "entities": [],
          "relations": [],
          "sentence_en": "2. Department self-management model"
        }
      ],
      "paragraph_en": "2. Department self-management model"
    },
    {
      "paragraph_id": "88",
      "paragraph": "1.科室自我管理模式定义：住院患者血糖由患者所住科室医护人员、健康教育工作者、营养师、患者等共同参与的血糖管理模式。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.科室自我管理模式定义：住院患者血糖由患者所住科室医护人员、健康教育工作者、营养师、患者等共同参与的血糖管理模式。",
          "start_idx": 0,
          "end_idx": 58,
          "entities": [
            {
              "entity_id": "T807",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T808",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 51,
              "end_idx": 53,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "1. Definition of departmental self-management model: A blood sugar management model in which hospitalized patients’ blood sugar is managed jointly by medical staff, health educators, nutritionists, and patients in the department where the patient is staying."
        }
      ],
      "paragraph_en": "1. Definition of departmental self-management model: A blood sugar management model in which hospitalized patients’ blood sugar is managed jointly by medical staff, health educators, nutritionists, and patients in the department where the patient is staying."
    },
    {
      "paragraph_id": "89",
      "paragraph": "2.科室自我管理模式适用患者：(1)集中收治在内分泌科的患者；(2)收治在非内分泌科病区患者：①入院前血糖控制可，住院期间可继续入院前控糖方案；②住院期间按照临床指南给予基础一餐时胰岛素注射方案，血糖容易达标；③收治重症病区患者，病区医师能够按照临床指南规范使用并合理调整胰岛素方案。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.科室自我管理模式适用患者：(1)集中收治在内分泌科的患者；(2)收治在非内分泌科病区患者：①入院前血糖控制可，住院期间可继续入院前控糖方案；②住院期间按照临床指南给予基础一餐时胰岛素注射方案，血糖容易达标；③收治重症病区患者，病区医师能够按照临床指南规范使用并合理调整胰岛素方案。",
          "start_idx": 0,
          "end_idx": 142,
          "entities": [
            {
              "entity_id": "T809",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 90,
              "end_idx": 93,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T810",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 98,
              "end_idx": 100,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T811",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 136,
              "end_idx": 139,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T812",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 51,
              "end_idx": 53,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T813",
              "entity": "控制可",
              "entity_type": "Test_Value",
              "start_idx": 53,
              "end_idx": 56,
              "entity_en": "Control"
            }
          ],
          "relations": [],
          "sentence_en": "2. The department's self-management model is applicable to the following patients: (1) patients who are centrally admitted to the endocrinology department; (2) patients who are admitted to non-endocrinology wards: ① if blood sugar is well controlled before admission, the pre-admission blood sugar control plan can be continued during hospitalization; ② during hospitalization, a basic mealtime insulin injection plan is given according to clinical guidelines, and blood sugar levels are easily met; ③ patients admitted to critical care wards, ward physicians can use and reasonably adjust insulin plans in accordance with clinical guidelines."
        }
      ],
      "paragraph_en": "2. The department's self-management model is applicable to the following patients: (1) patients who are centrally admitted to the endocrinology department; (2) patients who are admitted to non-endocrinology wards: ① if blood sugar is well controlled before admission, the pre-admission blood sugar control plan can be continued during hospitalization; ② during hospitalization, a basic mealtime insulin injection plan is given according to clinical guidelines, and blood sugar levels are easily met; ③ patients admitted to critical care wards, ward physicians can use and reasonably adjust insulin plans in accordance with clinical guidelines."
    },
    {
      "paragraph_id": "90",
      "paragraph": "3.科室自我管理模式的优势和不足：(1)优势：患者能第一时间得到所住科室医护人员、健康教育工作者、营养师的指导及治疗。(2)不足：由于非内分泌科医护人员糖尿病知识的非专业性及患者健康教育不到位，非内分泌科住院患者血糖达标率低。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.科室自我管理模式的优势和不足：(1)优势：患者能第一时间得到所住科室医护人员、健康教育工作者、营养师的指导及治疗。",
          "start_idx": 0,
          "end_idx": 59,
          "entities": [],
          "relations": [],
          "sentence_en": "3. Advantages and disadvantages of the department's self-management model: (1) Advantages: Patients can receive guidance and treatment from the medical staff, health educators, and nutritionists of the department in which they are staying in the first place."
        },
        {
          "sentence_id": "1",
          "sentence": "(2)不足：由于非内分泌科医护人员糖尿病知识的非专业性及患者健康教育不到位，非内分泌科住院患者血糖达标率低。",
          "start_idx": 59,
          "end_idx": 113,
          "entities": [
            {
              "entity_id": "T814",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 20,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T815",
              "entity": "血糖达标率",
              "entity_type": "Test_items",
              "start_idx": 47,
              "end_idx": 52,
              "entity_en": "Blood sugar standard rate"
            },
            {
              "entity_id": "T816",
              "entity": "低",
              "entity_type": "Test_Value",
              "start_idx": 52,
              "end_idx": 53,
              "entity_en": "Low"
            }
          ],
          "relations": [],
          "sentence_en": "(2) Insufficient: Due to the lack of professional diabetes knowledge among non-endocrinology medical staff and inadequate patient health education, the blood sugar control rate of non-endocrinology hospitalized patients is low."
        }
      ],
      "paragraph_en": "3. Advantages and disadvantages of the departmental self-management model: (1) Advantages: Patients can get guidance and treatment from the medical staff, health educators, and nutritionists of the department in which they are staying at the first time. (2) Disadvantages: Due to the non-professional diabetes knowledge of non-endocrinology medical staff and inadequate health education for patients, the blood sugar control rate of inpatients in non-endocrinology departments is low."
    },
    {
      "paragraph_id": "91",
      "paragraph": "(三)会诊专业管理模式",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(三)会诊专业管理模式",
          "start_idx": 0,
          "end_idx": 11,
          "entities": [],
          "relations": [],
          "sentence_en": "3. Consultation professional management model"
        }
      ],
      "paragraph_en": "3. Consultation professional management model"
    },
    {
      "paragraph_id": "92",
      "paragraph": "1.会诊专业管理模式定义：非内分泌科住院患者血糖除由患者所住科室医护人员、健康教育工作者、营养师、患者等参与血糖管理外，血糖控制不良、临床状态特殊、控糖方案制定困难时，内分泌科医师通过会诊方式参与的血糖管理模式。在会诊专业管理模式中，有一种由内分泌科医生及糖尿病教育护士组成核心管理团队，其他非内分泌科室的护士也参与其中共同管理住院患者血糖的会诊模式，这一模式可以称为糖尿病团队管理模式。如果医院情况允许，也可以在团队中加入营养师、药剂师等多学科成员。糖尿病团队管理模式同样由内分泌科医生给出会诊治疗意见，但可以更多地发挥护士的职能，糖尿病教育护士可以协助内分泌科医生对非内分泌科的高血糖住院患者进行随访，反馈患者情况给内分泌医生并传达内分泌科医生的治疗意见。糖尿病团队模式需要医院行政管理层的支持和(或)非内分泌科室的良好合作意愿，同时要求内分泌科具有高效的医护团队，因此需要各医院根据自身情况来决定是否实施。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.会诊专业管理模式定义：非内分泌科住院患者血糖除由患者所住科室医护人员、健康教育工作者、营养师、患者等参与血糖管理外，血糖控制不良、临床状态特殊、控糖方案制定困难时，内分泌科医师通过会诊方式参与的血糖管理模式。",
          "start_idx": 0,
          "end_idx": 106,
          "entities": [
            {
              "entity_id": "T817",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 22,
              "end_idx": 24,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T825",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 54,
              "end_idx": 56,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T826",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 60,
              "end_idx": 62,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T827",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 99,
              "end_idx": 101,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T828",
              "entity": "控制不良",
              "entity_type": "Test_Value",
              "start_idx": 62,
              "end_idx": 66,
              "entity_en": "Poor control"
            }
          ],
          "relations": [],
          "sentence_en": "1. Definition of consultation professional management model: In addition to the blood sugar management of non-endocrinology inpatients by medical staff, health educators, nutritionists, and patients in the patient's department, when blood sugar is poorly controlled, the clinical condition is special, and it is difficult to formulate a blood sugar control plan, an endocrinologist participates in the blood sugar management model through consultation."
        },
        {
          "sentence_id": "1",
          "sentence": "在会诊专业管理模式中，有一种由内分泌科医生及糖尿病教育护士组成核心管理团队，其他非内分泌科室的护士也参与其中共同管理住院患者血糖的会诊模式，这一模式可以称为糖尿病团队管理模式。",
          "start_idx": 106,
          "end_idx": 194,
          "entities": [
            {
              "entity_id": "T818",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 25,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T819",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 62,
              "end_idx": 64,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T820",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 78,
              "end_idx": 81,
              "entity_en": "diabetes"
            }
          ],
          "relations": [],
          "sentence_en": "In the consultation professional management model, there is a consultation model in which the core management team is composed of endocrinologists and diabetes education nurses, and nurses from other non-endocrine departments also participate in the joint management of blood sugar of inpatients. This model can be called the diabetes team management model."
        },
        {
          "sentence_id": "2",
          "sentence": "如果医院情况允许，也可以在团队中加入营养师、药剂师等多学科成员。",
          "start_idx": 194,
          "end_idx": 226,
          "entities": [],
          "relations": [],
          "sentence_en": "If the hospital situation permits, multidisciplinary members such as nutritionists and pharmacists can also be included in the team."
        },
        {
          "sentence_id": "3",
          "sentence": "糖尿病团队管理模式同样由内分泌科医生给出会诊治疗意见，但可以更多地发挥护士的职能，糖尿病教育护士可以协助内分泌科医生对非内分泌科的高血糖住院患者进行随访，反馈患者情况给内分泌医生并传达内分泌科医生的治疗意见。",
          "start_idx": 226,
          "end_idx": 330,
          "entities": [
            {
              "entity_id": "T821",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T822",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 41,
              "end_idx": 44,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T823",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 68,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "The diabetes team management model also requires endocrinologists to provide consultation and treatment opinions, but nurses can play a greater role. Diabetes education nurses can assist endocrinologists in following up on non-endocrinology department inpatients with hyperglycemia, provide feedback on patients' conditions to endocrinologists, and convey the endocrinologists' treatment opinions."
        },
        {
          "sentence_id": "4",
          "sentence": "糖尿病团队模式需要医院行政管理层的支持和(或)非内分泌科室的良好合作意愿，同时要求内分泌科具有高效的医护团队，因此需要各医院根据自身情况来决定是否实施。",
          "start_idx": 330,
          "end_idx": 406,
          "entities": [
            {
              "entity_id": "T824",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "diabetes"
            }
          ],
          "relations": [],
          "sentence_en": "The diabetes team model requires the support of the hospital's administrative management and/or the good willingness of non-endocrine departments to cooperate. It also requires the endocrine department to have an efficient medical team. Therefore, each hospital needs to decide whether to implement it based on its own situation."
        }
      ],
      "paragraph_en": "1. Definition of consultation professional management model: In addition to the blood sugar management of non-endocrinology inpatients, which is carried out by medical staff, health education workers, nutritionists, and patients in the department where the patients live, endocrinologists participate in the blood sugar management model through consultation when blood sugar is poorly controlled, the clinical status is special, and it is difficult to formulate a glucose control plan. In the consultation professional management model, there is a consultation model in which the core management team is composed of endocrinologists and diabetes education nurses, and nurses from other non-endocrine departments also participate in the joint management of blood sugar inpatients. This model can be called the diabetes team management model. If the hospital situation permits, multidisciplinary members such as nutritionists and pharmacists can also be added to the team. The diabetes team management model also provides consultation and treatment opinions from endocrinologists, but the functions of nurses can be more utilized. Diabetes education nurses can assist endocrinologists in following up on non-endocrinology inpatients with high blood sugar, feedback the patient's condition to the endocrinologist, and convey the endocrinologist's treatment opinions. The diabetes team model requires the support of the hospital's administrative management and/or the good willingness of non-endocrine departments to cooperate. It also requires the endocrine department to have an efficient medical team. Therefore, each hospital needs to decide whether to implement it based on its own situation."
    },
    {
      "paragraph_id": "93",
      "paragraph": "2.会诊专业管理模式适用患者：(1)住院期间按照临床指南使用及调整胰岛素治疗方案，但血糖仍不能达标的患者；(2)合并特殊情况的患者：进食不规律、需肠内营养、应激、伴有糖尿病急性并发症、糖尿病妊娠、围手术期、合并使用糖皮质激素、免疫抑制剂等。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.会诊专业管理模式适用患者：(1)住院期间按照临床指南使用及调整胰岛素治疗方案，但血糖仍不能达标的患者；(2)合并特殊情况的患者：进食不规律、需肠内营养、应激、伴有糖尿病急性并发症、糖尿病妊娠、围手术期、合并使用糖皮质激素、免疫抑制剂等。",
          "start_idx": 0,
          "end_idx": 120,
          "entities": [
            {
              "entity_id": "T829",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 36,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T830",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 42,
              "end_idx": 44,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T831",
              "entity": "不能达标",
              "entity_type": "Test_Value",
              "start_idx": 45,
              "end_idx": 49,
              "entity_en": "Cannot meet the standard"
            },
            {
              "entity_id": "T832",
              "entity": "肠内营养",
              "entity_type": "Treatment",
              "start_idx": 73,
              "end_idx": 77,
              "entity_en": "Enteral nutrition"
            },
            {
              "entity_id": "T833",
              "entity": "糖尿病急性并发症",
              "entity_type": "Disease",
              "start_idx": 83,
              "end_idx": 91,
              "entity_en": "Acute complications of diabetes"
            },
            {
              "entity_id": "T834",
              "entity": "糖尿病妊娠",
              "entity_type": "Disease",
              "start_idx": 92,
              "end_idx": 97,
              "entity_en": "Diabetic pregnancy"
            },
            {
              "entity_id": "T835",
              "entity": "糖皮质激素",
              "entity_type": "Drug",
              "start_idx": 107,
              "end_idx": 112,
              "entity_en": "Glucocorticoids"
            },
            {
              "entity_id": "T836",
              "entity": "免疫抑制剂",
              "entity_type": "Drug",
              "start_idx": 113,
              "end_idx": 118,
              "entity_en": "Immunosuppressants"
            }
          ],
          "relations": [],
          "sentence_en": "2. The consultation professional management model is applicable to the following patients: (1) patients who use and adjust insulin treatment plans according to clinical guidelines during hospitalization but whose blood sugar levels still cannot reach the target; (2) patients with special conditions: irregular eating, enteral nutrition requirements, stress, acute complications of diabetes, diabetic pregnancy, perioperative period, and concomitant use of glucocorticoids and immunosuppressants."
        }
      ],
      "paragraph_en": "2. The consultation professional management model is applicable to the following patients: (1) patients who use and adjust insulin treatment plans according to clinical guidelines during hospitalization but whose blood sugar levels still cannot reach the target; (2) patients with special conditions: irregular eating, enteral nutrition requirements, stress, acute complications of diabetes, diabetic pregnancy, perioperative period, and concomitant use of glucocorticoids and immunosuppressants."
    },
    {
      "paragraph_id": "94",
      "paragraph": "3.会诊专业管理模式的优势和不足：(1)优势：内分泌科医师通过院内会诊参与非内分泌科住院患者的血糖管理可以提高患者血糖达标率、缩短平均住院日及改善患者临床结局。(2)不足：医疗资源的短缺使内分泌科医护人员不可能参与每个非内分泌科住院患者的血糖管理，更多的住院糖尿病患者血糖管理实际上由所在科室医护人员完成，得到专科医师的指导有限。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.会诊专业管理模式的优势和不足：(1)优势：内分泌科医师通过院内会诊参与非内分泌科住院患者的血糖管理可以提高患者血糖达标率、缩短平均住院日及改善患者临床结局。(2)不足：医疗资源的短缺使内分泌科医护人员不可能参与每个非内分泌科住院患者的血糖管理，更多的住院糖尿病患者血糖管理实际上由所在科室医护人员完成，得到专科医师的指导有限。",
          "start_idx": 0,
          "end_idx": 165,
          "entities": [
            {
              "entity_id": "T837",
              "entity": "血糖达标率",
              "entity_type": "Test_items",
              "start_idx": 57,
              "end_idx": 62,
              "entity_en": "Blood sugar compliance rate"
            },
            {
              "entity_id": "T838",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 129,
              "end_idx": 132,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T839",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 47,
              "end_idx": 49,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T840",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 119,
              "end_idx": 121,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T841",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 134,
              "end_idx": 136,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R209",
              "head_entity_id": "T841",
              "tail_entity_id": "T838"
            }
          ],
          "sentence_en": "3. Advantages and disadvantages of the consultation professional management model: (1) Advantages: Endocrinologists can participate in the blood glucose management of non-endocrinology inpatients through in-hospital consultation to improve the blood glucose control rate of patients, shorten the average length of stay, and improve the clinical outcomes of patients. (2) Disadvantages: The shortage of medical resources makes it impossible for endocrinologists to participate in the blood glucose management of every non-endocrinology inpatient. In fact, the blood glucose management of more inpatients with diabetes is completed by the medical staff of the department, and the guidance of specialists is limited."
        }
      ],
      "paragraph_en": "3. Advantages and disadvantages of the consultation professional management model: (1) Advantages: Endocrinologists can participate in the blood glucose management of non-endocrinology inpatients through in-hospital consultation to improve the blood glucose compliance rate of patients, shorten the average length of stay, and improve the clinical outcomes of patients. (2) Disadvantages: The shortage of medical resources makes it impossible for endocrinologists to participate in the blood glucose management of every non-endocrinology inpatient. In fact, the blood glucose management of more inpatients with diabetes is completed by the medical staff of the department, and the guidance of specialists is limited."
    },
    {
      "paragraph_id": "95",
      "paragraph": "(四)互联网系统管理模式",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(四)互联网系统管理模式",
          "start_idx": 0,
          "end_idx": 12,
          "entities": [],
          "relations": [],
          "sentence_en": "(IV) Internet system management model"
        }
      ],
      "paragraph_en": "(IV) Internet system management model"
    },
    {
      "paragraph_id": "96",
      "paragraph": "随着互联网技术的发展、医疗软件的开发利用以及智能手机、平板电脑等移动终端的普及，基于互联网的系统管理模式逐渐用于糖尿病患者血糖管理，通过信息技术合理配置医疗资源，提高医疗资源的利用率。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "随着互联网技术的发展、医疗软件的开发利用以及智能手机、平板电脑等移动终端的普及，基于互联网的系统管理模式逐渐用于糖尿病患者血糖管理，通过信息技术合理配置医疗资源，提高医疗资源的利用率。",
          "start_idx": 0,
          "end_idx": 92,
          "entities": [
            {
              "entity_id": "T842",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 56,
              "end_idx": 59,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T843",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 61,
              "end_idx": 63,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R210",
              "head_entity_id": "T843",
              "tail_entity_id": "T842"
            }
          ],
          "sentence_en": "With the development of Internet technology, the exploitation and utilization of medical software and the popularization of mobile terminals such as smart phones and tablet computers, Internet-based system management models are gradually being used for blood sugar management of diabetic patients, rationally allocating medical resources through information technology and improving the utilization rate of medical resources."
        }
      ],
      "paragraph_en": "With the development of Internet technology, the exploitation and utilization of medical software and the popularization of mobile terminals such as smart phones and tablet computers, Internet-based system management models are gradually being used for blood sugar management of diabetic patients, rationally allocating medical resources through information technology and improving the utilization rate of medical resources."
    },
    {
      "paragraph_id": "97",
      "paragraph": "1.互联网系统管理模式定义：利用住院患者互联网管理系统，与患者血糖监测数据管理系统相结合，使院内任一科室糖尿病患者都能及时接受糖尿病医护的远程系统管理，包括糖尿病教育、监测及治疗方案制定与调整。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.互联网系统管理模式定义：利用住院患者互联网管理系统，与患者血糖监测数据管理系统相结合，使院内任一科室糖尿病患者都能及时接受糖尿病医护的远程系统管理，包括糖尿病教育、监测及治疗方案制定与调整。",
          "start_idx": 0,
          "end_idx": 97,
          "entities": [
            {
              "entity_id": "T844",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 52,
              "end_idx": 55,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T845",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 63,
              "end_idx": 66,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T846",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 78,
              "end_idx": 81,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T847",
              "entity": "血糖监测",
              "entity_type": "Test_items",
              "start_idx": 31,
              "end_idx": 35,
              "entity_en": "Blood glucose monitoring"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R211",
              "head_entity_id": "T847",
              "tail_entity_id": "T844"
            }
          ],
          "sentence_en": "1. Definition of Internet system management model: Utilize the Internet management system for inpatients, combined with the patient blood glucose monitoring data management system, so that diabetic patients in any department of the hospital can receive timely remote system management of diabetes medical care, including diabetes education, monitoring, and treatment plan formulation and adjustment."
        }
      ],
      "paragraph_en": "1. Definition of Internet system management model: Utilizing the Internet management system for inpatients, combined with the patient blood glucose monitoring data management system, diabetic patients in any department of the hospital can receive timely remote system management of diabetes medical care, including diabetes education, monitoring, and formulation and adjustment of treatment plans."
    },
    {
      "paragraph_id": "98",
      "paragraph": "2.互联网系统管理模式适用条件及患者：建立好互联网系统管理模式的医院可以开展远程糖尿病系统管理，适合该系统的患者为已纳入系统管理，且录入信息准确，能配合医护治疗方案执行的患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.互联网系统管理模式适用条件及患者：建立好互联网系统管理模式的医院可以开展远程糖尿病系统管理，适合该系统的患者为已纳入系统管理，且录入信息准确，能配合医护治疗方案执行的患者。",
          "start_idx": 0,
          "end_idx": 88,
          "entities": [
            {
              "entity_id": "T848",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 40,
              "end_idx": 43,
              "entity_en": "diabetes"
            }
          ],
          "relations": [],
          "sentence_en": "2. Applicable conditions and patients of the Internet system management model: Hospitals that have established the Internet system management model can carry out remote diabetes system management. Patients suitable for this system are those who have been included in the system management, have entered accurate information, and can cooperate with the implementation of medical treatment plans."
        }
      ],
      "paragraph_en": "2. Applicable conditions and patients of the Internet system management model: Hospitals that have established the Internet system management model can carry out remote diabetes system management. Patients suitable for this system are those who have been included in the system management, have entered accurate information, and can cooperate with the implementation of medical treatment plans."
    },
    {
      "paragraph_id": "99",
      "paragraph": "3.互联网系统管理模式的优势和不足：(1)优势：①国内外互联网系统管理模式系统有所不同，对住院患者血糖控制改善率不一.但均能提高住院患者血糖达标率，降低低血糖发生率及平均住院日，改善预后；②提高患者糖尿病知识的知晓率，提高医护人员工作效率，同时提升患者满意度；③管理系统通过对患者连续的、主动的个性化服务与管理，实现了院内“分泌科-非内分泌科“血糖管理无缝衔接。(2)不足：①护理人员的工作量繁重、交互界面操作困难、内置提醒设置不充足及对错误的关注不足是互联网系统管理模式实施的主要困难；2低血糖发生在系统中被过分关注，导致护士为避免低血糖发生而不完全执行系统推荐的胰岛素注射剂量，增加血糖达标难度：③互联网系统管理模式所有信息建立在电子病历基础上，不能完全替代面对面的内分泌医师会诊评估。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.互联网系统管理模式的优势和不足：(1)优势：①国内外互联网系统管理模式系统有所不同，对住院患者血糖控制改善率不一.但均能提高住院患者血糖达标率，降低低血糖发生率及平均住院日，改善预后；②提高患者糖尿病知识的知晓率，提高医护人员工作效率，同时提升患者满意度；③管理系统通过对患者连续的、主动的个性化服务与管理，实现了院内“分泌科-非内分泌科“血糖管理无缝衔接。(2)不足：①护理人员的工作量繁重、交互界面操作困难、内置提醒设置不充足及对错误的关注不足是互联网系统管理模式实施的主要困难；2低血糖发生在系统中被过分关注，导致护士为避免低血糖发生而不完全执行系统推荐的胰岛素注射剂量，增加血糖达标难度：③互联网系统管理模式所有信息建立在电子病历基础上，不能完全替代面对面的内分泌医师会诊评估。",
          "start_idx": 0,
          "end_idx": 345,
          "entities": [
            {
              "entity_id": "T849",
              "entity": "血糖达标率",
              "entity_type": "Test_items",
              "start_idx": 68,
              "end_idx": 73,
              "entity_en": "Blood sugar standard rate"
            },
            {
              "entity_id": "T850",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 76,
              "end_idx": 79,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T851",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 99,
              "end_idx": 102,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T852",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 245,
              "end_idx": 248,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T853",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 267,
              "end_idx": 270,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T854",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 283,
              "end_idx": 286,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T855",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 293,
              "end_idx": 295,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T856",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 49,
              "end_idx": 51,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T857",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 172,
              "end_idx": 174,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T858",
              "entity": "注射",
              "entity_type": "Method",
              "start_idx": 286,
              "end_idx": 288,
              "entity_en": "injection"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R212",
              "head_entity_id": "T849",
              "tail_entity_id": "T850"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R213",
              "head_entity_id": "T855",
              "tail_entity_id": "T853"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R214",
              "head_entity_id": "T858",
              "tail_entity_id": "T854"
            }
          ],
          "sentence_en": "3. Advantages and disadvantages of the Internet system management model: (1) Advantages: ① The Internet system management model systems at home and abroad are different, and the improvement rates of blood sugar control for hospitalized patients are different. However, they can all improve the blood sugar control rate of hospitalized patients, reduce the incidence of hypoglycemia and the average length of hospital stay, and improve prognosis; ② Improve the patient's awareness of diabetes knowledge, improve the work efficiency of medical staff, and at the same time improve patient satisfaction; ③ The management system achieves seamless connection of blood sugar management between the \"endocrine department and non-endocrine department\" in the hospital through continuous, proactive and personalized service and management of patients. (2) Disadvantages: ① The heavy workload of nursing staff, difficult operation of the interactive interface, insufficient built-in reminder settings and insufficient attention to errors are the main difficulties in implementing the Internet system management model; 2 Hypoglycemia is overly concerned in the system, resulting in nurses not fully implementing the insulin injection dose recommended by the system to avoid hypoglycemia, increasing the difficulty of achieving blood sugar control: ③ All information in the Internet system management model is based on electronic medical records and cannot completely replace face-to-face consultation and evaluation by endocrinologists."
        }
      ],
      "paragraph_en": "3. Advantages and disadvantages of the Internet system management model: (1) Advantages: ① The Internet system management model systems at home and abroad are different, and the improvement rates of blood sugar control for hospitalized patients are different. However, they can all improve the blood sugar control rate of hospitalized patients, reduce the incidence of hypoglycemia and the average length of hospital stay, and improve prognosis; ② Improve the patient's awareness of diabetes knowledge, improve the work efficiency of medical staff, and at the same time improve patient satisfaction; ③ The management system achieves seamless connection of blood sugar management between the \"endocrine department and non-endocrine department\" in the hospital through continuous, proactive and personalized service and management of patients. (2) Disadvantages: ① The heavy workload of nursing staff, difficult operation of the interactive interface, insufficient built-in reminder settings and insufficient attention to errors are the main difficulties in implementing the Internet system management model; 2 Hypoglycemia is overly concerned in the system, resulting in nurses not fully implementing the insulin injection dose recommended by the system to avoid hypoglycemia, increasing the difficulty of achieving blood sugar control: ③ All information in the Internet system management model is based on electronic medical records and cannot completely replace face-to-face consultation and evaluation by endocrinologists."
    },
    {
      "paragraph_id": "100",
      "paragraph": "4.互联网系统管理模式的前景：互联网系统管理模式是未来极具前景和应用推广价值的住院血糖管理模式，但牵涉到住院患者管理系统、终端末梢血糖监测系统、血糖管理系统及网络服务器的整合，需一定财力、物力的投入及医院多部门协作。在信息技术和互联网技术的发展下，互联网系统管理模式需不断更新、改进，其安全性、有效性及性价比有待进一步提高。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.互联网系统管理模式的前景：互联网系统管理模式是未来极具前景和应用推广价值的住院血糖管理模式，但牵涉到住院患者管理系统、终端末梢血糖监测系统、血糖管理系统及网络服务器的整合，需一定财力、物力的投入及医院多部门协作。",
          "start_idx": 0,
          "end_idx": 108,
          "entities": [
            {
              "entity_id": "T859",
              "entity": "血糖监测",
              "entity_type": "Test_items",
              "start_idx": 65,
              "end_idx": 69,
              "entity_en": "Blood glucose monitoring"
            },
            {
              "entity_id": "T860",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 41,
              "end_idx": 43,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T861",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 72,
              "end_idx": 74,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "4. Prospects of the Internet system management model: The Internet system management model is an inpatient blood glucose management model with great prospects and application promotion value in the future, but it involves the integration of inpatient patient management system, terminal peripheral blood glucose monitoring system, blood glucose management system and network server, which requires certain financial and material resources and collaboration among multiple departments of the hospital."
        },
        {
          "sentence_id": "1",
          "sentence": "在信息技术和互联网技术的发展下，互联网系统管理模式需不断更新、改进，其安全性、有效性及性价比有待进一步提高。",
          "start_idx": 108,
          "end_idx": 162,
          "entities": [],
          "relations": [],
          "sentence_en": "With the development of information technology and Internet technology, the Internet system management model needs to be continuously updated and improved, and its security, effectiveness and cost-effectiveness need to be further improved."
        }
      ],
      "paragraph_en": "4. Prospects of Internet system management model: Internet system management model is a hospitalized blood glucose management model with great prospects and application promotion value in the future, but it involves the integration of inpatient management system, terminal peripheral blood glucose monitoring system, blood glucose management system and network server, which requires certain financial and material investment and cooperation among multiple departments of the hospital. With the development of information technology and Internet technology, Internet system management model needs to be continuously updated and improved, and its safety, effectiveness and cost-effectiveness need to be further improved."
    }
  ]
}